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PREFACE
With the completion of this volume and after six years with the National 
Agricultural Biotechnology Council, I will be stepping down as Executive 
Director of the NABC. Jane Baker Segelken, Executive Coordinator, will assume 
the oversight of the NABC office and its day-to-day operation. As it grew from 
the original four institutions: Boyce Thompson Institute for Plant Research 
(BTI), Cornell University, University of Iowa and University of Califomia- 
Davis, to its present membership of 2 4 , 1  have been privileged to work with 
some of the leaders of agricultural research in the U. S. and Canada. Through-
out my tenure, I have worked closely with the several chairs of the NABC, 
Roger L. Mitchell, University of Missouri-Columbia; Robert G. Gast, Michigan 
State University; Bill R. Baumgardt, Purdue University; and Ralph W. E Hardy, 
Boyce Thompson Institute. Following his retirement from BTI, Ralph Hardy, 
cofounder of NABC in 1988, will be assuming the newly created position of 
president of NABC moving the organization into a more proactive stage.
However, the goals of NABC remain as stated in the preface of NABC Report 1:
“The Council, through sponsorship of meetings and workshops, and 
NABC Reports, strives to facilitate the development of policy recommen-
dations for the safe and efficacious development and use of agricultural 
biotechnology products and processes for the benefit of society; to involve 
all interested and affected groups in a holistic, rather than disciplinary- or 
constituency-oriented evaluation of the potential impact of biotechnology 
on agriculture and development of policy alternatives; and to promote 
increased understanding of agriculture and biotechnology.”
NABC from its first annual meeting at the University of Iowa in 1989 through 
its seventh at the University of Missouri-Columbia has constructed its meetings 
around a common format: a series of lectures to provide a common informative 
base for dialogue in the subject area workshops, which are the heart of NABC 
meetings.
As is common to all of NABC Reports, this volume offers in Part I a general 
overview to provide the reader with some of the flavor of the meeting as well 
as a short synopsis of each of the lectures and a summary of the consensus 
recommendations developed by the workshop participants. The full workshop 
reports, prepared by the co-chairs and reviewed by all workshop participants, are 
presented in Part II. For those who want more specific information, the keynote 
addresses and the topical lectures are in Parts III and IV, respectively.
Since this Report is not a traditional proceeding, I have taken the editor’s 
prerogative and organized the topical papers in Part IV to provide the reader 
with a view of the many issues surrounding intellectual property rights (1PR) 
from the perspective of the laboratory scientist to the field researcher to the 
producer of a crop. These papers are followed by perspectives from a member 
of industry, a farmer and a representative from a developing country. The final 
two papers focus on the several international efforts of ownership and access to 
genes and genomic material, and the South-North debate.
NABC hopes that this report, representing the range of perspectives on gene 
discovery, ownership and access, will contribute to increased understanding 
of the various issues, the different viewpoints on these issues, and provide a 
foundation for the reader’s meaningful dialogue for addressing these critical 
issues in the agricultural biotechnology area.
I wish you pleasant reading and productive dialogue.
June Fessenden MacDonald 
Executive Director
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NABC 7: An Overview
G .  Michael  Chippendale
Chair, NABC 1 Planning Committee 
University of Missouri-Columbia 
Columbia, Missouri
After a day and a half of discussion and debate on the issues of gene discovery, 
of gene ownership and access to genes, the recommendations of the f 40 partici-
pants at the 7th annual National Agricultural Biotechnology Council meeting 
centered on a few critical issues. Those included ensuring the survival of long-
term basic research and inserting social responsibility into the agenda-setting 
process to facilitate discoveries and their development and commercialization 
to ultimately benefit the public.
At each of the previous annual meetings, organizers strove to get participants 
thinking about the issues from all perspectives and to ultimately formulate 
recommendations they can then share with policymakers. This year’s meeting, 
held on the campus of the University of Missouri-Columbia, certainly 
succeeded in achieving its goals. Workshop members and plenary speakers 
from a variety of backgrounds offered suggestions that reflected their concerns 
and goals on the issues of competing rights, the role of governments and public 
institutions, and research policy related to gene discovery, ownership and access.
The timing of the meeting was especially appropriate because agricultural 
biotechnology is advancing at such a rapid rate that obtaining answers to 
questions about gene ownership and access have become critically important. 
The major agenda item was the discussion of policies about intellectual 
property rights (1PR) that control the transfer of knowledge in the molecular 
biology of agricultural commodities to new technology for users. These policies 
generally establish the ownership rights to intellectual property, the obligation 
to disclose inventions and conditions of access, the rights of research sponsors 
to intellectual property resulting from funded research, and the rights from 
informal innovation by farmers.
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As one can imagine, the viewpoints set forth were as varied as the 12 
speakers and the conference participants who represented consumer groups, 
industry, government and academia. For example, Wisconsin family farmer, 
John Kinsman, who is also President of the National Family Farm Defenders 
and the Wisconsin Family Farm Defense Fund, focused on the rights of farmers 
who feel a strong need for self determination, while Ronald Sederoff, Professor 
of Forestry and Director of the Forest Biotechnology Group at North Carolina 
State University, voiced his concern about gene ownership restricting access for 
research. Representing one view of industry, Jack Tribble, Patent Council for 
Merck & Co., Inc., explained there is a need for cooperation among industry 
and university researchers so that each can achieve its goals and objectives.
Speaking about defining and ascribing ownership to genes and farmers’ 
rights, Jose Solleiro, Senior Researcher in the Centre for Technological 
Innovation of the National University of Mexico, asked “how do you put a 
value on generations of background knowledge that is being tapped for 
agricultural biotechnology?” In his opinion, more consideration needs to be 
given to the informal innovation of indigenous peoples, both nationally and 
internationally.
The speakers echoed essentially the same concerns, namely the effects IPRs 
have on public and private research efforts and ultimately the production and 
delivery of products which are essential if society is to benefit from the public 
and private investment.
. . the heart of the research enterprise is being constrained by the 
protection of intellectual property owned by others,” Sederoff said. It is his 
opinion that “Constraints on the research enterprise have significant implica-
tions for the well-being of society. When researchers are restricted in attempts 
to extend our knowledge of the world around us, society pays a cost of lost 
innovation, which is crucial for economic development and the well-being of 
our citizens.”
Concurring was Kathleen Merrigan, senior analyst with the Henry A. Wallace 
Institute for Alternative Agriculture, who stressed that: patents influence the 
university research agenda, overly broad patents stifle research, and patents lead 
to increased research costs. She explained that the current IPR system does not 
meet today’s needs and suggested that a radically different system is needed.
Yet Leanna Lamola, Attorney, sees IPR as helping to maintain the identity and 
profitability of value-added proprietary factors of identity-preserved varieties. 
Production contracts are the main mechanism by which producers will 
participate in identity-preserved systems, she said, adding that risk manage-
ment is the primary advantage of contract production for both the producer and 
the contractor. By controlling the timing, quantity, quality and specifications of 
production, economic efficiencies can be realized. However, production 
contracts can also present new risks, such as an inability to learn the true 
market value of products. Producers may increase returns in identity-preserved
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systems by moving into downstream activities such as processing. Likewise, 
producers may decide to fund the development of identity-preserved varieties 
through research agreements or other strategic alliances with private or public 
organizations.
In addition, participants identified several critical areas of 1PR that need 
further consideration: partnerships, valuation, proportionality and compensa-
tion. Kinsman and Solleiro both talked about proportionality: How do you put 
a proportional value on knowledge? Participants also agreed that IPR should be 
examined in relation to the public good, and policies may need to be estab-
lished regarding access to proprietary information in agricultural technology. 
Also, public access is needed to provide researchers with genes and tools to 
facilitate their use; a need exists to reassess the research exemption; and 
freedom of inquiry is required to preserve the research capability. Merrigan 
challenged the participants to come up with some action items, not just a set 
of passive recommendations.
Indeed, the recommendations from the workshops were action-oriented and 
specific, centering on concerns about the future of basic research and social 
responsibility in the agenda-setting process. It was felt by participants that 
policies should balance the social good versus private gain; ownership of genes 
can have a negative impact on research and skew the research agenda; and 
patents should have the appropriate breadth. In the U.S., the standards of 
patentability (novelty, utility and non-obviousness) should be strictly applied in 
agricultural biotechnology. In addition, IPR should be examined in relation to 
the public good and equity should be negotiated. With reference to the access 
to proprietary information in agricultural technology, new principles may need 
to be established. A need exists to reassess the research exemption. Freedom of 
inquiry is required to preserve the research capability. One important immediate 
concern is to deal with policy issues at the interface between ownership and 
access. The future of agricultural biotechnology requires aggressive discovery 
and equitable access. Then how is the balance achieved at the conjunction of 
ownership and access? When is access to be benefited at the cost of ownership 
and vice versa?
Specific recommendations developed in the workshops can be found on 
pages 13 to 17. The full workshop reports begin on page 29.
In line with the charge given by Merrigan at the first evening session, the 
following action items have been gleaned from the synthesis of the meeting 
activities:
1. Clarify the research exemption for use by public research institutions.
For example, clarify this exemption to enable gene sequence information 
and proven information from all areas to be available for research. The 
need is to preserve freedom of inquiry and investigation and curiosity- 
driven research in public institutions, even knowing that these 
institutions also engage in technology transfer.
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2. Establish policy in agricultural biotechnology that fosters legitimate 
germplasm exchange mechanisms to ensure the fairness of future 
transactions for the public good.
3. Foster cooperation among stakeholders in agricultural biotechnology. 
Partnerships are important, but they should be set up in such a way as to 
not violate the mission and direction of research at public institutions. 
New partnerships should be forged, but not at the expense of long-term 
research. The concept of mutual responsibilities among universities, 
industry and government to maintain vision and mission provides a 
useful framework for action.
4. Address the conflict between social good and private gain with reference 
to gene ownership. The main concern is the possible negative impact of 
ownership on universities or, more broadly, on the research enterprise.
5. Be open to other 1PR systems that might be more appropriate for other 
countries, and decide what kinds of agreements and partnerships are 
needed with the U.S. IPR system.
6. Consider what is the appropriate breadth of patent claims. This will 
mean looking at public-private interfaces and the various roles of 
different institutions.
7. Endeavor to create conditions to facilitate access to genetic resources 
through mutually agreed upon terms, informed consent, and sharing of 
benefits in a way that is clear up front. This would include working to 
empower third world farmers and indigenous peoples and countries to 
recapture some equitable compensation for their genetic material.
Clearly, each interest group must be actively involved in the development and 
promotion of new agricultural products. This is especially important for the 
general public who may not have the background and details to make informed 
decisions. As Richard Flavell of the John Innes Centre, Norwich, UK, advised, 
“The consumer acceptance of transgenic crops is not straightforward, and a 
major public educational effort is needed.” And according to Merrigan, there 
are several ways to help the public become more involved with the research 
going on at universities, in government agencies, and even within industry.
It was that agreement and understanding that prevailed . . . cooperation 
among all interest groups, and the recognition and understanding that not 
everyone will come to the decision-making table with the same background or 
perspective.
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Plenary  Session  highlights
NABC 7 was organized around three plenary sessions: Gene Mapping and the 
Political Economy of Agricultural Research; Ownership: Economic, Legal and 
Institutional Issues; and Access: Public and Private. Speakers at these sessions 
provided a common core of information for workshop debates and hallway 
dialogue.
Gene  Mapping  and  the  Political  Economy  of  Agricultural  
Research
In the first plenary session the two keynote speakers dealt with the status of 
gene mapping and its implications for gene discovery.
Richard B. Flavell, John Innes Centre
Flavell discussed genes and gene mapping for agriculture. He pointed out that 
new combinations of genes in plants are one of the most valuable resources 
for future civilizations because they are sources of better food, feed and fiber; 
economic growth; potential stability; human health and a sustainable environ-
ment. Molecular biology is removing the constraints of classical breeding by 
detecting the presence of genes by their chemistry, and uncovering genetic 
variation. With the use of computers to determine the sequence and function 
of genes, the pace of gene mapping on chromosomes has increased rapidly. For 
example, 10,000 to 15,000 of the 25,000 genes of rice have been identified. In 
10 years all the rice genes should be identified along with their chromosomal 
location. Genetic information from bacteria to humans is being pooled and the 
field of molecular biology is being unified. Information of great value for animal 
gene sequence and function will come from the human genome project.
The consequences of this international effort in agricultural biotechnology 
are many: genetic determination of key traits will become known at the molecu-
lar level; geneticists working on related crops will use each other's information 
much more than they do now; plant breeding will be increasingly automated 
and selections will be performed by computer without growing plants; new 
genetic variation in defined genes will be produced at will; and increasingly 
crops will be modified to serve new customers, markets and industries. Plant 
improvement programs will be accelerated. There will be increased patenting 
of genes, and transgenic crops will require the adherence to specific legislation 
that needs to be harmonized globally. A major concern is that the patenting of 
genes will inhibit the free global flow of germplasm for use in other breeding 
programs. The consumer acceptance of transgenic crops is not straightforward, 
and a major public educational effort is needed. Flavell’s paper begins on 
page 51.
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Kathleen A. Merrigan, Henry A. Wallace Institute for Alternative Agriculture
Merrigan spoke persuasively about unresolved problem areas of gene discovery 
and agricultural biotechnology. She pointed out that the public is now not 
engaged with the issues of agricultural biotechnology, yet their buy-in is 
critical. Current 1PR policies of broad patents have a negative impact on 
research in agricultural biotechnology, including conflict of interest issues 
and increased transactional costs. Regulatory gaps do persist. For example, 
currently only voluntary action is needed to prevent and/or delay the onset 
of public opposition to plants genetically engineered to contain pest or disease 
resistance factors. She offered several ways for the public to become more 
involved in biotechnology policy, including having lay people involved 
in decision-making at universities, seeking the opinions of leaders in the 
community, and having all undergraduates take a citizenship course that 
covers biotechnology. Merrigan’s paper can be found beginning on page 61.
Gene  Ownership : Economic , Legal  and  Institutional  Issues
The second plenary session presented four different viewpoints on the 
economic, legal and institutional issues surrounding gene ownership.
Ronald Sederoff, North Carolina State University
Sederoff spoke about gene mapping of forest trees, specifically the loblolly pine. 
He was particularly concerned about gene ownership restricting access for 
research. A key enzyme for molecular biology in forest biotechnology (Taq 
polymerase) has been patented by The Perkin-Elmer Corporation. This has 
essentially made the enzyme unavailable to researchers because of its high cost, 
and provides an example of how public research is restricted through patenting. 
At the same time, there is increased pressure on university scientists to work on 
short-term projects at the sacrifice of longer term fundamental research, thereby 
eroding our intellectual capital. Research being done at public institutions is 
affected by the patent process and the funding by private companies.
To foster long-term basic research in biotechnology, Sederoff advocated a 
research exemption from patents for public research. Many scientists have the 
false perception that there is a general exemption for university or government- 
based research if it is purely philosophical in purpose. Yet it has been argued 
that universities have lost the claim to a philosophical exemption because they 
file patents, exercise patent rights, and receive fees for licensing and royalties. 
Sederoff’s paper can be found beginning on page 71.
Jack L. Tribble, Merck & Co., Inc.
Gene ownership versus access: meeting the needs was discussed by Tribble 
who pointed out that patents are vital for industrial research incentives. He 
indicated that recent advances in the pharmaceutical industry made possible
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by biotechnology were achieved because of the patent incentive. At the same 
time, he said he understands the need for public research, and sees an inter-
dependence among industry and university researchers. Tribble discussed how 
policy attempts, such as the Bayh-Dole Act, to solve the problems of research 
access have been positive in intent, but largely unsuccessful. This legislation 
intended to make information and germplasm openly available for research 
purposes, but instead there has been a federal policy shift towards patents and 
away from putting information into the public domain.
He explained that Merck’s policy is to make materials available for research 
tools distinct from licensing for products. Merck supports a policy of licensing 
of patented inventions for research use, separately from licensing for commer-
cial development of products for sale. For example, the company has developed 
the Merck Gene Index Project, a catalog of sequence data, which will make 
cDNA sources available to all scientists. He indicated that Merck wants to foster 
collaboration among commercial laboratories and academic and governmental 
laboratories to allow science to advance, foster competition among commercial 
labs, and speed discovery of new products to benefit the public. See page 97 for 
Tribble’s paper.
Leanna M. Lamola, Attorney
Lamola spoke about intellectual property rights in agricultural genetics and 
their function in industrial agriculture. She indicated that identity-preservation 
is one type of an end-use oriented marketing system that is changing the 
structure of modern production agriculture. Intellectual property rights play 
a central role in identity-preserved systems, such as Calgene’s Flavr Savr™ 
tomato, because they allow rights holders to reduce investment risk, obtain 
premium prices, preserve the identity, and control the use of value-added 
factors in downstream or upstream arenas. According to Lamola, production 
contracts are the main mechanism by which producers will participate in 
identity-preserved systems. The producers may decide to fund the development 
of identity-preserved varieties through research agreements or other strategic 
alliances with private or public organizations. Such activities will add to the 
need to re-examine the traditional relationship between the land-grant 
university and agriculture.
Lamola suggested that there are a number of factors that can impact a 
contract producer’s ability to obtain higher returns, including relative bargain-
ing power. Recently, some contract producers have organized into associations 
to improve their bargaining position. Perhaps the most well known is the 
National Contract Poultry Growers Association, which has lobbied for state 
and federal legislation designed to prohibit unfair practices by integrators. 
Lamola’s entire paper can be found beginning on page 87.
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Jose Luis Solleiro, National University of Mexico
Solleiro, who spoke in this plenary session and the third one, talked about 
defining and ascribing ownership to genes and farmers’ rights. An issue close 
to the heart of ownership is valuation, he said. For example, how do you sort 
out the proportion of value added by an inserted gene from a plant found in a 
developing country when engineered into a plant variety originally developed 
in a long-term breeding program at a public institution supported by public 
U.S. funds? Today in agricultural biotechnology we are moving more toward an 
approach of putting different pieces of knowledge together, which is necessary 
to move forward. But how do we sort out ownership, credit and compensation?
According to Solleiro, it is essential to improve the legal framework to deal 
with these issues at all levels and to build domestic capacities to identify, 
conserve and use genetic resources, and better negotiate the terms of future 
agreements. See page 109 for his paper.
Access  to  Genes : Public  and  Private
The third plenary session presented four different viewpoints on the issue of 
public and private access to genes of importance to agricultural biotechnology.
Henry L. Shands, United States Department of Agriculture
Shands spoke about access: bartering and brokering genetic resources. He 
indicated that ownership of genetic resources has become a vocal issue 
surrounding the Convention on Biological Diversity, ostensibly because of 
the pharmaceutical industry’s profits from drugs developed from medicinal 
plant sources. However, much of the movement to curb the exodus of plant 
genetic resources from developing countries came as a result of developed 
countries intellectual property laws giving companies a legal basis to protect 
their varieties and inbred strains for hybrid production. He said that the most 
severe problem associated with the international access to genetic resources 
is that discussions are held in a political rather than a scientific context, 
without a logical concern for such issues as food quality and safety. The 
world’s agriculture is inextricably connected, and it is not sufficient to think 
about our own country’s system. United States Department of Agriculture has 
a policy of free exchange under the National Plant Germplasm System. How-
ever, with increasing restrictions to access of genetic information, the sharing 
of information by scientists will become a more serious problem in the future. 
He argued that the international community should provide open access to all 
genetic resources for food and agriculture, engage Material Transfer Agree-
ments (MTAs) to enable research and breeding with the material, facilitate a 
brokerage system for this exchange, establish a tracking system and compensa-
tion mechanism for germplasm, and promote a bartering system in which 
access is provided in exchange for training and/or technology. In addition, he 
said that an international fund is needed to support biodiversity. See page 117 
for his paper.
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Peter R. Day, Rutgers, the State University of New Jersey 
While discussing the impact of patents on plant breeding using biotechnology, 
Day admitted that the introduction of plant variety rights encouraged the 
development of private sector plant breeding. Although this has led to a decline 
in academic breeding programs, there remain many opportunities for germ- 
plasm enhancement research in our universities. Biotechnology patents are 
bringing about similarly profound, but far more complicated changes. Enhance-
ment through transformation almost always involves the use of patented genes 
and/or methods. Although investigators are free to use patented properties for 
research, there are severe constraints in the developed as well as the developing 
world to using them in agriculture to benefit farmers. Many believe that the 
constraints are justified as the price for protecting intellectual property. He 
noted that academic scientists are becoming just as involved as their colleagues 
in industry.
The extent of patenting single genes or enzymes that are part of a larger 
system of research has made basic research extremely complex. For example, 
Rutgers' scientists developing new cultivars for field tests have to take existing 
patents into account and have each interested party agree to use under a license 
that specifies payment required. Several of these licensing agreements may 
be necessary for one experiment to be conducted. The scope and extent of 
patenting is growing within industry and within U.S. universities and other 
public research arenas. For example, at Stanford University there is one patents 
officer for each ten faculty members. He agreed with Sederoff that universities 
are involved in research for profit, and he cautioned that scientific research with 
a specific product in mind can be a shortsighted approach. A related access 
issue arises in business decision-making with reference to minor crops. If a 
company is focusing only on top-priority opportunities, it may close down 
access to genes important for minor crops or for what seems to a company to 
be a marginal opportunity, but which might meet some important public need. 
The question can be posed as: How can we ensure that the public benefits in a 
wide array of ways through access to discoveries? His paper begins on page 79.
John G. Kinsman, National Family Farm Defenders and the Wisconsin 
Family Farm Defense Fund
During his presentation, Kinsman spoke about farmers’ rights: what is fair? He 
focused on the rights of farmers who feel a strong need for self-determination 
and now despair about their situation. He asked the question how can channels 
of communication between farmers and biotechnologists be opened up? He 
answered by saying that long term talks and constructive cooperation are 
needed and condescending attitudes towards farmers and hasty decisions 
should be avoided. He also said that IPR should be considered a lease rather 
than a right. What are the financial implications? What are the impacts of IPR? 
He feels that farmers were misled by those who assured them that agricultural
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chemicals are safe, in light of the reported contamination of well-water in 
the U.S. by these products. He commented how can we as grassroots farmers 
and consumers be assured of proper control and safeguards to our livelihood 
in agricultural biotechnology? He pointed out that the ethical and moral 
implications of emerging technologies need to be thoroughly examined and 
weighed for their impact on cultures and economies. Will the economic and 
lifestyle impact be progressive and stable, or will the impact be devastating 
to certain regions, countries or cultures? He wanted to know, as an average 
American citizen, how his basic rights will be affected. What safeguards are 
in place or need yet to be developed to protect the health of people and the 
environment in the release of genetically engineered bacteria and other life 
forms? See page 105 for Kinsman’s paper.
Jose Luis Solleiro, National University of Mexico
Speaking again during this session, Solleiro discussed IPR: key to access or 
entry barrier for developing countries. He indicated that IPR has become a 
basic objective of companies seeking to commercialize biotechnology derived 
products. This renewed interest in IPR has already triggered unilateral actions, 
such as those undertaken under the U. S. Trade and Tariffs Act as well as mul-
tilateral negotiations within the World Intellectual Property Organization and 
the General Agreement on Tariffs and Trade (GATT). Intellectual Property 
Rights played an important role in the North American Free Trade Agreement 
(NAFTA) negotiations. Many developing countries have already adopted 
modern IPR legislation, granting protection for most biotechnology develop-
ments. Solleiro described the Rio Convention on Biodiversity which granted 
access to genetic resources to individual governments, depending on their 
own domestic policy. He made the important distinction, though, that “free 
access does not mean free of charge.” Conventions, powerful countries and 
big companies claim that developing countries have protective rights, but he 
explained they cannot enforce them. He gave a hypothetical example illustrat-
ing how a small company in Mexico would not have the resources to sue a 
large multi-national company for infringement. He indicated that the system 
is still incomplete, and in its present state the IPR system benefits large 
multi-national corporations who receive patents and lawyers who sift through 
the mass of legal intricacies created by the system. From the perspective of 
developing countries, concern for protection under an IPR system takes a 
back seat to domestic concerns over such issues as a weak domestic industry, 
research limitations, conservative attitudes, poor economy and the lack 
of concern over agricultural education. He concluded that, for a country 
like Mexico, a protective system of IPR is not sufficient to allow access to 
biotechnology innovations. There should be a national commitment to 
agriculture research and development, and an adequate legal framework to 
handle international technology transfer. Solliero’s paper begins on page 123.
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Workshop  Recommendations
Participants in the three workshops, which are the heart of the NABC meetings, 
formulated recommendations for policymakers, participants and readers on 
research policy issues, competing rights, and the role of governments and public 
institutions related to gene discovery, ownership and access. The participants 
also considered how genetic discoveries should be exploited to maximize 
the public good and benefit society. Plant, animal and microbial aspects of 
agricultural biotechnology were considered from national-international, 
developed-developing countries, and public-private perspectives.
Research  Policy
(See page 29 for the complete report.)
University Agenda-Setting
• NABC should convene a forum to establish the public research agenda 
for agricultural biotechnology and identify high priority research tasks 
requiring attention.
• NABC should compile a repository of biotechnology experts and serve as 
a referral agency to outside organizations.
• NABC should survey its membership on the relative mix of industry- and 
public sector-sponsored biotechnology research at land-grant universities 
to provide baseline data to help inform the debate.
Research Exemption
• NABC should undertake an educational program aimed at clarification 
of the experimental use exemption in patent law.
• Universities and government agencies should be granted a research 
exemption as not-for-profit organizations in order to allow such groups 
to use patented technology in research for noncommercial purposes. A 
possible mechanism for such an arrangement would be the granting of 
a royalty free license to use patented inventions.
Patent Scope
• NABC should lead a public discussion on patent scope, recommend 
reasonable limits, and build consensus that patents should be narrow 
in scope.
• Strong utility requirements must be achieved before patents are granted. 
North-South Relations
• NABC should compile and synthesize the experiences, good and bad, of 
NABC members on exchanges of information and germplasm between 
universities in developed countries and universities in underdeveloped
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countries. Based on this information, NABC should develop a position 
paper on the principles and procedures of fair exchange.
• NABC, in partnership with farmers and all others involved in producing 
and utilizing agricultural products, processes and information, should 
find ways to fairly and equitably recognize contributions of land races 
and indigenous plant populations and knowledge. Such ways may include 
educational programs and pamphlets.
Competing  Rights
(See page 37 for the complete report.)
• There is a need to manage the basic gene pool for the common good. There 
has to be cooperation between the private sector and the public sector to 
work for the common good. Therefore it is the recommendation of this 
workshop that the public sector increase efforts to determine and set long 
term policy with broad constituency involvement, e.g., farmers, local 
government, universities, consumer groups, NGO’s and industry. The 
private sector should develop products in an environment compatible 
with genetic preservation and access.
• There should be formal recognition by potential users of biological 
resources of rights to control over and compensation for use of biological 
resources not only by individuals and nation states but also by local 
communities, cultural groups and regional groups.
• At forums such as the Fourth International Technical Conference on 
Plant Genetic Resources in Germany in 1996, and at the next meeting 
of the Conference of Parties to the Convention on Biological Diversity, 
November, 1995, in Indonesia, there should be encouragement of equitable 
and enduring agreement among those with rights in biological resources 
and between those with rights and potential users, which should include 
education of all parties on fundamental issues and long-term funding
of biodiversity conservation.
• NABC meetings should be organized to provide more background infor-
mation and direction to participants, including availability of expertise 
in legal, social and biotechnology issues; and should actively recruit 
participation of a broader range of views. This improvement should 
lead to more useful recommendations.
• NABC member institutions should establish outreach programs on 
biotechnology and associated intellectual property issues.
• Clarify the “research exemption” for utility patents for use by public 
research institutions.
a. Gene sequence information (all uses),
b. Process information (e.g., the enzyme Taq polymerase as a tool 
for research),
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Specifically:
c. A specific plan for action proposed by one participant, but not 
presented here as a consensus of the workshop was: Universities 
should challenge the ability of patent holders to restrict research 
at universities (using patented technology), and
d. If the challenge is unsuccessful, they should lobby Congress to 
change the law to allow such research.
Role  of  Governments  and  Public  Institutions
(See page 43 for the full workshop report.)
Need for Biotechnology Education
Access
• Each school or college of agriculture should identify biotechnology 
specialists who can be contacted by field/county extension staff for 
information, program development and program delivery.
• NABC should work with extension leadership to include biotechnology 
awareness and education in extension education programs.
• NABC should identify and encourage development of needed educational 
materials (e.g., brochures, e-mail bulletin boards, videotapes, etc.).
• NABC should encourage testing and evaluation of commercial biotech-
nology materials and products, including cost-benefit analysis, in public 
sector institutions.
• NABC should encourage input from user advisory groups to assist in 
setting applied biotechnology research priorities.
Public Awareness
Undergraduate education
• NABC should encourage incorporation of ability to understand and 
interpret biotechnology in undergraduate “core” curricula, with special 
attention to risk assessment, technical, ethical and socioeconomic issues.
K-12
• NABC should publish a list of educational materials on biotechnology.
• NABC should encourage state and local teacher groups to hold workshops 
on biotechnology.
• NABC should develop youth education programs, using programs such as 
4-H as a means of biotechnology education.
• NABC should work with vocational agriculture teachers and support 
efforts to incorporate biotechnology training in vocational agriculture 
curricula.
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Opinion leaders/public
• Scientists should appreciate the importance of and receive training in 
media relations.
• NABC should encourage TV programming (Discovery, NOVA, etc.) and 
other forms of mass media-based education to provide information to the 
public on biotechnology.
• Through its member institutions, NABC should encourage workshops, 
conferences and other public forums designed to include the broadest 
range possible of constituent groups in an on-going dialogue on 
biotechnology issues.
General
• NABC should involve educators in programs such as this meeting and 
provide specific, more targeted workshops for teachers to develop 
educational materials.
Intellectual Property Rights
• Graduate and undergraduate curricula should include specific training in 
intellectual property rights and issues.
• NABC institutions should develop a clear policy describing the rights and 
responsibilities of graduate students regarding intellectual property rights.
• NABC should act as a catalyst to develop a curriculum addressing 
intellectual property rights and ethical issues.
• NABC should act as a clearinghouse for educational programs and 
institutional policies on intellectual property rights.
Access to Intellectual Property from Genome Analysis and other Aspects of
Agricultural Biotechnology
• Policy for release of intellectual property by public institutions should
be based on a mandate to promote the public good rather than motivation 
to increase institutional financial resources.
• Public advisory groups should have input into setting policy for release 
of intellectual property by public institutions.
• Public policy should be devised to maintain broad access to tools of 
biotechnology (germplasm, genes, methods) developed at public 
institutions.
• Public law should provide a more liberal research exemption on patented 
intellectual property.
• The courts should apply anti-trust laws to ensure competition in the 
biotechnology industry.
• The term of ownership of patented intellectual property should be 
re-examined with the goal of balancing economic returns to investment 
versus opening the knowledge for future productivity and innovation.
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• While there was not unanimous support for this recommendation, many 
work-shop participants felt that the Patent and Trademark Office should 
issue utility patents only on the final product (plant genotype), rather 
than individual components or processes (e.g., genes or transformation 
methods).
Need to Identify and Involve Stakeholders in Defining the Public Good
• NABC, in collaboration with land-grant and other universities, and 
organizations such as CAST, should sponsor a national panel of 
stakeholders in agricultural biotechnology (farmers, consumers, 
environmental groups, government, seed trade associations, etc.) to 
define the “public good”; assess the effects of intellectual property 
rights on technology transfer and utilization; and issue a report.
• NABC should encourage greater participation of legislators and other 
government officials in NABC annual meetings.
• For public input to have impact, the public institutions should seriously 
listen to comments and be held accountable to public advisory groups.
• Appropriate research roles for the government and public institutions 
include enhancing the use of biotechnology in minor crops to promote 
diversification for family farmers, promoting new and innovative uses 
of agricultural commodities through biotechnology, and promoting 
environmental responsibility in the use of agricultural biotechnology 
products. These roles can be implemented only if public funding for 
agricultural biotechnology research is increased.
Research Incentives
• There should be motivation provided for fundamental and applied 
research, for commercialization of results from research and for exchange 
of information with other researchers, teachers and extension faculty.
Reinvestment of Profits from Publicly Funded Research
• Distribution of royalties and license fees from publicly funded research 
should be returned to the institution/unit that developed the intellectual 
property, to be reinvested in research.
Research Regulation and Safety
• Products posing different levels of risk should be treated with different 
levels of stringency in oversight. Care in regulation is of special concern 
regarding environmental release of genetically modified organisms with 
the ability to propagate in the wild.
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IS ABC 7: A Synthesis and Challenge
Laura  Meagher
Associate Dean/Associate Director of Research 
Cook College/New Jersey Agricultural Experiment Station 
Rutgers, The State University of New Jersey 
New Brunswick, New Jersey
There have been many good discussions throughout this meeting, and some 
very good speakers have made targeted comments that brought out the breadth 
of the issues involved. The workshop sessions have been good and there were 
fascinating individual conversations over meals. It is a tall order for me to try 
to pull this wealth of interaction together. 1 have decided to go back to what 
the organizers cleverly came up with originally — Discovery, Ownership and 
Access. I want to talk about some issues I see in those areas, and then at the end 
bring out some synthetic points or challenges that I see. My only reservation in 
talking about Discovery, Ownership and Access is that, as I was writing myself 
notes, 1 saw that the initials are D-O-A, possibly not a good omen.
Discovery
In Discovery, some of the questions to be asked are: Who discovers? With what 
purpose? How is the discovery process funded, and in what context does it 
take place? A key issue in discovery, of course, lies in the health and well-being 
of research, the discovery process in particular. As Dick Flavell described so 
well in the opening session, the pace of discovery related to genes is accelerat-
ing rapidly. The sharing of useful information that we have been doing in this 
meeting is just one example. Maybe we will find out more about minor crops 
or developing country crops as we learn about major crops. The prospects are 
very exciting. Breeders may exchange information more readily. There may 
be a real explosion of both knowledge and ability to implement. Ron Sederoff 
described the example of mapping the loblolly pine that would have been 
impossible two years ago and unthinkable ten years ago, but now it is being 
done. The question is: Will this pace continue? Will it accelerate? Or will it 
slow down due to obstacles or to costs exacted by intellectual property rights 
and the standard operating procedure of our university/industry/government 
interface as it exists today?
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We also heard some examples of work that is not going to be done. Forest 
tree genetics-environment interaction on a large scale is fundamental work 
that will not be done because of cost. Many issues exist that are fundamental 
to research policy, and many working papers have made recommendations 
accordingly. Can we develop and implement research policy that will protect 
discovery in agricultural biotechnology? The recommendations from the 
workshops tend to center on: ensuring the survival of long-term basic research 
and somehow inserting social responsibility into the agenda-setting process, 
facilitating discoveries that will ultimately benefit the public.
Ownership
In Ownership, some of the questions to be asked are: Who owns what? What is 
the “what” that is being owned? What are the overriding traditional principles 
governing ownership, and are there any new paradigms for principles to govern 
ownership? Are there new opportunities for sharing? In whose best interest are 
ownership practices right now? Is the public benefiting and is there equitable 
treatment? A central need in ownership is to address what often appears to be 
the conflict between social good and private gain. That dynamic tension has 
come up over and over again and will continue.
There is a whole cluster of concerns over possible negative impacts of 
ownership on universities or on the research enterprise. Kathleen Merrigan,
Ron Sederoff, Jack Tribble, Leanna Lamola and others raised relevant questions. 
Are we going to skew the agenda for what research is done? If we move towards 
shorter term research, or research that fits with private sector gain or that is 
shaped by consideration of intellectual property rights, are we using up our 
intellectual capital? We have been building useful discoveries on the basic 
work that has been done in the past; what do we do when we run out of such 
research results? Similar questions arise in education. Are there conflict of 
interest problems? What is the cost of not doing other kinds of research?
Lamola brought up commodity groups’ questioning of intellectual property 
rights. Those groups have always questioned some of our newer technology 
transfer approaches. It is an old controversy, but maybe there are some new 
lessons to be learned.
A key issue is the ownership system and the universality of its appropriate-
ness. Merrigan asked why we are so anxious to have all developing countries 
blindly take on our technology transfer/intellectual property rights system.
Jose Luis Solleiro pointed out significant differences between the U.S. and 
developing countries. For example, developing countries face different kinds 
of markets, domestic industry, research strengths and governmental priorities. 
The interface between the U.S. system arid intellectual property systems that are 
operational in other countries needs to be looked at. What can be done to make 
such an interface work? What kinds of understandings and partnerships do we 
need to reach?
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Another issue close to the heart of ownership is valuation. How would 
you sort out the proportion of value added by an inserted gene from a plant 
found in a developing country placed into a plant variety originally developed 
in a long-term breeding program at a public institution supported by public 
U.S. funds? Where is the incremental value? Where is the proportionality?
John Kinsman and Solleiro both talked about this. How do you put a pro-
portional value on knowledge? Today in agricultural biotechnology we are 
making the necessary move toward an approach of putting different pieces 
of knowledge together — which is crucial to forward movement — but how 
do you sort out ownership, credit and compensation? Compensation issues are 
key to ownership.
And, finally, and quite basic to the theme of ownership, what is covered by 
a patent? What is a novel gene? As we learn more about similarities among 
different species, how different do sequences have to be to be patentable? What 
is the appropriate breadth of a patent? 1 was told by a CEO of an agricultural 
biotechnology company a few days ago, when he heard 1 was to make this 
presentation, “Make sure to tell them that we have to have broad patents, or 
else there’s no incentive for industry.” And what we heard at this meeting was: 
“Be sure you have narrow patents so there’s incentive for everybody.” There is 
some lively controversy there. The scope of patentability and ownership is 
especially important when you consider, as Lamola discussed, the identity 
preserved systems or other systems when at any point in the whole, complex 
process of production, upstream or downstream, there might be some “moment” 
of intellectual property protection that will have an impact on the rest of the 
whole stream. Is that a strength or a vulnerability, and what are the implica-
tions? We have heard recommendations spanning the wide spectrum of “do not 
challenge the patent system, it works” to “do away with the patent system.”
Again, there are interesting differences in points of view. Clearly, it seems 
what everybody wants is some examination of intellectual property rights 
related to genes, related to agricultural biotechnology, and related more broadly 
to the public good. This is going to entail looking closely at public-private 
interfaces and different roles of different institutions. There were some recom-
mendations about that and about roles that the NABC might play as well. 
Another thought that surfaces is that distribution of profits and benefits should 
be equitable, whatever that truly means. One workshop group suggested that 
there will not be one easy answer; instead, the best distribution is probably 
going to be based on people coming together and negotiating what is equitable. 
That is probably true on a variety of levels.
Access
As far as Access: Who has access to what? What traditional principles guide us 
in access? Is there a need for new principles? Can we go further in making 
access equitable? Can we maximize the public good through approaches to
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access? Access can refer to researchers, research tools, and in some sense it can 
also refer to the public’s access to the products ultimately arising from research. 
That last idea is a worthwhile sub-theme to keep in mind. Obviously, one of 
the big points that caught on and was phrased in many different ways by the 
workshop participants is some sort of “research exemption.” That seems to 
have struck a real chord. However it is phrased or however it is implemented, 
that idea of preserving freedom of inquiry and investigation and curiosity- 
driven research in our institutions is important, even knowing that our 
institutions also engage in technology transfer. Preserving that capability 
seems to be one of the heartfelt responses of the conference. The NABC may 
well have a role in clarifying that situation, as well as specifics on materials 
transfer agreements and other agreements. The Association of University 
Technology Managers (AUTM) has clearly done a great deal in this area, and 
there seems to be a useful role for using the NABC as a dissemination vehicle.
Another issue, as Peter Day discussed from firsthand experience, is the sheer 
growing complexity of gene ownership. There are difficulties in access for 
research purposes and product development. If you have a gene, a vector, a 
promoter and an original cultivar all from different sources, are the university 
technology transfer offices ready to handle this? Is it just so mind boggling that 
it should stop you from doing research at the start? Do you need to start doing 
research and hope that you can hand it off to a company with a large regulatory 
staff to sort it all out later? Some kind of clarification up front is probably going 
to be necessary. But if we wait for a perfect, extensively legal clarification at the 
beginning we might not ever get going and do the research. The question of 
access is an important one.
A related access issue arises in business decision-making. As Day talked 
about, in some cases, such as the development of minor crops, the public may 
be a victim of cold, hard business strategies. If a company is focusing only on 
top-priority opportunities it may close down access to genes important for 
minor crops or for what seems to be a tangential opportunity. In fact, access 
to the genes might really serve some particular public component. How can 
we ensure that the public benefits in a wide array of ways through access 
to discoveries?
In relation to the access issue of management of information from genome 
sequencing, Flavell mentioned that the patenting of genes is very likely to 
inhibit the free global flow of germplasm. How are people going to handle 
this? How is information going to be handled? Are people going to slip things 
under the table, or are they going to have mammoth exchange agreements?
How can exchange of information be facilitated? Tribble mentioned that the 
Bayh-Dole Act intended to make information available, and yet somehow that 
is not happening. The effect is the opposite. Merck & Co., Inc. is trying an 
interesting experiment by making materials available for research tools separate 
from licensing for products. That kind of distinction may be a very useful one.
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That there is this wildly complex system within the U.S. is not enough.
The complexity across international borders also needs to be tackled. It was 
addressed as the North-South issue in many of the workshop discussions 
and background presentations. Henry Shands, Merrigan, Solleiro and others 
discussed this in relation to the Biodiversity Convention and other frameworks. 
Clearly, genetic resources from around the world are going to be crucial to 
future progress in agricultural biotechnology. But how should farmers’ rights 
be handled? Shands pointed out that, in the convention, parties are to endeavor 
to create conditions to facilitate access to genetic resources through: mutually 
agreed upon terms, prior informed consent, and sharing of benefits in a way 
that is clear up front. Those are not bad principles to live by in a variety of 
situations. If those criteria are reduced to practical human terms, it may 
actually be possible to make things work.
Solleiro also made an important distinction by noting that free access does 
not necessarily mean “free of cost” or “free of charge.” Equitable compensation 
issues are related to access issues. He offered a challenging question: “How do 
you translate moral recognition into an economic reward?”
Recommendations were presented regarding access in some equitable form: 
access to genes, to technology, to information; access for researchers, university, 
industry, government, farmers and consumers, the ultimate beneficiaries of 
products. Many recommendations on something like a research exemption 
were presented, as were recommendations on education so that people have 
a voice in decision-making with input into research agendas and a role in 
shaping policy. Again, this all comes back to the theme of benefiting the public 
good. There was also a strong recommendation to work with and empower 
Third World farmers and indigenous peoples and countries to recapture some 
equitable compensation for their genetic material.
A Few  Thoughts
Now that I have given a quick summary, 1 would like to offer a few thoughts 
that synthesize a little bit and leave you with a couple of challenges. Why do 
we care about genes and ownership and access and discovery? 1 think the 
answer is that at some level we are thinking about the public good. What are 
our public goals? Growth of knowledge, economic development, and a variety 
of benefits to a variety of publics. It seems to me that to achieve those goals, we 
are going to need a thriving interrelationship among discovery, ownership and 
access. We are going to have to optimize each, and they will be optimized more 
completely if each works well with the others. You can look at discovery as the 
engine of innovation, though I am a little worried that we are using up our fuel 
of past intellectual capital. The institutions that tend to drive discoveries are 
under pressure to take ownership, to deal with technology transfer offices and 
to bring in money. But they are also under pressure to provide easier access to 
what they discover; many are land-grant institutions with a traditional mission
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of serving the public. There are some interesting, competing pressures in the 
discovery process.
Ownership drives commercialization. I think many people would argue that 
without ownership there is no incentive for companies to make products that 
will ultimately benefit society. Can we help self-interest become enlightened 
self-interest?
If discovery is the engine and ownership drives the engine, then access 
may be like public transit, with ideals of democracy, efficiency and equitability. 
Obviously, access is necessary for discovery; discovery is necessary for owner-
ship and for access; and ownership is probably necessary in a capitalist system 
for the public’s access to products. We are going to need healthy discovery and 
equitable access, yet the tricky part is the conjunction of ownership and access. 
Where do you benefit access at the cost of ownership and vice versa? How do 
you achieve that balance? As Merrigan brought up at the beginning, it is often 
a good idea to question even our fundamental premises. Do we need the current 
intellectual property system? Do we need a new paradigm? We had recommen-
dations that NABC or others re-evaluate intellectual property rights related 
to agricultural biotechnology in order to make sure that we are moving towards 
the public good, and we asked many specific questions on patent scope and 
technology transfer and so on. Maybe it is useful to look at developing coun-
tries that do not have our overall system in place. I talked to someone at the 
National Academy of Sciences who worked with Pakistan to help that country 
put a technology transfer system into place, moving through various stages 
as a country that had not had intellectual property protection in the past. 
Looking at a country without our system is an opportunity to take a fresh 
look at why or how we do things. As we work with other countries, we can 
gain new perspectives on the possibilities.
One aspect of a fundamentally new paradigm, and nobody mentioned this 
that 1 heard, are the religious groups that are coalescing, to some degree or 
another, against the patenting of human and animal genes as described in a 
New York Times article in mid-May, 1995. I talked with Paul Thompson, an 
ethicist from Texas A&M University, a NABC member institution, who has 
talked with people involved who actually reflect a wide variety of motivations. 
One religious group may be against patenting human and animal genes for 
one reason, perhaps views of appropriate scope of laws of nature, while another 
group may be against it from a fundamentalist point of view. Yet, all these 
religious bodies are coming together, not for famine or war, but for biotech-
nology and patenting issues. In Europe, there are questions about patenting 
body parts and whether or not that includes DNA sequences in genes. This 
social and ethical dimension, which ties into education and the importance 
of listening to a variety of points of view, really needs to be part of the 
discussion, or part of our paradigm. There are some real challenges here.
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One clear theme that came out all though the talks is that change is happen-
ing. The role of land-grant universities and other institutions is changing and 
will continue to change. The Kellogg Foundation has funded a series of 12 
projects to: help land-grant universities talk to their constituencies; find out 
what these stakeholders want the world to be like in 2020; and figure out how 
the universities need to change fundamentally as institutions to help their 
constituencies reach that “vision.” Since the world is changing and the role 
of land-grant universities and other institutions is going to change anyway, 
do we want to float along with it or do we want to help shape the change?
That is a central challenge facing us in regard to the topic of this meeting.
New  Partnerships
One approach to addressing this challenge is to think about forming new 
partnerships. We have looked at the different roles of the private and public 
sectors. Maybe we can put partnerships together in new ways. That will mean 
change, issues, stress and complexity, but just maybe it is worth working 
through that. We have heard that the picture is not bright for research funding. 
That there is not a sugar daddy of federal funding out there waiting for us.
We will need to get all the leverage we can and figure out how each player 
can complement what the other is doing. Yet in building partnerships, we have 
to be careful about some things such as long-term research. 1 was talking with 
Dick Flavell earlier, and we discussed the fact that many times when partner-
ships are formed they are formed for some specific purpose, and that specific 
purpose is likely to be short-term. This is often true of the standard university/ 
industry contract. We may need to form special partnerships with some mutual 
education paying specific attention to long-term research and exploration.
John Kinsman, a Wisconsin farmer, told us that we need “constructive 
cooperation” rather than “deadly competition,” and I think that is true on 
many different levels. We have instructive examples of partnership building 
to consider. Merck has facilitated university, government and industry people 
working together to set up a database of human cDNA sequence fragments.
That is one example. While it is not something to slavishly copy at all times, 
it is an example of people getting together to grapple with some of these issues. 
In Europe, there is a yeast sequencing center, a consortium where information 
is disseminated and shared, even though there are opportunities to patent. 
Again, this demonstrates that effective and innovative partnerships can be 
formed. We want to protect the essential, long-term effort of investigation and 
discovery we make at our institutions. We want to somehow nurture partner-
ships and “mutual responsibilities,” as was said in one of the workshops. The 
concept of mutual responsibilities among universities, industry and government 
to maintain vision and mission provides a useful framework for action, 1 believe.
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The  Challenge
As a group, we have generated a good many recommendations. I hope that we 
will think about them, that we will engage others in conversation about them, 
and maybe even that we will pursue some of those action steps. I suspect that 
there is no one solution, no one thing that needs doing. I am going back to 
Flavell’s launching of the meeting when he talked about how, as the head of 
an institute, he plays as many threads as he can to try to make sure the public 
benefits. Sometimes that means handing intellectual property out for free, 
sometimes it means non-exclusive licenses, and sometimes it means exclusive 
licenses. Pursuing several different possibilities, as appropriate, can maximize 
the chance of success. More broadly, I think we are going to have to pursue 
several approaches as we work our way through intellectual property rights 
and genes, and discovery, ownership and access issues, looking for ways in 
which agricultural biotechnology can be of benefit to the public. The task 
of identifying appropriate approaches to addressing our challenges is helped 
immensely by the dialogue we have enjoyed throughout this meeting as people 
with different perspectives have come together, wrestled with tough issues and 
worked to come up with implementable action steps.
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The workshop began with each cochair summarizing the issues that, in his or 
her view, merited workshop attention. Jim Womack, an animal geneticist at 
Texas A&M, spoke first, and his remarks focused on three areas of concern. 
First, Womack reflected on plenary speaker Ron Sederoff’s presentation and 
asked workshop participants to consider whether certain proprietary rights 
and patenting arrangements serve to discourage basic research at land-grant 
universities. Second, Womack questioned the value of patenting small DNA 
sequences, such as expressed sequence tags (ESTs), when we have little to no 
idea of how such sequences function. Do these kinds of “discoveries” truly pass 
the utility test of patent law, Womack challenged, and do they hinder future 
research endeavors? Finally, Womack argued that we may be rewarding fairly 
mundane research with patents, and in doing so, discouraging longer-term 
innovative work.
Steve Baenziger, a small grains breeder at the University of Nebraska, focused 
on three critical issues. First, Baenziger raised concerns about the effective 
length of patents. If a germplasm line is patented, or worse, patent-pending, the 
patentee can prohibit other researchers from using that line in any crosses that 
would lead to commercial development for 17 years. As it takes 12 years to 
develop a variety from the time the cross is made, functionally no products 
from other breeding efforts would be available for 29 years. Conversely, if 
the patentee receives his patent before he has the commercial product to sell, 
the development time counts against the patent duration. Second, Baenziger
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questioned the patent notification process. There is a time lag between the 
time the patent is published and when it is filed. If a researcher uses knowledge 
that is not “patented” in this intervening period, only to find out later that it 
is patented, he or she cannot make a commercial product without the patentee’s 
approval even though he or she was working in good faith. Baenziger cited the 
silicon fiber transformation technology as an example of this problem. Finally 
Baenziger discussed the effect of patents and other intellectual property rights 
(1PR) on germplasm exchange. He stressed the freedom to operate. He pointed 
out the irony of the current system, arguing that if he releases a line and does 
not protect it, someone else can protect a derivative which effectively may 
prevent him from using the original line. The compounding aspect of this issue 
is the North-South relations where his germplasm donors may not understand 
his need to file “defensive” patents.
Presenting her “top 10” list of problems for workshop deliberation, Kathleen 
Merrigan, a policy analyst with the Henry A. Wallace Institute for Alternative 
Agriculture, noted that the first four problems on her list were not specific to 
patents but exaggerated by them. Those problems are:
1. Accelerating Bt (Bacillus thuringiensis) resistance;
2. Excessive industry influence on university research agendas;
3. Lack of public accountability in the land-grant system due to failure to 
enact strong conflict of interest and public disclosure guidelines; and
4. Uneven regulatory controls.
The remaining six problems are, Merrigan claimed, outgrowths of the current 
patent system, and she presented them in the form of questions:
5. Are patents akin to R&D taxes in that they simply raise the cost of 
research overall?
6. Are some patents too broad (e.g., species-wide claims) or inappropriate 
(e.g., altering one amino acid only) and ultimately hinder research?
7. Should we worry that defensive patents are having an adverse impact 
on science?
8. How do we reasonably recognize and reward the germplasm contribu-
tions of the South and of farmers?
9. Do we need to formalize a research exemption under utility patent law 
akin to what exists under the Plant Variety Protection Act? and
10. Should universities patent or should we design a new system that puts 
land-grant university discoveries into the public trust?
Focusing on four specific areas, Bill Crosby, from the National Research 
Council in Saskatoon, Saskatchewan, echoed many of the concerns raised by 
the other speakers. First, he discussed the lack of a “fence” between “R” and 
“D” funding and the role patents can play in fusing these together. Second, he
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urged workshop participants to consider innovative arrangements to maintain 
critical scientific information in the public domain. To illustrate, Crosby cited 
the British consortium effort to unravel the yeast genome, now 50 percent 
complete, and its commitment to keep all information in public hands. Crosby 
challenged U.S. scientists to do the same with the Arabidopsis genome and 
similar undertakings. Third, Crosby talked about problems of herbicide 
resistance and how patents drive universities to focus research on herbicide 
resistance at the expense of basic weed science because patents and other 
financial awards dictate the agenda. Finally, Crosby described the incremental 
nature of most discoveries, and asked workshop participants to consider how we 
go about compensating inventors for contributions made to a “discovery” that 
precedes the patent award. He cited the Calgene Flavr Savr™ tomato arrange-
ment with growers as a way a company can, in a small way, compensate farmers 
for their development of characteristics that give birth to patented genes.
Priority  Issues
After listening to the speakers, workshop participants divided into four 
subgroups and began the process of identifying key issues. At the close of the 
first day, four issues emerged as top concerns across all subgroups: university 
agenda-setting, research exemption, patent scope, and North-South relations. 
The following day each subgroup identified possible recommendations to 
propose to the entire workshop. A number of recommendations identified by 
individual workgroups achieved consensus during the final collective Research 
Policy workshop session and were presented to meeting participants as final 
NABC recommendations. Overall, workshop participants discussed the need for 
a more aggressive role for NABC and recommended that workshop reports be 
tied with action plans.
University  Agenda -Setting
By large measure, the concern that dominated discussion across subgroups was 
whether public university research agendas are unduly influenced by industry. 
Researchers commented at length on the problems created by the decline in 
public funding for research and agreed that many problems would be solved by 
a larger public investment. However, participants acknowledged that the likeli-
hood of increased public spending on research is low. In fact, participants noted 
with alarm that it may be difficult to maintain support for current budget levels.
Faced with that reality, participants concurred that it was appropriate and 
necessary for industry to fund research at public universities. Some participants 
argued that in an imaginary era of unlimited public funding, partnerships with 
industry would still make sense and be necessary for efficient technology 
transfer. At the same time, many participants shared personal stories illustrating 
the pressure placed on researchers to seek industry dollars to keep laboratories
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afloat and testified to the disproportionate influence industry has on the 
research agenda. After considerable debate, participants agreed that there is 
a need to maintain some balance between public sector and industry control 
over research agendas to ensure the kind of freedom of inquiry essential for 
scientific advancement. But, this conclusion led to a host of questions. Where 
do we draw the line on industry investment and participation? Are hiring 
decisions influenced by the ability of researchers to attract private sector 
support and, if so, is this problematic? Are patents necessary to get university 
research off the shelf and into useful form? In pursuit of patent relationships 
with industry, are universities making a profit or simply recovering costs? Do 
deans have the power to control the research agenda if they wanted to? Should 
controls be instituted that limit the kinds and quantities of extramural funds 
that public universities can accept?
Thirteen issues and possible recommendations were identified and debated 
as ways to address the need for balance in university agenda-setting;
1. Convene public listening sessions to publicly explore this issue in depth;
2. Focus national research institutions on fundamental research, thereby 
avoiding duplicative efforts with industry;
3. Determine a formula for an acceptable mix of industry and public source 
funding devoted to research at public universities;
4. Establish criteria for partnership relationships between industry and 
public universities;
5. Develop a NABC national biotechnology expertise registry and referral 
station;
6. Set aside an unencumbered pot of money for curiosity-driven research;
7. Require matching fund arrangements between industry and public sector 
dollars;
8. Solicit industry funds to a national account that becomes a “third party” 
distributor of resources thus breaking the direct “purchasing power” of 
industry at universities;
9. Establish a relationship between universities and companies that puts 
the profits back into research;
10. Limit the conditions in research contractual agreements that now 
constrain research, and develop a model NABC contract;
11. Adhere to strong conflict of interest guidelines;
12. Ensure sufficient public funding for research; and
13. Insulate hiring decisions from industry sponsorships.
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Recommendations
Workshop participants reached consensus on three recommendations:
• NABC should convene a forum to establish the public research agenda 
for agricultural biotechnology and identify high priority research tasks 
requiring attention.
• NABC should compile a repository of biotechnology experts and serve as 
a referral agency to outside organizations.
• NABC should survey its membership on the relative mix of industry- and 
public sector-sponsored biotechnology research at land-grant universities 
to provide baseline data to help inform the debate.
Research  Exemption
Early in the discussion, it became clear that many researchers lack an 
understanding of patent law and operate under the misconception that an 
overall research exemption exits. Under the Plant Variety Protection Act, an 
exemption is granted to researchers to allow them free use of plant materials 
that have been issued a plant variety certificate. However, no such exemption 
exists in the Plant Patent Act, nor more importantly, in utility patent law under 
which most biotechnology inventions are protected. Several researchers shared 
stories of ad hoc arrangements with industry that allowed them free access to 
patented materials. Other researchers described blatant patent infringements, 
citing the analogy of resource-poor students photocopying copyrighted books 
while university officials cast blind eyes to this regular practice. Without 
exception, researchers expressed relief and gratitude that industry has not fully 
enforced its patent rights because to do so would seriously retard science. As 
well, certain universities have not enforced patents fully. A well-known example 
of this is the lax enforcement by Stanford University of the Cohen-Boyer patent 
on recombinant DNA technology that would, if enforced, require all universities 
to pay $10,000 to Stanford to use this basic process. Many researchers called for 
statutory amendment to formalize special access by university scientists to 
inventions, not wanting to leave such arrangements to good will. Looking into 
the future, many predicted that exchange problems will emerge between public 
universities now that an increasing number of schools, as well as industry, are 
seeking patents to supplement revenue.
A “two-tiered” system in the UK was discussed as a possible model for the 
U.S. to consider. In the UK, the government grants patents to industry but at 
the same time negotiates a reasonable price with patent awardees that must 
be extended to all public sector researchers for patented material. This and 
other novel arrangements were discussed, and several important questions were 
raised. How do public research institutions share profits with industry? Are 
we entering an era where universities compete with industry? Since everyone
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agreed that it is unreasonable for a company to charge 10,000 times the cost of 
producing a patented invention as in the example cited by Sederoff, participants 
then asked how acceptable profit margins are determined? If universities are 
provided special access, will such “deals” pass on added industry costs to the 
guy on the street? In patenting inventions, are universities making a profit 
or simply recovering costs? Should a distinction be made between items 
researchers need over and over again and products that are a onetime purchase? 
Are price controls preferable to and more realistic than patent restrictions or 
patent elimination? How could price controls be negotiated?
Six issues and possible recommendations were identified and debated as 
possible ways to address the lack of an overall research exemption in patent law.
1. Seek statutory authority to lock in a research exemption;
2. Provide university researchers with a “whole hog” exemption in ex-
change for universities’ agreement not to pursue patents independently;
3. Provide educational institutions’ exemptions from process patents;
4. Establish price controls with NABC members working together to 
enhance the collective’s purchasing and negotiating power;
5. Expand adoption of the Merck model (country sells all genetic rights to 
a private company in exchange for set fee and percentage of any profits 
made); and
6. Develop model materials transfer arrangements for use by the NABC 
members.
Recommendations
Two consensus recommendations emerged from discussion of the workshop 
as a whole:
• NABC should undertake an educational program aimed at clarification 
of the experimental use exemption in patent law.
• Universities and government agencies should be granted a research 
exemption as not-for-profit organizations in order to allow such groups 
to use patented technology in research for noncommercial purposes.
A possible mechanism for such an arrangement would be the granting 
of a royalty free license to use patented inventions.
Patent  Scope
Little time was spent discussing the issue of patent scope, since there was 
immediate agreement that recent patent awards have been far too broad. 
Researchers cited the Agracetus patent on transgenic cotton and the 
W. R. Grace & Co. application for a patent on transgenic soybeans among 
the examples of unreasonably broad ownership claims. There was universal 
agreement that it is necessary to return to the original intent of utility in 
patent law so that in the future patents will not be awarded for “pieces” of
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information that fail to equal a whole invention. Researchers cited the Ventor/ 
NIH human genome patent and sequencing award as an example where a 
patent was awarded without adequate demonstration of utility. Researchers 
concluded that progress in biotechnology will be threatened if the trend in 
awarding broad patents continues.
Four potential recommendations were identified and debated as ways to 
narrow patent scope:
1. Return to strong and demonstrated utility requirements for patent 
awards;
2. Disallow patent awards on sequences;
3. Disallow species-wide patent awards; and
4. Seek independent funding to review NABC member-held patents and 
their impact on innovation.
Recommendations
The group achieved consensus on the two following recommendations:
• NABC should lead a public discussion on patent scope, recommend 
reasonable limits, and build consensus that patents should be narrow 
in scope.
• Strong utility requirements must be achieved before patents are granted.
North -South  Relations
Maps of the world’s germplasm show many genetic resources are concentrated 
in developing countries near the equator. Participants discussed the North- 
South divide where developed countries in the North recognize intellectual 
property rights while developing countries in the South do not. The differing 
stages of development and concepts of ownership led participants to ask several 
questions. Is it important to maintain access to germplasm for all researchers 
around the world, and if so, how can this be accomplished? Is there reason to 
side with southern countries that prefer plant breeder rights over patents?
How far do you go back in recognizing and rewarding germplasm innovation? 
Should the dictates of relationships between the North and South be left to 
the discretion of individual researchers or determined at the university or 
government level? Since many current exchange arrangements have developed 
at the South’s urging, is the onus truly on the North to bring up equity issues?
Many participants concurred with plenary speaker, Henry Shands, that the 
U.S. has contributed a great deal back to the South in its efforts to preserve and 
repatriate germplasm around the world. Although germplasm exchange is not a 
one-way relationship, the U.S. is not recognized for its contributions. Other 
participants felt that looking at this issue as a “North-South” divide was too 
simplistic and that, at its heart, it really is an issue about how society should 
recognize and value the contributions of indigenous people to germplasm 
improvement.
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Six recommendations were suggested and debated as ways to improve 
relations between developed and developing countries.
1. Develop institutional policies on fair exchange to help ensure equal 
trades by NABC members;
2. Apply the concept of “restricted use” in a way that would allow the 
South to use patented inventions at no/low cost but with restrictions;
3. Encourage the South to organize themselves on germplasm;
4. Educate Southern leaders on the extent of the U.S. contribution to 
germplasm preservation;
5. Develop a NABC paper that compiles experiences of the NABC members 
on North-South relations synthesizing these experiences and recom-
mending a model of exchange for land grant universities to use; and
6. At NABC 8, include speakers from developing countries to further 
the dialogue.
Recommendations
The workshop agreed that:
• NABC should compile and synthesize the experiences, good and had,
of NABC members on exchanges of information and germplasm between 
universities in developed countries and universities in underdeveloped 
countries. Based on this information, NABC should develop a position 
paper on the principles and procedures of fair exchange.
• NABC, in partnership with farmers and all others involved in producing 
and utilizing agricultural products, processes and information, should 
find ways to fairly and equitably recognize contributions of land races 
and indigenous plant populations and knowledge. Such ways may 
include educational programs and pamphlets.
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The focus of this workshop was on the “competing rights” of native peoples, 
genetic explorers, researchers and commercial entities to genetic resources, i.e., 
“genes.” There is a growing recognition that native peoples have rights to genes 
that are part of their culture, just as the discoverers and developers of these 
genes in the industrial world have rights. And there is appreciation of the moral 
obligation to find means for providing equitable compensation to all who have 
justifiable claims to the genes.
The purpose of this workshop was to raise and discuss issues regarding these 
“competing rights” and to recommend improvements in policies covering these 
competing rights in order to maximize social benefit — with the understanding 
that definitions of “benefit” differ widely among individuals and communities 
and will have to be negotiated between parties who are treated as equals.
The first workshop session had about 30 participants, including the four 
co-chairs and the facilitator. Each cochair was introduced and then presented 
a brief description of his perspective on the issue of competing rights. The 
participants were then placed into one of four subgroups, each led by one 
of the co-chairs, and the identification of issues began. The resulting issues/ 
questions/comments/ideas are listed under three categories entitled Ownership, 
Access and NABC Workshop Process and Related Issues.
Issues
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Ownership
1. The Intellectual Property Rights of local communities and indigenous 
farmers should be considered on an equal basis with those of industrial 
countries. Decisionmakers need to be informed that there are alternative 
ideas concerning Intellectual Property Rights and about the nature of 
these ideas.
2. Industry needs to educate society on how they treat intellectual property:
Explanations should be understandable by the lay person; and
The education should be designed to increase public trust in the 
process and the owners of intellectual property.
3. The Intellectual Property Rights system currently works well — leave 
it as it is.
4. Do away with Intellectual Property Rights entirely; they no longer 
provide net social benefit. In assigning value to genes, a “farmer’s” 
investment in development of “domesticated” sources should be 
recognized in contrast to “wild” sources. But “local” knowledge 
about the use of “wild” plants and animals should be recognized 
and compensated accordingly.
5. Indigenous people need to be empowered to enforce their rights under 
biodiversity treaties both internationally and nationally. The possible 
means to assist this effort:
Public defender resources in world court, and
Easy forum for initial rights determination.
6. Does the public want to know details regarding intellectual property 
rights and issues, or simply that such rights exist and that they should 
be handled fairly?
7. Who decides what is reasonable compensation for intellectual property 
rights? We endorse the principle that compensation should be fair and 
equitable. However, we are at a loss to recommend methods to achieve 
this end other than through negotiation.
8. Place an international tax on natural product derivatives in order to 
maintain biodiversity and/or compensate owners of the genes from 
which such products are derived:
Establish and international pool to dispense compensation;
Require matching funds from the country? Industry?
National tax or check off on product areas for research, e.g., 
tax on middleperson, on consumer, but NOT on farmer; and
If there are no intellectual property rights, who will pay for 
innovation?
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9. Biotechnology must serve the interests of the majority. Who will
determine the research agenda for biotechnology and how do intellectual 
property rights affect this? Economic return is not equal to “success.” 
Alternatively, how do we measure research success? Could human 
beings, if born after gestation in a non-human species, be ownable and 
patentable? How can society provide for accountability over industry to 
solve problems that are not discovered until they reach the consumer? 
For example, the peanut allergy factor.
Access
1. Broad patents limit access to genetic material for domestic and 
international research. Therefore a panel composed of government/ 
university/industry representatives should be established to review this 
issue and recommend guidelines.
2. Reverse the trend to privatize the basic gene pool by:
Public education;
Providing long-term, guaranteed research funding wherein universities 
and NGOs [nongovernmental organizations] give up all Intellectual 
Property rights, i.e., knowledge is handled on a “free in, free out” 
basis, and a research exemption is granted to public not-for-profit 
research institutions for patented technologies;
Providing long-term funding for biodiversity preservation;
Determining how the public and private sectors can best work together 
for the common good; and
Not granting intellectual property rights in genetic resources to private, 
for-profit institutions.
3. The research exemption for patents needs to be clarified.
4. NABC should support class action challenges to patent holders who 
prevent use of materials and processes for research; and strive to change 
basis of research exemption for utility patents from “purely philosophi-
cal” to “research for nonprofit” entities through lobbying for change in 
the law.
5. NABC should hire lawyers to get some type of research exemption for 
universities. Should there be a pro bono effort to challenge patents?
6. Consolidation of ownership in the food industry, e.g., turkey production, 
presents two potential problems: First is the vulnerability to environ-
mental and biological hazards of food production systems dependent on 
a very narrow genetic base, and second are the capital requirements of 
such systems that control access to the most productive genotypes and 
reduces genetic variability within commercial populations.
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Workshop  Process  and  Related  Issues
1. There is a need to educate people on issues of biotechnology and 
bioethics, therefore NABC member institutions should establish outreach 
programs on biotechnology and associated intellectual property issues.
2. NABC should develop policies and procedures among member 
institutions for:
Materials exchange (NIH model);
Cross-licensing of intellectual property rights and management within 
the NABC group;
Information exchange; group confidentiality agreement?
Go to Congress, if necessary, for antitrust relief;
Interaction with industry groups such as American Seed Trade 
Association and North American Plant Breeders Association; and
Easing the interaction of researchers at member institutions.
3. NABC should get lawyers to advise participants at these meetings. NABC 
should be organized by specific topics, with agendas and efforts made to 
include a broader spectrum of views.
Recommendations
In subsequent workshop sessions, participants discussed the above ideas and 
attempted to distill them into four to five recommendations that might be the 
basis for action by appropriate organizations. The workshop co-chairs presented 
the following recommendations on behalf of the participants.
• There is a need to manage the basic gene pool for the common good.
There has to be cooperation between the private sector and the public 
sector to work for the common good. Therefore it is the recommendation 
of this workshop that the public sector increase efforts to determine and 
set long term policy with broad constituency involvement, e.g., farmers, 
local government, universities, consumer groups, NGO’s and industry.
The private sector should develop products in an environment compatible 
with genetic preservation and access.
For the common good to be served, policies and procedures dealing with the 
intellectual property rights of all stakeholders must be established. To assure 
acceptance of these policies and procedures, all stakeholders must be involved 
in establishing and implementing them.
• There should be formal recognition by potential users of biological 
resources of rights to control over and compensation for use of biological 
resources not only by individuals and nation states but also by local 
communities, cultural groups and regional groups.
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• At forums such as the Fourth International Technical Conference on 
Plant Genetic Resources in Germany in 1996, and at the next meeting 
of the Conference of Parties to the Convention on Biological Diversity 
November, 1995 in Indonesia, there should be encouragement of equitable 
and enduring agreement among those with rights in biological resources 
and between those with rights and potential users, which should include 
education of all parties on fundamental issues and long-term funding of 
biodiversity conservation.
The issues before this NABC workshop are the subject of an intense inter-
national debate. The situation is extremely fluid and the issues that require 
resolution very real. As just one example, the control of existing worldwide 
germplasm collections, and access to them, is currently in flux.
While international and national agencies, and local communities are 
developing policies, companies and universities (gene explorers) continue 
to operate, albeit in an uncertain environment. However, they can attempt to 
identify rightful stakeholders in a gene, seek the consent of those stakeholders, 
establish reasonable value for the gene based on negotiation, and provide some 
means for compensation of all stakeholders.
While the rights of explorers, nation-states and individuals are usually 
covered by current intellectual property law in developed countries, the 
possibility of community and farmers’ rights has typically not been recognized. 
By recognizing and valuing these rights, companies and universities can begin 
the process of providing equitable and enduring compensation for all stake-
holders, not just those protected by current laws.
If the international community can formalize such community rights and 
farmers’ rights, then current policies and procedures can be modified to 
accommodate such rights rather than establishing totally new intellectual 
property laws.
If mechanisms are not in place for legal recognition of community and 
farmers’ rights and for providing appropriate compensation for such rights, 
companies and universities may be able to assign value to those rights and 
reserve funds to provide compensation at a future date when mechanisms are 
in place.
• NABC meetings should be organized to provide more background 
information and direction to participants, including availability of 
expertise in legal, social and biotechnology issues; and should actively 
recruit participation of a broader range of views. This improvement 
should lead to more useful recommendations.
Although there is value in independent identification, discussion and 
resolution of issues, much of this workshops time was devoted to educating 
participants on the current thinking regarding the issue of competing rights. In 
addition, the participants did not represent the broad range of parties with inter-
ests in this issue. The value of these recommendations is therefore diminished.
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• NABC member institutions should establish outreach programs on 
biotechnology and associated intellectual property issues.
One specific suggestion is to provide the forum for public discussion of pros 
and cons of these issues. In this way, universities can hopefully maintain 
credibility as an unbiased source of information.
A second suggestion is to target decisionmakers in local communities. Make 
them aware of current intellectual property practices and the issues related to 
these practices that are being discussed by organizations involved in mainte-
nance and use of germplasm resources.
• Clarify the “research exemption” for utility patents for use by public 
research institutions.
a. Gene sequence information (all uses),
b. Process information (e.g., the enzyme Taq polymerase as a tool for 
research),
Specifically:
c. A specific plan for action proposed by one participant, but not 
presented here as a consensus of the workshop was: universities 
should challenge the ability of patent holders to restrict research 
at universities (using patented technology), and
d. If the challenge is unsuccessful, they should lobby Congress to 
change the law to allow such research.
This topic generated much of the discussion in the workshop sessions, and 
most of the discussion after the workshop’s formal presentation. The issue is 
becoming extremely important to university researchers as they recognize that 
current patent law does not contain such a broad research exemption. The 
enforcement of patent rights against university researchers seems counter with 
the intent of the patent system to encourage disclosure of a patentable idea and 
to educate the public. There is a perception that the philosophy of companies 
is changing to be more hostile and litigious towards universities.
If patent policy is intended to make inventions available to the public and 
to provide the means to increase societies collective knowledge base, then a 
clarification, and if necessary expansion, of the scope of the existing research 
exemption is beneficial and essential.
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The stated purpose of this workshop was to consider: 1. what responses are 
needed from government to deal with new knowledge about plant, animal and 
microbial genomes; 2. how the interest and investment of the public is best 
protected; and 3. what ways government can make investments toward useful 
new knowledge about genomes. The viewpoints of federal and state government, 
governments of other countries, land-grant universities, other public universi-
ties, and federal and state agencies were to be included in the discussion.
During the first workshop session, the co-chairs introduced themselves to 
the group and provided brief descriptions of their interest and involvement in 
the roles of governments and public institutions in genome related issues. The 
co-chairs personal interests ranged from direct involvement in the discovery, 
analysis and exploitation of genes from various organisms, to roles in assessment 
of public policy and technology, to development of regulations for oversight of 
the introduction of genetically modified organisms into the environment.
Following these brief statements, the workshop participants separated into 
four subgroups that were each led by one of the co-chairs. During the next two 
workshop sessions, subgroup participants identified, clarified and prioritized 
issues of concern to the subgroup, and formulated recommendations to address 
these issues. In the final workshop session, representatives presented a sum-
mary of the issues and recommendations from each subgroup. Following these 
presentations, the workshop participants discussed all of the subgroup issues 
and recommendations. They then merged them into a set of six areas of concern 
with component issues and accompanying recommendations. The participants 
then prioritized the six areas of concern by group vote.
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Areas of Concerns
The following are summaries of the six areas of concern and the workshop 
participants’ consensus recommendations for addressing them. Areas of concern 
are presented in the priority order established by the group vote.
Need  for Biotechnology Education
Issue 1. Agricultural producers (farmers) require access to information on 
biotechnology. Extension and research personnel have a critical role in 
providing this information.
Recommendations
• Each school or college of agriculture should identify biotechnology 
specialists who can be contacted by field/county extension staff for 
information, program development and program delivery.
• NABC should work with extension leadership to include biotechnology 
awareness and education in extension education programs.
• NABC should identify and encourage development of needed educational 
materials (e.g., brochures, e-mail bulletin boards, videotapes, etc.).
• NABC should encourage testing and evaluation of commercial biotech-
nology materials and products, including cost-benefit analysis, in public 
sector institutions.
• NABC should encourage the use of input from user advisory groups to 
assist in setting applied biotechnology research priorities.
Issue 2. There is a need for increased public awareness of biotechnology issues. 
Only through education can the public be empowered to participate in debates 
on specific biotechnology issues and products. Education is needed at all levels 
— from K-12 to undergraduate curricula — to dialogue with opinion leaders. 
For the general public to make educated choices and decisions, they need a 
strong knowledge base about the technology and related issues. They need 
skills in evaluating information.
The researcher has the responsibility not only to do high quality research, 
but also to communicate clearly research results and their significance to the 
public. The researcher should serve as an educated, unbiased voice, available 
to all parties. Public institutions also have a responsibility to increase public 
awareness, and should work with professional organizations, community 
groups, farm organizations, industry and educational organizations to satisfy 
this responsibility.
One example of a forward thinking program is USDA’s Ag in the Classroom 
program. Pioneer Hi-Bred’s Living History Farm is also an example of the kind 
of educational tool that could be developed.
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Recommendations
Undergraduate education
• NABC should encourage incorporation of ability to understand and 
interpret biotechnology in undergraduate “core” curricula, with special 
attention to risk assessment, technical, ethical and socioeconomic issues.
K-12
• NABC should publish a list of educational materials on biotechnology.
• NABC should encourage state and local teacher groups to hold workshops 
on biotechnology.
• NABC should develop youth education programs, using programs such 
as 4-H as a means of biotechnology education.
• NABC should work with vocational agriculture teachers and support 
efforts to incorporate biotechnology training in vocational agriculture 
curricula.
Opinion leaders/public
• Scientists should appreciate the importance of and receive training in 
media relations.
• NABC should encourage TV programming (Discovery, NOVA, etc.) and 
other forms of mass media-based education to provide information to 
the public on biotechnology.
• Through its member institutions, NABC should encourage workshops, 
conferences and other public forums designed to include the broadest 
range possible of constituent groups in an on-going dialogue on 
biotechnology issues.
General
• NABC should involve educators in programs such as this meeting and 
provide specific, more targeted workshops for teachers to develop 
educational materials.
Issue 3. The increasing role of intellectual property rights in academic research
has had a substantial impact on graduate students and the research environ-
ment, and should thus be addressed in graduate education.
Recommendations
• Graduate and undergraduate curricula should include specific training 
in intellectual property rights and issues.
• NABC institutions should develop a clear policy describing the rights and 
responsibilities of graduate students regarding intellectual property rights.
• NABC should act as a catalyst to develop a curriculum addressing 
intellectual property rights and ethical issues.
• NABC should act as a clearinghouse for educational programs and 
institutional policies on intellectual property rights.
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Access to Intellectual Propert  from Genome Analysis and Other Aspects of Agricultural Biotechnology
Current intellectual property rights laws and policies, and the increasing 
reliance of researchers at academic institutions on private sector sources of 
research support: restrict public access to genetic materials, technologies and 
information; limit free market competition; reduce research opportunities and 
innovation; limit the knowledge base; and restrict educational opportunities.
Recommendations
• Policy for release of intellectual property by public institutions should
be based on a mandate to promote the public good rather than motivation 
to increase institutional financial resources.
• Public advisory groups should have input into setting policy for release 
of intellectual property by public institutions.
• Public policy should be devised to maintain broad access to tools of 
biotechnology (germplasm, genes, methods) developed at public 
institutions.
• Public law should provide a more liberal research exemption on 
patented intellectual property.
• The courts should apply anti-trust laws to ensure competition in 
the biotechnology industry.
• The term of ownership of patented intellectual property should be 
re-examined with the goal of balancing economic returns to investment 
versus opening the knowledge for future productivity and innovation.
• While there was not unanimous support for the recommendation, many 
workshop participants felt that the Patent and Trademark Office should 
issue utility patents only on the final product (plant genotype), rather 
than individual components or processes (e.g., genes or transformation 
methods).
Need  to Identify and Involve Stakeholders in  Defining the Public Good
There is a need to identify and involve stakeholders in defining the “public 
good” with respect to intellectual property rights, and in setting agendas and 
policies for public institutions.
Recommendations
• NABC, in collaboration with land-grant and other universities, and 
organizations such as CAST (Council for Agricultural Science and 
Technology), should sponsor a national panel of stakeholders in 
agricultural biotechnology (farmers, consumers, environmental groups, 
government, seed trade associations, etc.) to define the “public good;”
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assess the effects of intellectual property rights on technology transfer 
and utilization; and issue a report.
• NABC should encourage greater participation of legislators and other 
government officials in NABC annual meetings.
• For public input to have impact, the public institutions should seriously 
listen to comments and be held accountable to public advisory groups.
• Appropriate research roles for the government and public institutions 
include enhancing the use of biotechnology in minor crops to promote 
diversification for family farmers, promoting new and innovative uses 
of agricultural commodities through biotechnology, and promoting 
environmental responsibility in the use of agricultural biotechnology 
products. These roles can be implemented only if public funding for 
agricultural biotechnology research is increased.
Research Incentives
The shift from public to private funding is influencing the direction of research 
programs. Support is still needed for quality research and outreach with the 
public good in mind, regardless of short-term potential for commercialization. 
The incentives for the researcher need to be considered as the funding structure 
and the research products change.
Recommendation
• There should be motivation provided for fundamental and applied 
research, for commercialization of results from research and for exchange 
of information with other researchers, teachers and extension faculty.
Reinvestment of Profits from Publicly Funded Research
Publicly funded research generates valuable intellectual property which, in 
turn, may generate income to public institutions.
Recommendation
• Distribution of royalties and license fees from publicly funded research 
should be returned to the institution/unit that developed the intellectual 
property, to be reinvested in research.
Research Regulation and Safety
There is a need for appropriate balance between caution, innovation and 
commercial development in the regulation and the release of new products 
from biotechnology.
Recommendation
• Products posing different levels of risk should be treated with different 
levels of stringency in oversight. Care in regulation is of special concern 
regarding environmental release of genetically modified organisms with 
the ability to propagate in the wild.
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Recent Progress in Gene Isolation and 
Gene Mapping: Implications for 
Agricultural Biotechnology
Richard  B. Flavell
John Innes Centre 
Norwich Research Park 
Norwich, UK
The improvement of plants and animals for specific purposes has been at 
the heart of economic prosperity and stability of societies throughout history.
It remains so today for all societies, although the economic importance of 
domesticated crops and animals differs widely between countries. The basis 
of improving organisms for specific purposes is changing combinations of 
genes. It always has been that way and always will be, because the properties 
and performance of one individual of a species versus another, in a given 
environment, is closely related to the genetic differences between them. 
“Classical’’ plant and animal breeders have achieved major improvements 
by selecting parents, making crosses and selecting progeny that serve human 
beings much better than wild strains in domesticated agriculture. However, 
relatively few species have been subjected to intense artificial selection. Many 
improvements have been made by the incorporation of a few genes, and 
sometimes a relatively rare version of a single gene, into already successful plant 
cultivars. Most advances have resulted from recombining versions of many 
genes into new and better combinations.
In spite of substantial progress achieved by breeders in the past, our crops 
and animals still do not serve us optimally because the right genes and gene 
combinations have not been found. Furthermore, our needs and rural, economic 
and political environments keep changing. Preferences for land usage and 
local demands for food, fiber and feed also rarely remain constant. Thus, the 
objectives for breeders keep changing and changes are expected to continue.
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Our crop plants and forests regularly suffer in yield and quality due to 
environmental stresses of flooding, drought, heat and cold. They also suffer 
from pests and diseases, sometimes to dramatic extents. Often, yields are 
sustainable only with inputs of artificial fertilizer, fungicides and insecticides 
that may not always be available or are considered undesirable because of their 
perceived effects on the environment or on human health. There is concern 
over undesirable linkages between human health and possible “toxins” in food. 
Furthermore, improvements in appearance of food, taste, cooking properties 
and other quality traits are continually being demanded. Improved plants and 
trees as raw materials for industrial processes are also needed around the world.
Improvements in all these vital characteristics can be made by utilizing genes 
in new ways and in new combinations. 1 would maintain it is a very high 
priority to continue to do so. Societies that fail to adapt crops and animals to 
its needs and to changing environments will certainly fail. In this short paper 
I highlight some of the progress and issues of plant biotechnology that are 
emerging from discoveries of genes and gene mapping. Plant biotechnology 
is emphasized because this is my own area of specialty. Nevertheless, most of 
the salient conclusions are relevant to farm animal biotechnology.
Gene  Mapping
Gene mapping, that is the determination of the localization of genes in a 
genome, is now an integrated part of the process of improving the genetic 
constitution of organisms to serve humans better. We need gene mapping to:
Know how traits, simple or complex, are genetically determined;
Make selection of gene combinations more efficient in breeding programs;
Assess genetic diversity within a species at defined loci; and
Identify the role of isolated genes in specifying phenotypic traits.
We have vast stores of genes and variants of genes in the organisms of the 
earth. It is essential that we maintain good representative samples of gene 
variants and combinations of genes in seed and embryo banks. Plant breeders 
have utilized some of these genes over the centuries without, of course, 
knowing of their existence as chemical, functional units; as genes. Before the 
recent phase of molecular biology, we knew of the existence of a gene only 
when two individuals had different variants of the gene and the alternative form 
could be identified in the progeny of a sexual cross and mapped to the same 
chromosomal position. This was the genetics that Mendel opened up for us.
To map one gene locus on a chromosome a second identifiable gene is 
needed, because gene mapping involves localizing one gene with respect to 
another. Major problems in producing maps have been a shortage of genes 
easily identified from their effects on the properties of an organism and the 
shortage of reference, identifiable marker genes in the same individuals.
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Nevertheless, in a few plant species that have been the subject of much 
attention by geneticists (maize and pea) genetic maps displaying many localized 
genes have been produced. Now, thanks to the introduction of the techniques of 
molecular genetics, the opportunities are very different. First, it is not necessary 
to have variation in the effects of a gene to identify it — it can be identified by 
its chemical characteristics. Second, molecular reference markers that map all 
over the genome are readily created for many species. These detect variation in 
DNA sequences that are so abundant that it usually exists in all individuals. 
These two advances have revolutionized the making of genetic maps.
Maps of maize, soybean, wheat, rice and pine, for example, have been created 
in the last few years with many hundreds or thousands of markers. It is now 
possible to generate a comprehensive molecular marker map from scratch in 
less than one year, if plants with segregating genetic variation are available. The 
commonly used molecular markers are:
1. Short fragments of DNA (probes) that hybridize to one or only a few 
sites per genome and are used to find fragments in total DNA cleaved by 
restriction endonucleases. Variation between individuals in endonuclease 
recognition sites leads to fragments of differing length (Restriction 
Fragment Length Polymorphism, RFLP) which are easily recognized 
using the DNA probe after fractionation of the DNA fragments into 
different size classes.
2. Fragments of DNA in one or two copies per genome that terminate in 
specific short sequences that are recognized in vitro by DNA primers 
that can initiate DNA synthesis and consequently be amplified in the 
polymerase chain reaction (PCR). Variations in the primer binding 
sequences or in the length of DNA between the primer binding sites 
give rise to differences in the product of the PCR.
3. Fragments of DNA recognized by a combination of: 1. and 2. above 
(Amplified Fragment Length Polymorphism, AFLP).
Geneticists and breeders are now in a phase of rapidly expanding genetic 
maps using molecular DNA markers and genes specifying easily scorable 
properties in the phenotype or in the test tube.
Where DNA sequence or other easily scored markers are present all over 
the genome it is much easier to discover the genetic components (QTLs) of 
genetically complex traits and map their location reasonably accurately. This 
opportunity is providing geneticists and breeders with the means of locating 
very important genes that were previously unrecognizable.
IDENTIFICATION OF GENES VIA LARGE-SCALE GENOME PROJECTS
The identification of genes and their mapping is growing by the application of 
DNA sequencing techniques. Gene products are being sequenced as well as the 
genes themselves. Messenger RNAs, present wherever genes are expressed in
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cells, can readily be copied in vitro into DNA using the enzymes reverse 
transcriptase and DNA polymerase. The DNA copies can be amplified in 
bacteria, isolated and readily sequenced. Parts of such DNA copies have been 
sequenced from some 18,000 Arabidopsis and 20,000 rice genes, for example. 
Assuming plants contain 20,000 to 30,000 different sorts of genes, clearly most 
genes of these species will be characterized by sequencing in the relatively near 
future. Once the sequences are in databases, they can be compared with all 
other genes similarly sequenced in any other species. Now that the functions 
of so many genes and parts of genes are becoming known in bacteria, yeast, 
Drosophila, C. elegans and mammals, clues to the function of an unknown gene 
can be readily obtained. Thus, plant gene identification is now being aided by 
the molecular genetics of many species across the kingdoms — a very significant 
change for plant scientists.
To get a more complete understanding of a gene’s function it is useful to 
discover if it maps on a chromosome at a site known to influence a specific 
character. Also, it is desirable to insert the gene into the species to inactivate 
the resident gene and then observe the change to the organism. This is readily 
done in many plant species, even though it is relatively time consuming. 
Alternatively, if some gene sequence is known, it is possible to screen large 
populations of plants to find individuals where a roving transposable element 
has been inserted into or near the gene of interest and see what effects the 
mutation, insertion (and inactivation), has on the individual.
The application of these approaches to Arabidopsis and rice, as representatives 
of the dicot and monocot groups of plants, is providing molecular markers and 
tools for exploring all plant genomes. These tools have greatly expanded our 
knowledge of genes and ways of mapping genes and ascribing functions to them.
Another approach to identifying and mapping genes is to sequence long 
chromosomal regions, discover the genes from the sequence, scrutinize each 
sequence against other known genes, and investigate the effects of mutations 
in the gene via experimentation or by discovering if the gene co-localizes with 
known mutations. An international program has been established to sequence 
the complete Arabidopsis genome (except perhaps the repetitious telomeric 
and entromeric regions) by 2004. A major initiative to sequence the rice genome 
is being undertaken by the Japanese. These major plant genome sequencing 
projects sit alongside programs to sequence the human genome, and those of 
several bacteria, yeast and C. elegans. Thus, in a decade or so nearly all genes 
in some species will have been recognized and it will be possible to investigate 
the role of every gene in an organism. However, there will be the need to 
investigate the variation within key species, the allelic variation, because 
improvement depends upon utilizing specific alleles. These are not necessarily 
easy to construct in vitro from other alleles without knowledge of the subtle 
links between structure and function, especially for regulatory genes.
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Specific genes can be isolated from banks of clones of plant mRNAs or 
chromosomal sequences if a means of recognizing a specific gene in the banks 
is available. The bank can be screened using a DNA fragment with the same or 
similar sequence or an antibody against the gene product. Single gene 
sequences can also be amplified from mixtures of mRNA or chromosomal 
sequences by the polymerase chain reaction (PCR) using short DNA sequence 
primers known to be specific for the desired gene. Often, however, the sequence 
of the desired gene is unknown, if a gene is mapped relative to nearby known 
molecular markers, the gene can be isolated by first isolating the chromosomal 
DNA fragments containing the marker and then finding the neighboring 
fragments by sequence homology between overlapping fragments and by 
“walking” along overlapping fragments until the desired gene is reached and 
identified. This route to genes is an important reason for developing the means 
of mapping genes on chromosomes in fine detail.
Genes are also being isolated in maize, Antirrhinum, petunia and Arabidopsis 
following their inactivation by the insertion of a “jumping gene” into them. 
Purification of the jumping gene fragment from its new location leads to 
co-purification of the inactivated gene.
Mapping of Genes Based on  Conservation of  Gene Order During Evolution
Recognition of a gene in one species can help recognition of the equivalent gene 
in another species. This can be through similarity in sequence where this is 
known, but plant breeders and geneticists wish to select parents and analyze 
genetic variation where the varying sequences are unknown. Now, from recent 
knowledge of genetic maps, it is possible to predict the location of genes in one 
species from their location in related species. This is because the sequence and 
linear order of the genes along chromosomal segments are conserved during 
evolution. Thus, once the related chromosomal segments are identified (this is 
relatively easily done using conserved molecular markers) genes known on a 
segment of one species can be expected to occur in a similar location in the 
related chromosome segments of other species. This discovery is of profound 
significance for plant breeding and genetics. The genetics of related species can 
be combined into a common pool of knowledge. The genetics, physiology and 
biochemistry knowledge gained about one species can be used to aid the 
genetics and breeding of its relatives. Therefore, the knowledge of genetics, 
physiology and biochemistry of rice can be transferred to maize, wheat, etc., 
and vice versa in all combinations. This discovery will serve to unite plant 
genetics and plant geneticists whether studying a model species or a crop.
It is clear that genes, gene products and/or segments of genes are conserved 
across the kingdoms and strongly within the dicots and monocots. Thus, 
information and genes isolated from model species such as Arabidopsis or
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rice are extremely useful for isolating and mapping genes and discovering 
the function of genes in crop plants. The case for a role for research into 
model species to underpin crop improvement is now proven. This gives crop 
improvement research a very different profile and has substantial implications 
for research funding bodies.
Impact  of  Gene  Mapping  on  Agricultural  Science
We are already witnessing the impact from the incorporation of the new 
gene mapping into agricultural sciences. Plant breeding companies are now 
able to learn which chromosome segments they have selected in successful 
improvements over the past decades, which segments are associated with 
what traits, which segments are desirable, and which carry undesirable genes.
It is possible to conclude where recombination sites are localized, what genetic 
linkages are readily broken, and which are very difficult to break. The intro-
duction of known desirable segments into elite cultivars by backcrossing is 
now achieved much more rapidly and precisely using molecular diagnostics 
for the segment.
As breeding companies recognize the segments they wish to preserve or 
substitute it will be possible to define the desired genotypes by a collection 
of markers. The assembly of genotypes by molecular markers will be followed 
by computers. The whole process of breeding could be monitored by computers 
with little need for field trials, especially in the early generations of genotype 
assembly. This approach is dependent upon markers being measured rapidly, 
efficiently and cheaply. Automation of such procedures is being tackled by the 
large breeding companies, but it has yet to be proven as cost effective through-
out large breeding programs. The DNA “fingerprinting” of elite germplasm by 
molecular markers will lead to companies being able to recognize their specially 
selected gene combinations in the breeding material of other companies. Legal 
suits have already emerged from companies marketing the germplasm of others.
A big impact of mapping will be as part of the large program of discovery 
of new genes. As the determinants of key traits, including those determined 
by many genes, become known at the molecular level, new variants will be 
recognized and followed as DNA molecules, not just as chromosome segments 
in breeding programs. When specific genes from any organism are redesigned 
for use in plants and inserted into crops by transformation techniques it is 
possible to create variation in plants at will and evaluate it. The impact of 
being able to improve any attribute by adding a limitless supply of genes from 
the genome projects of species from all the kingdoms and their variants is going 
to be enormous. New ways of achieving improved plants will be devised and 
these plants will serve new customers, markets and industries. The possibilities 
will be limited by our imagination and no longer by the gene pools within the 
species. Agricultural science will become much richer.
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Social,  Economic,  Patenting  and  Ethical  Issues  Created  by  Gene  Technology
The issues created by the new gene technology are very substantial and rapidly 
evolving. The details vary considerably from crop to crop and society to society. 
Therefore, the future is difficult to predict with precision. One can be certain, 
however, for the foreseeable future the application of gene technology to crop 
improvement will be a topic for debate. Many views abound on the ethics of 
manipulating genes, but many of them are based on scientific ignorance of the 
processes involved and of the past history of crop improvement. This, however, 
does not make the views any less important. Some people insist that they wish 
to know if “foreign” genes created by a scientist have been inserted into their 
food. They, therefore, seek to have all food with additional genes labeled as 
such. This creates huge problems of how to create meaningful labels and how 
specific variants are kept separate in distribution systems, especially in com-
modity crops. Food safety is a very important issue and anything that could 
undermine food safety carries much risk in the minds of the public. Assessment 
of what is healthy and safe is very expensive and long-term. The issue is made 
more complex by specific food constituents having adverse effects on some 
individuals but not others.
Conditions on how genetically manipulated foods and non-food crops will 
be introduced in the U.S., Europe and other countries have been agreed upon. 
They are probably acceptable to most citizens, but not to all. There are sig-
nificant groups of people in certain societies that are hostile to the technology. 
These groups, aided by sections of the media, may make it difficult for super-
markets and restaurants to sell genetically engineered products. At present, 
retailers are cautious about marketing such products, requiring evidence of 
public confidence before proceeding.
A major issue that will impede international trading of genetically engineered 
products is the lack of harmony between legislation and licenses governing the 
sale of such items in different countries. There is, therefore, an urgent need for 
international agreements on legislation and licensing.
Plant improvement has always provoked product displacement and changes 
in land use, producing economic and social consequences that benefit some 
societies and/or individuals and harm others. The new genetics will no doubt 
lead to new uses of plants as raw materials that will change farming patterns. 
Production of novel oils in temperate crops may substitute for imports of 
tropical crop oils, for example. Pharmaceutical proteins could be produced in 
plants instead of bacteria or animal cells and novel starches could be produced 
in potato instead of maize.
Plant improvement will become much more complex — technically and intel-
lectually. It will, therefore, become more expensive. Plant breeding in western 
countries is likely to be increasingly dominated by the multinational companies. 
There are concerns that this may decrease choice for farmer and consumer.
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One of the major concerns of the adoption of transgenic plants is their 
potential effects on the environment. If foreign genes are spread via pollen 
into populations of wild relatives and accumulate, the natural populations 
could be genetically contaminated forever. In this area there are ethical as 
well as scientific issues. It is not easy to predict gene flow from cultivated 
crops to wild relatives or the ecological consequences of such gene flow.
The principles are not different from the present growing of highly selected 
agricultural variants in places where wild relatives also grow. However, the 
specific outcomes may differ on a case by case basis and are not easy to predict. 
Plant species have always evolved by changes in gene frequency and plant 
breeders and agriculture has inevitably influenced ecosystems dramatically.
Will the continual and ever-increasing use of novel genes designed by 
researchers provide disruption at too great a rate? Or will rates of change 
be influenced little by changing the gene pools of our crop plants?
If any environmental damages were to result from the use of novel genes who 
will be responsible? Who will pay? These legal issues are likely to influence the 
extent to which improved transgenic crops are used enthusiastically.
The use of purified genes in crop improvement is a patentable activity. This 
is making a major change in academic institutions and industry. It will have a 
major effect on how such genes and improvements are used in commerce to 
benefit the consumer. If patents are to be valuable then they need to be filed 
before publication. This means that academic institutions and industries need 
to recognize the value of a gene long before full information on their practical 
potential is available and more than 10 years before a product is likely to be 
realized. This scenario creates problems for academic institutions and industry.
Academic institutions have to worry about when and what to publish, when 
and how to interact with industry, and on what terms. Industry is challenged 
to make decisions about future technology that is unproven or not reduced to 
practice. Industries argue for exclusive licenses that can cause great problems 
for the academic research scientist because it may be necessary to work with 
other companies in the future to progress research involving the licensed 
materials. Many scientists and academics are concerned that with patenting 
of the principal sources of added-value in the cultivars of the future they will 
compromise their public-sector status and become increasingly motivated 
by monetary rewards rather than scholarship. Many inventors and academic 
institutions wish to see their discoveries benefiting a large community. It will 
be important to assess whether industries holding exclusive licenses will make 
arrangements with breeders worldwide to move advantages to many societies 
or will be very restrictive. Many people are concerned about whether patents 
will deny developing countries the advantages of biotechnology or whether 
such societies will use them avidly and risk that no legal issues of any 
consequence will result.
58 Genes for the Future: Discovery, Ownership, Access
If plants, in contrast to genes, are allowed to be patented this is likely to 
inhibit the flow of elite germplasm around the world. Free flow of germplasm 
has been very important in the history of plant improvement.
It is not possible for any individual or group to predict or control all these 
issues. Societies must monitor the issues and develop laws and case history to 
ensure that the production and exploitation of gene technology realizes its 
potential, globally, to help the health and wealth of all societies.
Concluding  Remarks
The advances in gene technology and genetic mapping are driving plant and 
animal improvement into a new era. It is an era that will be very exciting and 
productive but will also have argument, economic change and some social 
chaos. This is probably inevitable given the way genes and gene combinations 
can be recognized, redesigned and exploited as never before in the history of 
plant breeding. The industry will change, as will the role of research in public 
sector institutions underpinning the industry. There is tremendous scope for 
the new genetics to influence agricultural research — it has already begun — 
but consumer acceptability, investment needs, and laws will have a greater 
influence than ever before. The way forward is complex. But hopefully the 
needs to provide food and materials in a sustainable way will always be at the 
top of the agenda.
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Property is Nothing More than Persuasion
Kathleen A. Merrigan
Senior Analyst
Henry A. Wallace Institute for Alternative Agriculture 
Greenbelt, Maryland
I am not persuaded that the U.S. system of intellectual property rights (IPR) 
makes sense, especially as it pertains to plants. I wonder: if many people are like 
me and are not persuaded by our property rights, does the system really exist? It is a 
bit like that age-old question: if a tree falls into the wood and no one is there to 
hear it, does it make a sound?
My library includes a new (1994) but already dog-eared book, Property and 
Persuasion, by Carol Rose. Rose is fascinated by the ways “people make up and 
change their minds about property and the strategies and arguments they use in 
persuading others to do the same.” The book cover is a photograph of a rickety 
fence held up by string. Rose points out that anyone could topple the fence 
but because people are persuaded of the property right, the fence is respected 
and the property right coffered. Force and violence are signals that a property 
regime is faltering. Her conclusion is the underlying basis of property must 
be persuasion.
The  Indictment
Why am I not persuaded? I could approach the patent issue many ways and raise 
questions. But since this is a meeting with many researchers participating, most 
from public universities, let me step inside your shoes and consider three facts.
Fact: Patents influence university research agenda. University researchers are 
under pressure to supplement dwindling budgets with industry-sponsored 
projects and pursue joint university-industry IPR efforts. Nowhere is this pres-
sure more evident than in the field of weed science. Weed science departments 
receive a minimal share of university budgets since scientists are expected to 
raise their own funds from industry sources eager to “buy” university time to 
develop herbicide-tolerant crops. As a result, weed scientists have few resources 
to dedicate to nonchemical weed control research. Patent seeking can also
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lead to unintended conflict-of-interest problems. For many years 1 served as 
the principal staff person dealing with bST (recombinant bovine somatotropin) 
in the U.S. Senate. When safety questions were raised and the Government 
Accounting Office (GAO) began its inquiry, it was a struggle to find a single 
university expert who had not, at one time or another, been on the industry 
dole. By the way, do include Jane Smiley’s new novel Moo on your reading list.
A central theme is the effect of industry sponsorship on land-grant university 
research.
Fact: Overly broad patents stifle research. Most researchers argued that the 
European Union soybean and Agracetus cotton patent awards were too broad. 
Researchers were also upset by the Ventor/NIH sequencing patent because of its 
lack of utility. These are just some better known examples of misapplied patent 
authority that had the potential to stifle research and development worldwide.
Fact: Patents lead to increased research costs. Patents carry high transaction 
costs and the people pocketing most of the profit are lawyers. Patents can also 
be viewed as research and development (R&D) taxes, with the oncogene mouse 
serving as a prime example. Rather than improving research conditions as 
advertised, the mice sell at such exorbitant prices that they have, in turn, raised 
the price tag of scientific inquiry throughout the system.
Since 1 am only looking at patent problems from the research vantage point, 
my indictment has merely scratched the surface of what will be an extensive 
discussion to follow. My basic point is that the U.S. IPR system has so many 
problems that I am not persuaded it is a system worth supporting. And 1 am 
not alone in this skepticism.
Problem  1: U.S. Citizens  Are  Not  Persuaded
I am a member of a tiny club of people who have sat in the patent library 
studying plant patents. How tiny you ask? I spent a summer reviewing more 
than 2,000 plant patents and only once did I come across another human being. 
I remember the day well. I was so excited — could this be a compatriot in plant 
patent inquiry? No, explained the man as he pulled a box of patents from the 
shelf, just a guy in search of a nice rose sketch to photocopy for his mom’s 
birthday card.
The public is hardly persuaded that our current system of IPR is a good one. 
Since passage of the first U.S. plant patent law more than six decades ago, the 
issue of plant IPR has received little public attention in this country. In a playful 
but instructive exchange, biotechnology watchdog Jack Doyle once said, “Nine 
out of ten people walking down the street do not even know you can patent a 
plant.” To which biotechnology gadfly Steve Witt responded, “Frankly, nine out 
of ten don’t know what a patent is!” The lack of public interest and knowledge 
about patenting and biotechnology is dark cloud hovering over researchers, 
industry and public interest groups alike.
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The legislative history of plant IPR is telling. Despite its importance, plant 
1PR issues have received no more than cursory attention from our policy-
makers. In 1930, finally responding to the pleas of Thomas Jefferson, the 
U.S. Congress passed the Plant Patent Act after little debate and by voice vote. 
In 1967, President Lyndon Johnson appointed a commission to study the entire 
patent system. Ironically, just three years after the commission concluded that 
the patent system was not the proper vehicle for plant protection, the U.S. 
Congress passed the Plant Variety Protection Act following only one hour 
of debate. In 1980, the Supreme Court ruled in Diamond v. Chakrabarty that 
patents are to be allowed on all living matter. Following this decision, the 
U.S. Department of Agriculture (USDA) commissioned a study to evaluate 
the implication of the Court’s ruling for agriculture. The study uncovered little 
relevant data and recommended that the USDA undertake additional analysis; 
work that has never been done.
Given the limited public debate, I was amazed at the fervor with which the 
Bush Administration argued for plant IPR during the Earth Summit and the 
Clinton Administration fought for interpretative statements to accompany the 
Convention on Biological Diversity. You would think that all of America was 
up in arms on the topic. However, the sad truth is that most Americans were 
oblivious to the fact that these fights took place; “our” position was defined 
by a few industry leaders. U.S. policymakers would be wise to review domestic 
laws and engender a public discussion about appropriate IPR systems before 
leaping onto the international scene to impose “our” answers on the rest of 
the world.
Problem  2: Our  Southern  Neighbors  Are  Not  Persuaded
I was asked to comment on gene mapping. Richard Flavell has done so well in 
covering the topic (see paper, page 51) that 1 would like to turn the assignment 
around and ask you to think of gene mapping in a more literal way. Politically, 
the most interesting gene map is the map of the world produced by good old 
Rand and McNally. If we plot the worlds germplasm resources on this map we 
discover that most of the world’s genetic wealth is concentrated in developing 
countries near or below the equator. This has led to what many of us refer to 
as the “North-South conflict.” The North has wealth; the South has germplasm. 
Developed countries in the North recognize IPR and push for worldwide 
adoption of such systems. Developing countries in the South reject Northern 
ways and are in search of property regimes better suited to their needs.
To avoid conflict and woo the South toward Northern IPR arrangements, 
three “lucrative deals” have been offered in exchange for access to Southern 
germplasm. I think it is important to reflect upon these deals because I have 
come to believe, with more time and information, that even popular game show 
host Monty Hall could not give them away.
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Behind door number one, we have the most popular deal — formal exchange 
between a developing country and a private company. Such a deal was struck 
between Costa Rica and Merck & Co., Inc., in 1992. Costa Rica agreed to 
provide Merck exclusive access to the country’s germplasm in exchange for 
one million dollars and royalties on commercially viable products produced 
from Costa Rican sources. Many analysts, including my colleagues at the World 
Resources Institute, hailed this as a breakthrough and have urged developing 
nations to replicate this model. To me, this is neither a good nor lasting deal. 
First, it outraged other Latin American countries who suspect that some of 
their germplasm resources are closely related, if not identical, to the germ- 
plasm found in Costa Rica. Therefore, the Merck deal may hinder the ability 
of neighboring countries to develop their own property. Second, the deal pro-
vides no assurance that traditional knowledge and resources will be preserved. 
Rather, it will likely lead to the preservation of certain resources over others, 
thereby accelerating the loss of biodiversity. Finally, it is inconceivable to me 
that a country with as many riches as Costa Rica would sell out for a measly 
one million dollars. Maybe the moral of the story is that poor countries sell 
cheap. However, I anticipate trouble in paradise if Merck makes billions of 
dollars from Costa Rican germplasm.
Behind door number two is the deal of extending “farmers’ rights” world-
wide. Farmers’ rights are the developing world’s response to our IPR. Rather 
than concede to Northern IPR demands, developing countries have devised 
a system that recognizes the contribution of farmers to the development of 
improved germplasm by allowing farmers free access to protected materials. 
This deal is a token payment for the decades of professional breeding provided 
by farmers and it interferes with the nonmarket logic for maintaining bio-
diversity among most indigenous communities. While some Southern leaders 
may now argue for farmers’ rights, convinced it is the best they can hope for, 
this deal is a cheap payoff and it fails to address fundamental equity issues.
Behind door number three is my favorite deal — a worldwide compensation 
fund. To remedy years of Northern harvesting of Southern germplasm and to 
placate any outstanding Southern ownership claims, an international fund has 
been established. Northern countries and industries are expected to contribute 
to this fund to preserve biodiversity in developing nations. I chuckle when 
I hear anyone assert that this fund will accumulate more than a few million 
dollars. Sure, industry may contribute some money, but resources are tight 
everywhere. Seed companies, for example, generally operate at a five percent 
profit margin and biotechnology companies remain long-term investments.
In Washington, Congress is cutting budgets left and right. Where will the 
money for this fund come from? The conclusion I draw is that this deal is 
nothing more than an empty promise.
It is only a matter of time before Southern leaders recognize that these deals 
are not worth the trade of their germplasm. Unless persuaded otherwise, it is
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unlikely that Southern leaders will go out of their way to enforce current deals 
that primarily benefit transnational corporations. Actually, if I was a Southern 
leader, I would argue that countries in the South should band together and 
close off borders to Northern plant prospectors. A germplasm embargo, 
modeled after the successful Ethiopian embargo on coffee, would bring the 
North back to the bargaining table and give the South more time to develop 
its own property protection strategies.
The world would be well served if the South sorted out its position on IPR 
sooner rather than later. That way we would all know where we stand. To 
encourage this, 1 suggest two actions. First, Southern nations need to hold a 
series of intensive meetings to address plant IPR issues and to develop alliances 
between Southern countries. Second, additional leadership is needed from non-
governmental organizations (NGOs) on this topic. For example, I can count on 
one hand the number of U.S.-based NGOs with sufficient expertise to engage in 
the plant IPR debate. The foundation community would provide a great service 
by funding NGO staff hires for IPR and supporting an international IPR summit 
for environmental, rural advocacy, progressive farm, and biodiversity NGOs.
Problem  3: The  Experts  Are  Not  Persuaded
I like nothing better than a good book. 1 sometimes rush through, wanting 
desperately to know how the story ends. Once in a while I am disappointed. 
Maybe you have had this experience. You read hundreds of pages anticipating 
a grand ending, but the author seems to run out of steam at the last minute, 
leaving the reader a hurried, unsatisfactory conclusion.
This experience happened to me a couple years back in reading the National 
Academy of Science (NAS) report, Global Dimensions of Intellectual Property 
Rights in Science and Technology. After years of study and almost 400 pages 
of analysis, the book “concluded” with a list of issues for future research. 
Described by the authors as a “coda” to the main body of the report, they 
raised questions at the very heart of the biodiversity struggle. For example, 
the authors wonder the extent to which IPR can have detrimental consequences 
for innovation. They also worry that few have really studied the effect of high 
levels of IPR on the economies of developing countries. The NAS study team 
suggests closer scrutiny of the non-Western styles of property protection:
The introduction of IPRs throughout the world has involved propagating as 
broadly as possible a Western cultural view of the concepts of owner-ship 
and rights. Some non-Western countries have voluntarily adopted Western-style 
IPR laws in the process of modernization. Western countries cannot necessarily 
count on a continuation of this pattern of adoption.... Other cultures and legal 
traditions, including those in Asia and throughout the Islamic world, may have 
different concepts of optimal ways to encourage creative participation in society.
These alternative cultural traditions and practices must be better understood in 
building a new global IPR paradigm.
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It seems that after all their work, even the experts at the Academy are not 
persuaded that our system is the right one. My role is to raise questions — 
to provide a counterpoint to help stimulate our discussions during the next 
two days. I begin by issuing a challenge — let us leave Friday, not with a 
handful of good questions that will be shelved or compiled in a coda, but 
with action plans!
Let me give you an example of a specific action plan that appeals to me. 
While the emerging common property resource literature has exposed some 
diversity in existing property management schemes, I think that it is only a 
small beginning of the needed scholastic effort. My action plan would be to 
set up a Global IPR Dialogue. Foundations, universities, the NAS and other 
nonpartisan scientific institutions would pool resources to organize and fund a 
dialogue among scholars. The Dialogue would bring together 100 “Fellows” — 
individuals who are creative idea-generators. Geographic diversity is important 
and half of the Fellows would hail from developing countries to enrich the 
Dialogue with nonwestern IPR perspectives. The Dialogue would last three 
years, with much of it taking place over the Internet. However, Fellows would 
meet in six seminars to provide an opportunity for group exchange. Selected 
resource people from a variety of disciplines and professions would participate. 
The location of each seminar would be carefully chosen to fit the issues 
discussed. For example, resource conservation issues might be considered in 
Brazil where the riches of the Amazon are under dispute. Western patent law 
might be discussed in Washington, D.C., where direct access to the U.S. patent 
and agricultural libraries is available. Fellows would receive general research 
support during the three-year period and travel expenses to attend Dialogue 
seminars. In exchange for this support, Fellows would be responsible for 
rigorous reading and writing assignments, public presentations in their home 
countries, team-research projects with other Fellows, and publication of a final 
paper in an edited volume produced and distributed by the Dialogue.
At the very least the Dialogue would help bring attention to IPR issues, 
expose non-Western systems of IPR to greater scrutiny, and encourage more 
scholars to enter the field. At best, the Dialogue would begin to answer the 
questions raised by the NAS coda.
That is my attempt at an action plan. What is yours?
Confronting  QWERTY
To conclude my recommendations for summer reading, I suggest Paul Krugman’s 
new book — Peddling Prosperity: Economic Sense and Nonsense in the Age of 
Diminished Expectations. Krugman reflects back to a paper by Paul David 
and Brian Arther of Stanford in which they introduce the idea of QWERTY. 
Krugman describes QWERTY as “the economics of getting locked in” and 
defines it as aversion to change. It sounds like an odd word, but we have all 
stared at QWERTY a thousand times . . . QWERTY spells out the letters on
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the top left row of the typewriter keyboard. When the typewriter was first 
developed, the letters were arranged deliberately to slow people’s typing to 
avoid jamming the machine. Today however, machines can go much faster 
and yet people refuse to throw out the old keyboard and learn better ways.
1 conclude with QWERTY because I think we are stuck with an 1PR system 
that does not meet today’s needs. We need to radically change how we think 
about property. Until we are all persuaded that we have it right, our system is 
precarious at best.
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Intellectual property rights (IPR) in biotechnology are having a dramatic nega-
tive effect on the progress of nonprofit research. Although patent policy and 
law intend to facilitate research progress, the current practice has led to many 
barriers in access and use of genetic materials and DNA technology. Such bar-
riers restrict the free exchange of information and threaten the health of our 
nation’s scientific enterprise. Policies related to patents and licensing are increas-
ing the cost of research at a time when funds for research are being reduced.
We wish to discuss some current issues related to research in biotechnology 
carried out in academic institutions, particularly land-grant universities, and 
the rapidly changing roles of scientists in relation to intellectual property and 
industry. The rapid changes in the arena of intellectual property are more acute 
in the area of biotechnology, which is still in the early stages of development and 
where many issues are not yet well defined. Further consideration is needed of 
the costs and benefits of current patent policy and law. Problematic examples are 
discussed. Some provision (amendment or extension of law) should be made to 
foster the conduct of basic research in universities and other nonprofit research 
institutions, and to some extent provide an exemption from the law that governs 
commercial research and development.
Biotechnology  and  the  Land-Grant  Universities
Life is not simple for an academic institution engaged in biotechnology research 
today. As land-grant universities attempt to redefine their mission relative to 
society, conflicts arise over the interrelated roles of research and protection of
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intellectual property. Even as intellectual property rights are pursued more 
vigorously by universities, the heart of the research enterprise is being 
constrained by the protection of intellectual property owned by others. Industry 
can invest much more in obtaining and defending intellectual property than 
universities can. As the law stands, and as current policies are enforced, it is 
unlikely that the balance will tilt in favor of the universities.
In the last two decades, universities have redefined their approach to tech-
nology transfer. The universities have simultaneously viewed it as a channel 
for added revenue and as a vehicle for ensuring that the discoveries of the 
laboratory are transformed into goods and services beneficial to society. Aggres-
sive businesslike pursuit of protection for intellectual property generated at a 
university (which can then be licensed to a company for development) has led 
to the erosion of an apparent special status for universities as the home of ex-
clusively “philosophical” activities. With this change, university efforts actually 
receive no “research exemption” and university faculty have no special right to 
explore patented inventions or to utilize protected findings or technologies.
Constraints on the research enterprise have significant implications for the 
well-being of society. When researchers are restricted in attempts to extend our 
knowledge of the world around us, society pays a cost of lost innovation, which 
is crucial for economic development and the wellbeing of our citizens. It is of 
particular concern when the research is carried out with federal funds and the 
cost of the research is either greatly increased, or it becomes impossible to carry 
out the research at all.
The traditional relationship of scientists and their funding agencies has 
changed. Since the Bayh-Dole Act of 1980, funding agencies have allowed 
intellectual property to be owned by the institution where the research was 
conducted. Generally, universities will retain ownership of patents even if the 
majority of the funding for a specific project comes from outside sources. 
Industry-funded research at universities usually requires some specific industry 
rights to licensing that ensures some potential or expressed degree of access 
to intellectual property resulting from the research. If a company obtains 
exclusive rights to license, they can have a great deal of control over subsequent 
technology based upon the patents. In many cases, related projects conducted 
by the same scientist are derived from public funding, often confounding the 
issue of who owns what.
Issues  of  Ownership
Under appropriate conditions, the sequence of nucleotides that represents 
a gene may be patented. The patenting of genes must still satisfy criteria of 
novelty, utility and reduction to practice. Anonymous gene sequences with 
no knowledge of function are not sufficient for patent protection. It is not yet 
resolved to what extent similar sequences are covered by specific gene patents.
If a gene for a specific enzyme was patented, should that patent cover all genes
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encoding that function or only that specific sequence? Much of the variation 
between related genes for the same function could be significant and valuable. 
What if the gene was obtained from a related member of the same species that 
had a different sequence? What if the gene was from a distantly related species? 
Some principles of what constitutes “equivalence” for a particular gene remain 
to be resolved. The issue of equivalence is important because once a sequence 
of a gene of known function is made available through publication or through a 
public database. It is possible for a molecular biologist to obtain an equivalent 
gene from another individual of the same species or of a different species. The 
different species could be as distantly related as a plant and an animal.
Issues of ownership of genes have become more critical as more large-scale 
sequencing projects are carried out to identify genes from organisms for 
commercial application. Specific genes with potential application can then 
be patented which means that use of these genes could be removed from the 
public domain, and research into their potential applications could be curtailed.
It is common practice to use patents and licensing to protect some genes 
where commercial development is possible. Current procedures for obtaining 
use of licensed genes can be extremely cumbersome and expensive. In fact, 
negotiating agreements that allow universities to conduct research with genes 
owned by industry can delay research for years. Such delays are unreasonable 
when research objectives are noncommercial and are supported by federal 
funds. Similar situations arise for other DNA sequences used as promoters or 
vectors for transformation. In the past, constructs have been available with 
restrictions on distribution and potential commercial application, but without 
cost. This situation appears to be changing, and charges are being added to 
such agreements. A new promoter, highly expressed in plant cells, has recently 
been made available through a licensing agreement to individual university 
laboratories for $1500.
As individual genes have been patented, the question of patentability may be 
raised about genomic maps. The process of constructing gene maps is derived 
from genetic studies conducted before 1920, and is fundamentally unchanged, 
except for the new kinds of molecular markers and the computer software that 
greatly facilitates map construction. We know of no examples of the patenting 
of an entire genomic map. However, specific genetic markers on genomic maps 
have patent potential for specific purposes such as diagnosis. These genetic 
markers would also have utility for disease detection in humans, and in 
breeding of plants and animals. Once a specific marker is located that would 
predict resistance to a disease, for example, it would be relatively easy for a 
mapper to identify other markers that would be equivalent in their ability to 
predict resistance, but would bear no relationship to the original marker in 
sequence, only in genome location and linked to an allele of specific interest.
It remains to be resolved to what extent markers can be protected by patent, 
and whether such protection might extend to adjacent regions of the genome.
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A related issue to genomic mapping is the sequencing of entire genomes 
of specific organisms. The first entire sequence of a free living organism, the 
bacterium, Haemophilus influenzae Rd., has recently been completed. Such 
information could have industrial applications. However, the extent and utility 
of patentable information from genomic sequencing remains to be defined.
Genomic  Mapping  using  PCR
New polymerase chain reaction (PCR)-based genomic marker technology 
(discussed below) has revolutionized genetic analysis for many species of 
plants and animals. This use of PCR was unanticipated. It represented a new 
application of PCR on a very much larger scale for individual laboratories than 
had been anticipated. Licensing of PCR has dramatically increased the cost of 
genomic mapping. The costs of licensing for this type of genetic analysis raise 
the cost of each reaction from several cents to about 30 cents a reaction. A 
typical mapping experiment can require tens of thousands of reactions, and a 
large experiment may involve a million reactions. Experiments that would have 
cost hundreds of dollars for materials instead now costs many thousands due 
to the licensing strategy for PCR. These greatly increased costs result from the 
patented process of PCR, and from the unusual status of the enzyme, Taq 
polymerase, used for the PCR reactions.
Taq polymerase has an unusual status as a reagent for molecular biology 
because its purchase from an approved source confers a license to practice PCR. 
As a result of this licensing strategy, the costs have placed an unanticipated 
burden upon laboratories exploring the large scale use of PCR for genomic 
mapping and genomic sequencing.
Taq polymerase is a heat-stable DNA polymerase purified from the thermo-
philic bacterium Thermus aquaticus. A process patent on PCR and the use of 
a natural enzyme for this process, Taq polymerase, (US Patent Nos. 4,889,818 
and 5,079,352) have been licensed to the research community by the holders of 
the patents (Hoffman-La Roche Co.) through the purchase of the enzyme from 
specific suppliers (licensed by Hoffman-La Roche), and through the purchase of 
equipment and accessories from The Perkin-Elmer Corporation. The worldwide 
research community is considered to be an important market for the licensing 
of the PCR process and for the sale of the enzyme. As a result of the patenting, 
licensing and pricing strategy, the cost of the enzyme is far more expensive than 
most other widely used, easily purified enzymes of nucleic acid metabolism, 
such as restriction enzymes.
Of the hundreds of enzymes used as reagents in molecular biology, few are 
restricted through their use in a patented process. Taq polymerase cannot be 
purified legally by individual investigators for use with PCR. Scientists who 
wish to practice PCR are required to purchase the enzyme and are prohibited 
from purifying the enzyme for their own use. The purification of the enzyme 
is relatively easy and would provide the enzyme at a fraction of the current 
commercial price.
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RAPD Markers
Randomly Amplified Polymorphic DNA (RAPD) markers, developed by DuPont 
Co. scientists and almost simultaneously at the California Institute of Biological 
Research in San Diego, provided a novel DNA marker technology for genomic 
mapping in plants and animals. The method was advantageous because it could 
be applied with no prior information and could be done using small amounts of 
DNA. The method was particularly useful for species with no history of genetic 
analysis or DNA sequencing. The cost of Taq polymerase has been the major 
barrier to the application of this technology to a number of new problems, for 
example, a large site adaptation study planned for loblolly pine that would re-
quire 1.5 million PCR reactions, making the research too expensive to undertake.
Recently, a new patent has been issued to DuPont that covers the use of 
RAPD markers. DuPont has licensed exclusive rights to the use of this marker 
technique for certain species to an Australian company, ForBio Ltd., which will 
license RAPD markers to individual laboratories at a specific charge for each 
RAPD reaction. RAPD reactions also use PCR and require licensed use of Taq 
polymerase. However, ForBio and DuPont have decided not to charge fees for 
research carried out in universities or government laboratories that “has no 
commercial purpose.” This distinction deserves consideration; it could set a 
precedent for protecting freedom of inquiry.
Alternative  Marker  Technologies
The high cost of licensing both PCR and RAPD technology has stimulated 
interest in alternative methods. Several such methods are available, each with 
different advantages and disadvantages. These include microsatellites, amplified 
fragment length polymorphism (AFLP) or use of cDNA-amplified polymor-
phisms (CAPs) and others. All require PCR, except for the earlier methods of 
restriction fragment polymorphism (RFLP). RFLP methods are not well suited 
to large-scale experiments.
Unintended  Negative  Effects
For most if not all enzymes used in routine research in molecular biology, the 
cost of obtaining the enzyme from commercial sources is advantageous relative 
to the cost of producing enzyme in a research laboratory. The relative cost of 
production and the price of the product results in reasonable profit to the 
producers and savings in time to the purchasers. There is no incentive for 
infringement. The current circumstances surrounding the use and production 
of Taq polymerase are different. At a cost of a few thousand dollars, laboratories 
working on a small scale could, in short time, easily produce for their own 
research use what would cost millions of dollars through the current PCR/Taq 
polymerase licensing strategy. The ability to produce their own enzyme would 
allow some laboratories to conduct research that is essentially not affordable 
under current licensing requirements. Thus, the current environment could
Sederoff and Meagher 75
foster deliberate patent infringement to the detriment of both the patent system 
and the university research enterprise.
Advances in mapping technology based on PCR raise several issues that 
epitomize problems affecting the current national research effort and the future 
of publicly funded university-based research. There is no doubt that the 
invention of specific amplification of DNA through PCR has been one of the 
most significant new techniques in biotechnology. Current strategies of 
intellectual property protection and commercialization may impede or block 
research efforts, exacting a social cost. Proprietary constraints on the practice 
of PCR have three aspects: the practice of the invention, the specific enzyme 
used to practice the invention, and the equipment needed to practice. The 
patent holders have chosen to license the practice of PCR through the sale 
of enzyme and sale of equipment that can be used to practice PCR. In part 
because the large-scale application to mapping was unanticipated, the licensing 
strategy has had unintended negative effects on U.S. research, and related 
research worldwide.
Biotechnology arose from several decades of research based upon the free 
exchange of information and materials. Most research during these crucial 
formative years was “basic” and was supported by public funds or foundations. 
Little consideration was given to intellectual property, and new information 
was released and made available through publication or conferences. If many 
of the fundamental advances made during this time had been patented, it is 
unlikely that the field of biotechnology would have developed by this time. It 
is instructive to consider how the past 45 years of progress would have been 
constrained if each major discovery or new process was patented and licensed. 
Essentially no restrictions or licensing costs were placed on any processes or 
molecules involved in biosynthesis, in vitro synthetic processes, methods of 
purification, or products of these processes. These fundamentally important 
advances remain unconstrained today. The free exchange of information 
depended upon public funding, and a certain “culture” promoting free 
exchange in the conduct of research.
If a major shift occurs from public funding to industrial funding, and if 
current intellectual property protection strategies continue to be pursued, 
the nature of the university research enterprise related to biotechnology 
could change in dramatic ways. Industrial research is more likely to remain 
short-term in perspective and will focus upon practical applications and 
products for development rather than discoveries of general interest. Industry- 
driven research is more likely to be directed to produce patents rather than 
publications. Academic objectives of scholarly work are different from that of 
patents in purpose and standards of proof. One of the challenges to universities 
is the need to maintain the high standards of scholarship while pursuing 
patentable technology.
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What  is  the  Cost  of  Research  Not  Done ?
The value of university research lies in the addition to the knowledge base 
of our society. New information and resultant technology drive economic 
development, maintains a competitive advantage for the nation as a whole and 
leads to a better informed and more productive citizenry. If wisely applied, such 
information should provide a basis for the conservation of natural resources 
and the ability to extend a higher living standard to our citizens and others 
throughout the world. Thus, there is an assumption that the benefits of research 
have high value. Yet, the inability to quantify such benefits and to predict when, 
how, and specifically to whom the benefits accrue means that benefits may pale 
in comparison to the extremely visible and quantifiably high costs of doing 
research. However, if another nation has invested in research and as a result has 
a major technical and competitive advantage, the costs of research not done 
become large and obvious. Currently, intellectual property protection strategies 
have inadequately accounted for the value of basic research.
The success, not only of our research enterprise per se, but also of our 
improvement of quality of life, has stemmed in large part from the traditional, 
unfettered pursuit of basic knowledge that has been the hallmark of our 
universities. With the decline in public spending and the increasing focus of 
the private sector upon short-term results, we are in danger of failing to build 
the foundation for discoveries in the long term. The problem is exacerbated by 
the constraints placed upon academic researchers by current interpretations of 
intellectual property protection. When we restrict the ability of the not-for- 
profit research community to take findings and push them to new discoveries 
and when we create costs of doing research that are prohibitive, we hinder the 
innovation that has served this country well — innovation that we need more 
than ever before.
Need  for  a  Research  Exemption  for  Not-for-Profit  Research
In recent years, university professors have been surprised to find themselves 
restricted by copyright and patent laws that had not been defined or enforced in 
past decades. In practice, university researchers have often assumed that they 
could operate under a research exemption, not subject to the same constraints 
as industry, because they were supported by public funds and worked for not- 
for-profit or state-supported institutions. Recent rulings, however, have made it 
clear that these assumptions were not correct. Universities are subject to many 
of the same restrictions as any industrial organization. In contrast to the 
currently held belief of most university faculty, there is no general research 
exemption for university-based research.
Many scientists have the false perception that there is a general exemption for 
university or government-based research if it is purely philosophical in purpose. 
It is argued that universities have lost the claim to a philosophical exemption
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because they file patents, exercise patent rights, and receive fees for licensing 
and royalties. A different basis for exemption based on the sovereign rights of 
the states and their agency to enjoy immunity from patent infringement, has 
been ended by an amendment of the Copyright Act of 1990 that put the states 
on the same footing as other defendants. The federal government, however, has 
not lost these rights of sovereignty and could expand the scope of an exemp-
tion. Federal employees and recipients of federal grants could be considered 
agents of the government for such purposes, thus effectively receiving an 
exemption for government-sponsored research.
In conclusion, there is a need to modify patent policy or law in order to 
encourage basic research. The current status of the law and its interpretation is 
unnecessarily restrictive and impedes innovation and discovery. Even though 
universities will continue to play a role in discovering information that will be 
useful to industry, publicly funded basic research should still be distinguished 
from corporate research for profit. It is important that our current intellectual 
resources, the envy of the world, be fostered and maintained for future 
commercial development and for the well-being of our citizens.
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My first job after graduation was breeding tomato plants for resistance to a 
fungus disease. It was a simple program that involved the introduction of 
dominant genes for resistance, from other cultivars and from wild relatives, 
in a backcrossing program that employed several widely grown cultivars as 
recurrent parents. The first lines from this program appeared to be so promising 
that 1 sent them to some greenhouse tomato growers for small trials. The 
growers agreed that they were resistant to disease but said they were also 
resistant to yield. This taught me the important lesson — that no matter what 
new gene a crop cultivar may contain, unless its genetic background supports 
good agronomic performance it will be of no practical interest to growers and 
farmers. For this reason, a major part of the application of biotechnology to 
plant breeding has been the field trials to prove the agronomic qualities of 
newly engineered forms.
Field Trial  — A Guide  to  What  is  Happening
Goy and Duesing (1995) reported a survey of field trials over the period 1986- 
1993. During this time, they examined records of some 1,025 field trials in 
32 countries. Table 1 (on page 80), adapted from their paper, shows the range 
of characters introduced into the five most widely tested crops. The tobacco 
field trials for the most part reflect its use as an easily transformed crop plant 
model. Although the first field trials were carried out largely by the private 
sector, the first in the UK was a trial of a potato transformant carrying the 
gus marker gene. That trial was carried out in 1986 at the Plant Breeding 
Institute (PBI) in Cambridge. By 1993, the private sector was responsible 
for 71 percent of all trials, although by then a total of 61 public institutions 
and 88 companies had submitted applications or notifications to the various 
regulatory organizations controlling field tests of genetically manipulated 
plants (Goy and Duesing 1995).
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Table  1. Number  of  Field  Trials  and  Traits  Tested
TRAIT Potato Canola Tobacco Corn Tomato
Herbicide resistance 16 (5) 94 (7) 29 (6) 54 (3) 21 (5)
Quality 31 (9) 57 (5) 13 (4) 15 (2) 39 (3)
Virus resistance 60 (12) 2 (2) 24 (7) 10 (4) 20 (9)
Insect resistance 34 (4) 3 (3) 19 (3) 24 (2) 16 (1)
Marker gene 23 (7) 17 (5) 28 (9) 8 (4) 4 (3)
Fungal resistance 9 (7) 5 (4) 9 (4) 2 (1)
Multiple traits 8 (7) 2 (1) 4 (3) 0
Bacterial resistance 9 (3) 1 (1) 0 0
Not specified 3 1 5 5 3
Total 193 181 128 120 105
Data are from 1986 to 1993 Adapted from Goy & Duesing 1995
71 percent of trials are by the private sector
Private  and  Public  Plant  Breeding
Throughout the last 50 years some major changes have affected the way 
varieties are released and how breeders are compensated for their work. Plant 
variety rights legislation is now common in many countries and protects the 
originators of new cultivars against theft and illegal sales of seeds and planting 
stocks by unauthorized propagators. In Europe, the introduction of these 
schemes spawned the development of the plant breeding industry by making 
investment in the technology profitable through the return of royalties on seed 
sales. As the private sector grew in strength and capability, there was a steady 
trend away from reliance on public sector plant breeders to produce new 
cultivars of the major agronomic crops. In the UK this culminated in the 
privatization of the Plant Breeding Institute in 1987, leaving only remnants 
of the public sector breeding that had largely supported British agriculture 
over the period from 1910 to the seventies. Although traumatic for those who 
lived through the transition, it re-emphasized the important role of the public 
sector in basic research. However, the demise of the PBI did destroy a unique 
and very successful organization that directly coupled basic and applied science 
for crop plant improvement.
In the U.S. there was a similar, if less dramatic, trend towards a reduced 
reliance on land-grant university and federal breeding programs. Some excep-
tions include crops, such as oats and alfalfa, which the private sector regarded 
as too small, in terms of seed sales, to be profitable. For corn, exclusive 
ownership of the inbred lines needed to make up Fj hybrids provided an 
alternative to plant variety rights.
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Patents
Although plant variety rights provided reasonable protection for conventionally 
bred varieties, the scheme could not protect the hard won fruits of biotech-
nology. The capital and personnel investments in molecular biology were 
considerable. These costs, and the precedents from earlier decisions for 
patenting living organisms, made it clear that utility patents were the answer.
As a result, there has been a tremendous increase in the filing of patents to 
protect discoveries such as cloned genes, methods of effecting transformation, 
and the development of systems for using molecular mapping as an aid to 
selection. At Rutgers, this is reflected in the appointment of additional staff 
to the University Office of Corporate Liaison and Technology Transfer, which 
has six people who assist faculty and graduate students in patent filing. The 
total number of faculty at Rutgers is about 1,100. However, in one U.S. private 
university that evidently has great expectations of continuing to benefit from 
licensing fees and royalty income, the number of staff with this function is now 
approximately one per ten faculty members.
To illustrate my concerns and the practical problems caused by patents, 
let me review a situation that we now face at Rutgers and which 1 am sure 
is paralleled elsewhere. A most successful plant breeding program at Cook 
College is a turfgrass-breeding program led by Reed Funk. This program has 
been responsible for a number of leading varieties that are widely grown in 
North America. In the course of developing a transformation method for one 
of the turf grass species — Agrostis palustris or creeping bentgrass — we made 
use of the bar gene for resistance to the herbicide bialaphos (Hartman et al. 
1994). The bar gene is widely available for research use but two patents cover 
commercial use, as a selective marker in the laboratory, for recovering products 
of transformation, or for field use to confer herbicide resistance. We have also 
worked with several other herbicide resistance genes that have been introduced 
into the same grass species. Following greenhouse and field trials, we had 
expected to begin discussions with the owners or licensees of these patented 
genes to explore how the most promising lines we had selected might find their 
way into the hands of commercial grass breeders. During the course of several 
years of meetings, correspondence and telephone calls, we have encountered 
a number of problems that have made this a far from easy task. Among the 
problems were the following. The patent owners:
1. Have other plans for the use of the gene in more important crops.
2. Fear that herbicide-resistant creeping bentgrass, a species commonly 
used on golf course greens, might escape as a weed and invalidate the 
use of these herbicides on other more important crops.
3. Are concerned that horizontal spread of the genes, by cross-hybridization 
with other native Agrostis spp. that are weeds, could more seriously 
compromise the use of these genes and their relevant herbicides in 
combination.
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4. Some of the owners are concerned about development, and other costs, 
to obtain a registration label authorizing the use of their herbicide on a 
new crop species.
5. In other cases, research agreements prevent us from publicly acknowl-
edging that we have certain genes and are working with them and may 
even prevent publication of our findings.
The first is clearly beyond our control. The second we naively thought would 
be resolved by the lack of any record in the literature that A. palustris is a weed 
species. It has been recorded as a weed in Kentucky bluegrass lawns but the 
absence of any reports that it is not a weed of field crops seems to be of little 
comfort. The third has been in part addressed by hybridization studies carried 
out by breeders to introduce new genetic variation into creeping bentgrass. The 
fourth question is a legitimate concern. Although bentgrass is not part of the 
human food chain, the environmental impact of increased herbicide use on golf 
course greens and eventually on lawns must be considered even though the 
newer herbicides we work with are environmentally benign. They are used at 
low doses, are rapidly biodegraded in the soil, and have very low mammalian 
toxicides.
Even when a public sector unit isolates and clones its own genes, which it 
may well decide to patent, there are still other problems. I am grateful to Ken 
Barton of Agracetus, Inc., for the following example. A new genetically 
engineered cultivar arising from work of this kind has to take account of 
additional patents and protection as follows:
1. The Cohen-Boyer patent for cloning DNA in a plasmid in E.coli, even 
though it only has several years left to run, underpins the technology of 
recombinant DNA.
2. The method of transformation is also subject to patent protection: For 
example, the gene gun is covered by the Sanford & Wolf patent (for 
grasses and ornamentals) whereas the DuPont Co. has patent rights for 
other plant species.
3. The plant material to be transformed may be covered by patents. For 
example an Agracetus patent, that is presently being disputed, gives the 
company rights to all transformed cotton cultivars no matter how they 
are produced. If a named crop cultivar is used, and the new cultivar is 
essentially similar except for the new gene, the owner of the original 
cultivar has rights that must be respected.
4. 1 have already discussed the question of ownership of the gene, or genes, 
that give a genetically engineered cultivar its new features. Nearly all 
single gene traits that have been cloned are protected. However, other 
genes may be required that are owned by other parties. For example, 
markers such as kanamycin resistance, the glucuronidase gene (gus)
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and herbicide resistance may be needed. In order to ensure maximal 
expression at the appropriate stage of plant development, the introduced 
genes must be controlled by elements such as the CaMV 35s promoter, 
an organ or tissue specific promoter, or be used with an expression 
enhancer such as the omega sequence from tobacco mosaic virus (TMV).
Each interested party, or patentee, has to agree to the proposed use of their 
materials under license. Each will expect either an up-front fee, or a share of 
royalty income, which have to be negotiated individually. Small wonder that 
public sector programs with limited resources and experience in negotiating 
licensing fees are finding it increasingly difficult to compete with large 
companies who are patent holders, and thus have bargaining chips to use 
in negotiating deals with each other. In theory, the patent system is supposed 
to make material available for further research by protecting the interests of 
the patent holder. In practice, the patent holder can find many ways to block 
distribution of the patented materials and to limit the uses made of it.
Are patents as useful as publications for evaluating faculty for tenure and 
promotion? Probably not, but they are unlikely to hurt an academic candidate 
and could be regarded as an indicator of his or her awareness of the relevance 
of their work. Patents are, of course, much more important in industry. Judging 
the quality of awarded patents is much more difficult. Patents are examined by 
patent office specialists. They are not peer reviewed, and their treatment is 
entirely different to that given journal articles or grant proposals.
Are  Present  Intellectual Property  Laws  a  Barrier  to  Exchange  and  Access ?
In my view, these laws restrict meaningful access to genetic information. Before 
patent protection is filed for, the investigators are unable to describe their work 
to others for fear of invalidating their patent claims. Even after the patent is 
filed and granted, access to the material can be denied by failure to answer 
requests. Such access as may be granted may not be meaningful since profitable 
use of the materials may be prohibited and, even if allowed, is subject to 
restrictions. The result is that the laws sometimes limit, or even prevent, 
beneficial applications. This is the cost of protecting private sector investment 
in plant improvement. Without it, private plant breeding would not have 
flourished.
What of the trend among universities to patent and protect information 
gained with taxpayer support? Although some have been critical, many believe 
that universities should benefit from the income accruing to such protection. 
They believe that it will reduce the tax burden, enhance facilities for teaching 
and research, reward and encourage faculty inventors, and create wealth and 
jobs for the community. However, these incentives can distract university 
faculty from teaching, research and more traditional forms of service to the
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community. There is the danger that they may become more concerned 
with raising capital, establishing and managing external development or 
manufacturing facilities, and lining their own pockets. Negotiating contracts, 
licenses and royalties has now become so complex that research universities 
must employ specialists in these areas to protect their interests and maximize 
returns. A senior faculty committee at Rutgers recently spent much time in 
revising its scheme for dividing the spoils from royalty income between the 
university central administration and the deans, department chairs and 
researchers themselves.
Present  Day  Role  of  Public  Sector  Breeding  Programs
Some years ago the late William Brown of Pioneer Hy-Bred International,
Inc., was concerned about the reduction in plant breeding in U.S. land-grant 
colleges. He was worried by the prospect that the private sector would be 
unable to recruit young men and women trained in the technology. During 
several annual seminars organized by Pioneer Hi-Bred in the 1970s that 
brought together public and private scientists, it became clear that training 
in plant breeding would increasingly become the province of private sector 
breeding companies. Their new recruits would have had training over a 
broader range of subjects than before. This would include not only the 
traditional subjects such as genetics, plant physiology, agronomy and 
statistics, but also molecular biology, biotechnology, biochemistry and cell 
biology. Much like engineering trainees, they would learn the idiosyncrasies 
of individual crops, the practice of selection and the management of trials 
in company plots and fields. I believe that this is working well. I am less 
optimistic about the technology transfer of the products of long term basic 
research in plant molecular biology carried on in our universities. The 
separation between basic research and the technologies that need it and 
can make best use of it means that they are uncoupled in our universities.
The problems and pitfalls involved in patenting exacerbate this situation. 
Even producing new breeding lines for release to commercial breeders is 
no longer simple.
I will finish by reviewing my own experience in the UK. In a sense it 
represented for me the culmination of the introduction of Plant Variety 
Rights. I joined the Plant Breeding Institute in Cambridge in 1979. At 
the time its varieties dominated or were prominent on the UK national 
recommended lists for winter wheat, spring barley, potatoes, marrowstem 
kale, and oilseed rape (canola). The National Seed Development Organiza-
tion (a state organization) distributed these, and other products of public 
plant breeding, collected the royalties and passed them on to the Treasury.
By the early 1980s the PBI’s share of these royalties exceeded its annual
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grant-in-aid from the state. Some of the UK private sector breeders resented 
the success of “Her Majesty’s Plant Breeders” who were supported in part by 
the taxes they paid on their profits. Unlike the system in The Netherlands, 
where state breeders offered the private sector advanced breeding materials 
and were prevented by law from releasing finished varieties, the PBI breeders’ 
best materials went right through to the ultimate test — the farm and the 
marketplace. The competition between state and private breeders, although 
not on an equal footing, was good for the British farmer. For example, there 
had been a steady increase in the proportion of homegrown wheat in bread-
making grists brought about by systematic breeding for breadmaking quality 
coupled with high yield. The end came when the government realized that 
the generation of royalty income was a salable asset and the PBI was priva-
tized in 1987. In my view, the most damaging result was the uncoupling of 
theory (genetics, plant molecular biology and plant pathology) and practice 
that resulted. The dialogue between breeders and others at PBI was at times 
difficult and unrewarding, but in the long run was responsible for the 
achievements made over 75 years.
If we are to benefit from current technologies, that were pipe dreams 15 
years ago, we must facilitate and enhance the coupling between discovery 
and its broad use. Where intellectual property rights and agreements hinder 
this we must strive to find ways to make things work fairly and efficiently.
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The Role of Intellectual Property Rights in 
Modem Production Agriculture
Leanna  M. Lamola
Attorney
Sacramento, California
The term “modern production agriculture” requires constant redefining 
because our food and fiber system continues to develop and change.
Raymond Goldberg, head of the Agribusiness Program at the Harvard School 
of Business Administration, describes four factors that characterize the 
ongoing industrialization of agriculture:
The consolidation of firms at every stage of the food chain;
The coordination of the food system through long-term legal relationships;
The biotechnology revolution; and
The information revolution (Goldberg 1993).
These factors are contributing to the development of new, end-use oriented 
marketing systems that run alongside or, in other cases, displace traditional 
commodity systems. One such end-use oriented system is for products that 
derive from what are commonly known as “end-use tailored” or “identity- 
preserved” varieties. These varieties carry distinct traits that are preserved from 
the time of production through marketing to processing and consumption.1
Trying to describe identity-preserved systems in a single sentence, I came up 
with: The global coordination of research, development, production, processing and 
marketing of new animal breeds and plant varieties with special traits that fill a 
particular producer, processor or consumer need and which are protected by 
intellectual property rights.
1 Identity-preserved also refers to products produced according to a particular process, such as according 
to organic standards
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Biotechnology  and  Identity-Preserved  Systems
The life sciences, particularly biotechnology, will play a central role in the 
development of identity-preserved systems. Advances in physiology and 
classical and molecular genetics allow for the isolation, characterization and 
transfer of valuable traits. More generally, the majority of future productivity 
gains are expected to come from improved crop and livestock genetics.
Robert Fraley of Monsanto Company spoke at NABC 6 on the new products 
and industries that plant biotechnology will spawn (Fraley 1994). Many, if not 
all, of the new products for improved pest, disease and nutrient management; 
food processing; nutritional profiles; chemicals and polymers; and biofuels will 
be identity-preserved.
The technology behind identity-preserved systems will be consumer driven, 
not just in terms of the products, but in terms of the processes by which they 
are made. Speaking at NABC 6, R. James Cook, Chief Scientist at the United 
States Department of Agriculture’s National Research Initiative Competitive 
Grants Program, said: “The very use of molecular methods to produce disease 
and pest-resistant varieties of some fruits and vegetables is being driven by 
consumer demand” (Cook 1994). This is because consumers not only demand 
fruits and vegetables free of pesticide residues, they demand those varieties that 
allow for pesticide use reductions.
By responding to downstream demand, identity-preserved systems will more 
closely link producers to consumers and other end users. Thomas N. Urban, 
President and CEO of Pioneer Hi-Bred International, Inc., who has written and 
spoken on the implications of identity preservation, noted: “We are getting to 
the point where we can almost identify certain farmers with certain shelf space” 
(Urban 1993).
The  Role  of  Intellectual  Property  in  Identity-Preserved  Systems
Intellectual property rights will be critically important in identity-preserved 
systems for livestock, field crop and horticultural varieties. This is because 
intellectual property rights ensure the preservation and control of the value- 
added factor through the food chain.
There are two basic ways that intellectual property rights maintain the 
identity and profitability of value-added proprietary factors of identity- 
preserved varieties. First of all, intellectual property rights reduce research 
and development investment risk. This holds true for all commercial products 
requiring substantial research and development outlays and is the basic policy 
rationale behind intellectual property laws. The biotechnology industry 
presents an extreme case in that it is more capital intensive than most 
and its products easily copied. Thus, plant breeders’ rights, trade secrets, 
trademarks and patents are particularly important in the agricultural 
biotechnology industry.
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Pioneer Hi-Bred Patent Counsel, Michael J. Roth, writes: . . we need more
protection for the fruits of our research than has traditionally been available . . . 
By providing a higher level of protection . . . patents help to insulate protected 
technology against risk, particularly that the technology will be copied by 
persons who have invested and risked nothing in its creation” (Roth 1994).
Second, intellectual property rights allow those who control the flow of 
value-added components in the food chain to obtain downstream premiums.
A quick look at the percentage of the consumer food dollar spent on upstream 
versus downstream added-value reveals that the lion’s share of profits in the 
food industry derive from downstream activities. For example, the annual retail 
market for fresh tomatoes in the U.S. is $3.5 billion versus a $300 million 
annual retail market for tomato seed.2
Identity-preserved products provide downstream added-value, for which 
the processor and consumer are willing to pay a premium. (Goldberg 1993). 
Identity-preserved products, separated from their cousins in traditional com-
modity markets and controlled by proprietary rights holders, will allow a 
greater portion of the downstream food dollar to flow to upstream actors.
In fact, actors at any point in food chain who obtain proprietary rights in 
identity-preserved technology can profit from interactions at points upstream 
or downstream. For example, consider the food processor that contracts out the 
production of its proprietary identity-preserved variety and then processes and 
markets an identity-preserved product under its brand name. It also may license 
out the same identity-preserved technology to upstream research firms.
The distribution of proprietary rights and royalties under these coordinated 
systems will depend on one’s position in the food chain—whether a university, 
biotechnology firm, producer, processor, packer, retailer, etc. Moreover, the 
development of a harmonized global intellectual property system as a result of 
recent changes in the General Agreement on Tariffs and Trade (GATT) will 
facilitate these interactions on a global scale.
The  Calgene  Flavr  Savr ™ Tomato - An  Identity-Preserved  System
To illustrate these concepts, let us look at the most famous agricultural 
biotechnology product on the market today—the Calgene Flavr Savr™ tomato.
In 1984, Calgene, Inc. entered into an agreement with the Campbell Institute 
for Research to develop technology for production of premium vine-ripened 
tomatoes. According to the agreement, Calgene would obtain patents on any 
relevant isolated genes and Campbell Soup Company would receive an 
exclusive, worldwide license for their use.
2Calgene, Inc. 1995
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In February 1989, Calgene, was issued a U.S. patent on the tomato poly-
galacturonase gene sequence and the use of its antisense orientation. In April 
1992, the company was issued a broad process patent covering the use of 
antisense RNA technology in all plants. In 1991, Zeneca A.V.P., a subsidiary 
of ICI, Inc., filed and was granted an interference by the U.S. Patent Office 
between the 1989 Calgene patent and Zeneca’s 1986 patent application on 
a similar technology. All three companies entered into negotiations and in 
February 1994, a final distribution of rights was determined.
Campbell and Zeneca co-own exclusive rights to grow and use Flavr Savr™ 
technology for processed tomato products. Calgene Fresh owns exclusive, 
worldwide, royalty-free rights to produce and sell fresh market tomatoes 
containing the Flavr Savr™ gene.
Let us see how the Flavr Savr™ production, handling and marketing system 
places it outside the larger traditional commodity tomato system, commonly 
known as the “gas green” system.
Flavr Savr ™ or "Vine-Ripe ” System
Calgene, Inc. scientists engineered Flavr Savr™ technology into tomato 
varieties bred in the 1950s for superior taste, but which had fallen out of 
production because they were inappropriate for the gas-green system. Because 
the Flavr Savr™ tomato requires special growing, packing and transportation 
to preserve the vine-ripened taste and consistency factors, Calgene decided 
to manage the entire system.
Calgene Fresh, a wholly-owned subsidiary of Calgene, Inc., was formed in 
1992 to manage the Flavr Savr™ system. The company has entered into year- 
round production contracts with a number of growers in California and Florida, 
and expects to have growers soon in Mexico. Under the contracts, Flavr Savr™ 
growers do not take ownership of the seed or progeny tomatoes.
Contract growers must abide by a set of strict growing protocols that include 
integrated pest management and nutrient management techniques. The Flavr 
Savr™ technology allows the tomatoes to be picked ripe. Calgene Fresh sorts 
the tomatoes into three quality grade categories, the highest quality of which 
are designated for marketing under the brand name MacGregors®. Calgene 
contracts with shippers to transport MacGregors® tomatoes at temperatures 
above 50°F to supermarkets.
Calgene Fresh has developed its own marketing program for MacGregors® 
tomatoes that uses brand development and support techniques traditionally 
employed for processed and other branded food items. This involves the use 
of trained food brokers to sell and support the product in retail supermarkets. 
Each tomato carries a sticker denoting it as a product of genetic engineering 
and brochures on the product are available at the point of purchase.
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“Gas-Green "System
Most producers of fresh tomatoes in the “gas-green” system grow on contract 
for a packer/shipper. The varieties used were derived from publicly-released 
varieties developed for machine harvesting. These tomatoes are picked green 
and purchased by the packer/shipper, who sorts and packs them using special 
machinery. Prior to shipping, ethylene gas is applied to induce ripening. The 
tomatoes are sold to one or two repackers, who in turn sells to the retailer. 
These tomatoes are shipped at temperatures below 50°E More time is required 
to take the product to the consumer under the gas-green system because of the 
middlemen involved.
Comparing the two systems, we can readily see how MacGregors® tomatoes 
fit Goldberg’s description of identity-preserved systems: “The tailor-making of 
identity-preserved food products allows the input supplier to provide branded 
ingredients at the farm supply and farm level; these ingredients, in turn, enable 
both the branded food manufacturer and the private label food retailer ... to 
differentiate their final products to the consumer” (Goldberg 1993). Here,
Flavr Savr™ technology is supplied at the farm level and preserved for the 
consumer under the MacGregors® brand name. On the other hand, there is 
no value-added factor preserved from production to consumption in the gas 
green system and no identifiable relationship between growers and consumers.
IDENTITY-PRESERVED SYSTEMS AND PRODUCTION AGRICULTURE
The mechanism by which the identity-preserved system links producers to the 
rest of the food chain is the production contract. Contract production in the 
U.S. is by no means a new phenomenon. Integrated systems based on contract 
production have existed for some time in poultry, fruit and vegetables and are 
increasing in hogs where the percentage raised under contract has grown from 
two percent in 1980 to 18 percent in 1990 (Kelley 1994). It is predicted that 
an increasing percentage of these contracts will involve identity-preserved 
varieties. For instance, Thomas Urban expects nearly 25 percent of all corn 
grain production in the U.S. to be on an identity-preserved, contract basis by 
the year 2000 (Urban 1991).
Minneapolis attorney Christopher R. Kelley classifies production contracts 
(here, between producer and processor) into four categories:
Market specification contracts — set the price, quantity and quality of 
the product;
Production management contracts — give the processor direct control 
over production methods;
Resource-providing contracts — allow the processor to provide all or part 
of the inputs, incorporating strict quality standards throughout the 
production process; and
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Vertical integration contracts — completely shift production control to 
the processor, with the producer supplying only labor, land and other 
fixed inputs (Kelley 1994).
Production contracts involving protected identity-preserved varieties are 
licenses. Because such contracts license a specific quantity of the proprietary 
identity-preserved variety, they are called bailments.3 For example, the Flavr 
Savr™ contract producer takes possession of a fixed quantity but no property 
interest in Flavr Savr™ seeds or progeny. Therefore, as the number of identity- 
preserved systems involving proprietary varieties and special production 
practices increases, we would expect to see an increase in the last two 
types of contracts.
The primary advantage of contract production for both the producer and 
the contractor is risk management. By controlling the timing, quantity, quality 
and specifications of production, economic efficiencies may be realized. 
Coupled with long-term marketing arrangements, these factors can help 
promote stability. Contract production of identity preserved varieties may 
provide producers with better returns than those obtainable in traditional 
commodity markets. Thomas Urban writes, “As opposed to producing a 
commodity that is then transformed by some portion of the food chain, 
farmers themselves are going to receive a premium” (Urban 1993) for the 
identity-preserved factor. For example, I learned that retailers pay twice as 
much for the Flavr Savr™ tomato as for the gas-green tomato.
There are a number of factors that can impact a contract producer’s ability to 
obtain higher returns. In his book on production contracts, Drake University 
Law Professor Neil Hamilton discusses an important point about privately 
negotiated contract production systems — the loss of publicly discovered 
pricing mechanisms, so that the producer cannot learn the real market value 
of the products (Hamilton 1995).
Another factor influencing a producer’s return under a production contract 
is relative bargaining power. Recently, some contract producers have organized 
into associations to improve their bargaining position. Perhaps the most well 
known is the National Contract Poultry Growers Association, which has 
lobbied for state and federal legislation designed to prohibit unfair practices 
by integrators.
In an effort to improve returns over those available under contract pro-
duction alone, some producers have moved into value-adding, downstream 
activities, such as processing and marketing of identity-preserved varieties.
For proprietary varieties, this would necessitate a license to grow, process and 
sell products of the variety.
3The legal relationship created in the standard seed production contract is a bailment.
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An example of the above is the American White Wheat Producers Associa-
tion (AWWPA), a marketing cooperative of western and Midwestern wheat 
producers formed in 1988. AWWPA has exclusive licenses to grow, process 
and sell flour of two proprietary hard white wheat varieties. Members grow the 
varieties under contract with AWWPA, which retains marketing rights. AWWPA 
mills the wheat and sells flour to bakeries and processors. It has a trademark for 
its flour, which is displayed on wheat products. This eliminates a number of 
middlemen and has increased members’ profits (Burchett 1993).
Another option for producer groups is to obtain proprietary rights in or 
exclusive licenses to identity-preserved varieties through research agreements 
or other strategic alliances with the private or public sector. Alternatively, 
producer groups may contract for research services or establish their own 
private research institutes.4
Traditionally, producers have funded land-grant university research with 
grants from private commodity groups and with checkoff funds managed by 
marketing order boards. Until recently, technology developed using these 
funds was considered a public good and transferred to state industry by state 
extension services and experiment stations. Today, land-grant universities 
protect inventions with intellectual property rights, enter into research 
agreements with and exclusively license technology to the private sector.
The legal status of a commodity group can affect its ability to take a 
proprietary interest in or license proprietary agricultural technology. For 
instance, federal and state marketing order boards are part of and serve in 
an advisory capacity to their respective departments of agriculture. As a 
result, marketing order boards are not separate legal entities and cannot take 
a proprietary interest in or license technology for commercial use. On the 
other hand, commodity commissions are created by specific legislation to 
perform the same function as marketing order boards but are separate legal 
entities within state governments and therefore can take a proprietary interest 
in or license technology for commercial use.5 &
Where producer groups choose to continue to fund land-grant university 
research, should the university give them a preference in licensing proprietary 
technology generated with such funds?
4For example, a coalition of California dairy industry groups have established a private dairy research 
institute at the California State University at San Luis Obispo.
Recently, some California state marketing orders have restructured as commissions in part to give 
themselves the option of owning or licensing the technology they funded independent of the State 
Department of Food and Agriculture. (See, for example, the Fresh Strawberry Program Act, Cal. F
& Agric. Code §§77401-77505).
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This is a topic of current debate in California. A 1994 report by the California 
Commodity Commission6 criticized the University of California’s intellectual 
property rights and technology transfer policies and questioned the University’s 
commitment to California agriculture:
The university’s preeminent reputation . . . has resulted . . . from its close 
interaction with commercial farmers and from their strong support and coopera-
tion ... A break in this close connection with and clear commitment to California 
agriculture increases the likelihood that technology developed with tax dollars 
or funds provided by private industry, commodity groups and agencies could 
become equally available to competing industries in other states and nations 
(California Commodity Committee 1994).
The report gives examples where new technology developed with state 
commodity program grant money was licensed to an out-of-state competitor 
before the state commodity group knew about the technology. The report 
recommends that the university adopt a policy to ensure that research is 
directed toward developing patents of practical value to California agriculture 
and that groups sponsoring research have preference in licensing and 
partnership agreements. The University is currently reviewing its policies 
with input from California commodity groups.
Conclusion
Identity-preservation is one type of end-use oriented marketing system which is 
changing the structure of modern production agriculture. Intellectual property 
rights play a central role in identity-preserved systems because they allow rights 
holders to reduce investment risk, preserve the identity, and control the use of 
value-added factors in downstream or upstream arenas. Production contracts 
are the main mechanism by which producers will participate in identity- 
preserved systems. Production contracts can reduce risks and offer premium 
prices, but they also can present new risks such as inability to learn the true 
market value of products. Producers may increase returns in identity-preserved 
systems by moving into downstream activities such as processing. Likewise, 
producers may decide to fund the development of identity-preserved varieties 
through research agreements or other strategic alliances with private or public 
organizations. Such activities will add to the need to re-examine the traditional 
relationship between the land-grant university and state agriculture. 6
6This committee represents California commodities that are organized under a marketing order, com-
mission, or a related state or federal commodity marketing program.
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Gene Ownership versus Access: 
Meeting the Needs
Jack  L. Tribble
Patent Counsel 
Merck & Co., Inc. 
Rahway, New Jersey
Two developments, which simultaneously and independently occurred 
in the 1980s, have substantially impacted the way drugs are currently 
being discovered and developed. First, there was a significant change in 
the technology employed for drug discovery. Traditionally, drugs were 
discovered using organs, tissues, cells or extracts thereof in screens to 
identify active pharmaceuticals. These traditional methodologies have 
been replaced by the use of technology involving specific molecular 
targets. These biotechnological targets may be receptors responsible for 
unique cell interactions associated with a disease or an enzyme that can 
catalyze a distinct biochemical reaction associated with a disease. The 
ability to identify and produce these unique proteins by recombinant 
techniques has resulted, in turn, in a wide range of mechanism-based 
screens. Of the 40 top selling drugs (worldwide sales 1993), 25 were 
identified by a specific mechanism of action: 13 were receptor agonists/ 
antagonists; eight were enzymes/protease inhibitors; and four were 
channel blockers.
Second, the unencumbered availability of the materials and processes 
used in drug discovery has been noticeably decreasing. Prior to the rapid 
development of biotechnology, most pharmaceutical or chemical patents 
claimed active therapeutic agents, intermediates leading to active agents, 
processes of making active agents and intermediates, and methods of 
using active agents. The basic methodologies for chemical research were 
not generally patented. In 1980, Congress passed both the Stevenson-
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Wydler Technology Innovation Act1 and the Bayh-Dole Act2 . Together, 
these Acts allowed government contractors, small businesses and nonprofit 
organizations to retain certain patent rights in government sponsored 
research and permitted the funded entity to transfer the technology to third 
parties. The original legislation was expanded in 1983 by Presidential Order3 
to include all government contractors. The 1980 legislation and subsequent 
amendments4 (collectively termed Bayh-Dole) permit the contractor to grant 
exclusive licenses to government-funded contractor inventions. With the 
passage of the Federal Technology Transfer Act of 19865, Congress 
authorized federal laboratories to enter into cooperative research and 
development agreements (CRADAs) with private companies. The Act also 
required federal laboratories to agree in advance to assign or license to 
the collaborating party patents on inventions made by federal employees 
in the course of the collaborative research.
The stated intent of Bayh-Dole was to ensure that the patented results 
of federally funded research would be broadly and rapidly available for all 
scientific investigation, irrespective of the objectives of the research and 
the terms under which licenses are granted for the sale of products under 
the patents. Bayh-Dole effectively shifted federal policy from a position of 
putting the results of government-sponsored research directly into the public 
domain for use by all, to a pro-patent position that stressed the need for 
exclusive rights as an incentive for industry to undertake the costly invest-
ment necessary to bring new products to market. As a result, many of the 
basic materials and laboratory procedures that are universal to biotechnology 
and modern drug discovery have been the subject of patents and patent 
applications. As a result, accessibility is restricted.
The biotechnology materials and procedures that enhance drug discovery 
have been termed Research Tools. Research Tools are defined herein as 
biological or biochemical materials or processes that are useful for drug 
discovery and exclude materials or processes when used commercially. 
Examples of Research Tools include cDNA clones, receptors, monoclonal 
antibodies, transgenic animals and other inventions that can be used for 
drug discovery.
'Pub. L. No. 96-480, 94 Stat. 2311 (1980) (codified as amended at 15 U.S.C. §§ 3701-3714).
2Pub. L. No. 96-517, § 6(a), 94 Stat. 3015, 3019-27 (1980) (codified as amended at 35 U.S.C. §§ 201- 
211) .
'Presidential Memorandum to the Heads of Executive Departments and Agencies, Subject: govern-
ment Patent Policy, 1983 Pub. Papers 248.
4Pub. L. No. 98-620, 98 Stat. 3335 [Trademark Clarification Act of 1984).
3Pub. L. No. 99-502, 100 Stat. 1785 (amending the Stevenson-Wydler Technology Innovation Act
of 1980).
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It is well recognized that one purpose of Bayh-Dole is to permit government 
funded patentees to grant exclusive licenses for the commercialization of 
products. This purpose can be accomplished while the broader intent of the 
Acts — that inventions be utilized as broadly as possible, is met. Accordingly, 
we believe that a federally funded patentee should grant non-exclusive licenses 
for Research Tools independent of licenses for products for sale. Further, we 
believe that the non-exclusive licenses should be available for reasonable fees. 
This broad access to Research Tools discovered under federally funded research 
programs by a non-exclusive license acts to foster competition among com-
mercial laboratories to discover and ultimately develop novel human health 
products, thereby meeting the Congressional intent of Bayh-Dole. Because 
Merck supports a policy of licensing of patented inventions for research use 
separately from licensing for commercial development of products for sale, 
Merck Research Tool inventions are accessible for research purposes.
The current avalanche of genetic information from the Human Genome 
Project and other sequencing sources promises even greater advances for 
molecular medicine from Research Tools identified by these programs. With 
a complete, high resolution map of the human genome and an understanding 
of the genetic basis for disease, scientists should be able to create mechanism- 
based drugs that will result in improved therapies for known diseases and 
new therapies for diseases as yet unconquered. For this to happen in a timely 
manner, the basic Research Tools required for drug discovery must be readily 
available to the academic, governmental and industrial biomedical research 
community. Thus, availability will likely depend on ownership of genes and 
gene products and the methods of using those gene products.
Ownership of human genes first became a national and international issue 
when in 1992, the National Institutes of Health (NIH) filed patent applications 
claiming thousands of partial cDNA sequences which Craig Venter had termed 
expressed sequence tags (EST) (Adams et al. 1991). The NIH claimed the EST 
patent applications were filed to preserve a proprietary position for presumed 
valuable inventions (McGregor 1992). The NIH assumed that patent claims 
would issue with sufficient breadth to attract licensees that would develop 
products related to the partial genes. The NIH applications, however, created 
a worldwide controversy. American scientists associated with the human 
genome project strongly opposed the filing of EST patent applications because 
they believed the patents would have a negative impact on genome research 
(Roberts 1991). The science ministries of numerous European countries were 
very outspoken about how the patenting of genetic information would likely 
slow down the human genome project and change the economics of biomedical 
research. Due to the outcry from the worldwide scientific community and the 
inability to overcome the U.S. Patent and Trademark Office’s (USPTO) rejection 
of the applications claims, the NIH simply did not respond to actions from the 
USPTO and the applications went abandoned.
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The NIH applications raised questions about the patentability of human gene 
segments. The USPTO has issued patents claiming isolated and purified DNA 
(cDNA or genomic DNA) which encode a functional protein of known activity. 
Indeed, patents have been issued on short DNA fragments that are useful as 
diagnostics. The issuance of DNA patents requires that a compound (a gene, 
genomic sequence or cDNA sequence) must have been removed from its 
natural setting, be new, useful, unobvious and be enabled by the patent 
application.6 An invention is considered novel if it has not been placed in the 
public domain, i.e., is not described in a publication or placed in commerce.
The utility requirement can generally be met by demonstrating a particular 
use, such as a DNA sequence for gene therapy or as an intermediate for the 
manufacture of the encoded protein with an established function. A nonobvious 
invention is one that could not have been made with a reasonable expectation 
of success by a hypothetical person of “ordinary skill” in the relevant scientific 
field from publicly available information. Enablement requires that a patent 
application teach one skilled in the scientific area how to make and use the 
invention. In the case of the NIH partial sequences (EST) as discussed above, 
the USPTO maintained that the ESTs did not meet the utility requirement nor 
did the applications enable the inventions.
The Court of Appeals for the Federal Circuit (CAFC) has affirmed the 
validity of claims to full length cDNA or genomic DNA molecules, e.g., human 
erythropoietin and insulin like growth factor.7 Indeed, obtaining a patent on 
a specific DNA molecule is quite beneficial in developing a patent portfolio 
around a specific protein therapeutic. In some instances, the protein may be 
known and not patentable and the only patent protection available will be for 
the isolated and purified DNA that can be used to make the protein therapeutic. 
This is important because large proteins may not be economically made by 
nonbiotechnological means. Product exclusivity through patent protection is 
required to offset the high research and development costs and the extended 
time to bring a product to market. The current estimate for this high risk 
enterprise is an average of 12 years from discovery to market and an investment 
of over $350 million.
With the lapse of the NIH EST patent applications the subject matter 
entered the public domain and was available to all researchers. The scientific 
community hoped that all genomic Research Tools would be readily available 
for biomedical research. Unfortunately, the privatization of EST research has 
thwarted this goal.
635 U.S.C. §§ 100-103 and 35 U.S.C. § 112.
7Amgen Inc. v. Chugai Pharmaceutical Co., 927 E 2d 1200,18 USPQ2d 1016 (Fed. Cir.), cert, denied, 
502 U.S. 856 (1991) and In re Bell, 991E 2nd 781; 26 USPQ2d 1529 (Fed. Cir. 1993)
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Several organizations are attempting to establish proprietary control over 
much of the sequence data on expressed human genes, including ESTs. Com-
panies such as Human Genome Sciences (HGS) and Incyte are generating large 
EST data bases and are licensing access on an exclusive or non-exclusive basis 
to commercial entities (Dickson 1994a; Gen. Tech. News 1994). HGS initially 
maintained control over the utilization of the cDNA resources in their database 
and restricted access to collaborators, such as SmithKline Beecham, who were 
willing to invest significant sums of money for sequence information and rights 
to patented genes. Recently HGS has allowed academics limited access to the 
database but only if the institution agrees to allow HGS to develop any product 
identified by the use of the information gained from the database (Dickson 
1994b). Unfortunately, this type of private ownership may prevent genomic 
scientists from pursuing full-length sequencing, mapping, and gene-based 
discoveries that would realize the goals to the Human Genome Project.
Merck has taken the view that the information represented by ESTs should 
be made broadly available with no commercial obligations. Indeed, access to the 
ESTs plus the corresponding physical cDNA clone will provide the key Research 
Tools that will speed the development of new biomedical knowledge. This 
knowledge should lead to new therapeutics for a wide range of diseases as the 
underlying pathophysiological mechanisms are better understood. The medical 
and commercial results of these efforts will benefit all interested parties, while 
providing opportunities and preserving incentives for investment in gene-based 
product development.
To this end, Merck has organized a collaborative effort termed the Merck 
Gene Index Project. This effort will make cDNA resources rapidly available 
to all scientists, for gene identification and mapping (Williamson and Elliston 
1994). The Merck Gene Index will be a catalog of sequence data and identified 
clones arrayed from numerous cDNA libraries representing various organs 
and tissues and a variety of developmental stages. All scientists, whether 
public or private, will have full access to this standard set representing one 
clone per unique expressed gene. These clones will be characterized by single 
pass DNA sequencing and will be arrayed into microtitre plates and on filters 
as a publicly available resource. In cooperation with the IMAGE consortium 
(Integrated Molecular Analysis of Gene Expression), coordinated by Greg 
Lennon of Lawrence Livermore National Laboratory, a set of appropriate 
clones will be identified for sequencing by Robert Waterston, Richard Wilson, 
and their colleagues at the Genome Sequencing Center of the Washington 
University School of Medicine in St. Louis, Missouri. By identifying the 
repetitive and uniquely expressed genes, the number of clones that must 
be sequenced to capture all unique genes in a given sample should be reduced 
by an order of magnitude.
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Washington University will generate sequence data from both the 5' and 3' 
ends of about 200,000 individual cDNA clones. The 3’ end sequences will help 
facilitate mapping and full-length sequencing of specific cDNAs on human 
chromosomes, and facilitate the identification of a minimal set of unique gene 
cDNAs. The 5' end sequences will assist in identifying human cDNA sequence 
similarity to proteins of known function in existing databases. The new 
sequence data generated by Washington University will be submitted regularly 
via Database EST to Genbank (managed by the National Center for Biotech-
nology Information) where all interested researchers will have immediate and 
unrestricted access to the data, not only in the U.S., but also through Genbank’s 
collaborative arrangements with its international partners, including the 
European Bioinformatics Institute, National Center for Genomic Resources 
and DNA Database of Japan. All users will be asked, though not required, to 
contribute results obtained using the Merck Gene Index data and/or clones to 
appropriate public databases.
The set of roughly 200,000 cDNA clones to be sequenced by Washington 
University will also be available from appropriate commercial and not-for-profit 
organizations, in the form of polymerase chain reaction (PCR) products gridded 
onto nylon membranes, and as individual clones and sets of clones in 384-well 
plates. These resources will then be distributed at reasonable cost via estab-
lished networks to researchers who wish to do sequencing and mapping of 
individual genes or sets of genes, or for any research purpose.
This effort is anticipated to characterize between 50 percent and 85 percent 
of the unique expressed human genes, and to increase dramatically the amount 
and quality of publicly available sequence information on expressed genes. 
Scientists worldwide will have ready access to and be able to exploit particular 
clones as singletons or sets. The associated bioinformatics effort will ensure that 
the data generated are also captured in standardized fashion and made broadly 
available in public databases. These subsequent efforts using the Merck Gene 
Index as a research resource will likely lead to the identification of nearly 100 
percent of expressed human genes.
The continued expansion of biomedical science and the discovery and 
development of unique highly specific therapeutics will depend on the 
availability of Research Tools to the academic, governmental and commercial 
research scientists. This can best be accomplished by having federally funded 
Research Tools available non-exclusively and by encouraging collaborations 
between commercial laboratories and academic and governmental laboratories 
to develop Research Tools, such as the Merck Gene Index. This broad access to 
Research Tools will advance science, accelerate the progress of medicine, and 
foster competition among commercial laboratories to discover and ultimately 
develop new human health products that will benefit all.
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Farmer's Rights: What is Fair?
John  Kinsman  
President
National Family Farm Defenders 
Wisconsin Family Farm Defense Fund 
Im Valle, Wisconsin
One evening as I walked to the pasture to herd my cows home for milking,
I took a detour through my managed forest. What a thrill to come upon two 
young great horned owls perched on a fallen log. They solemnly allowed me to 
come within thirty feet of them before flying to a higher perch where they could 
still stare at me while 1 stared at them.
Raptors such as these giant owls, as well as hawks and eagles, have been 
making a comeback in this area of Wisconsin after all but disappearing a dozen 
or more years ago. DDT and like compounds had concentrated in their bodies 
and destroyed their reproductive capabilities. Banning the use of DDT finally 
allowed them to make a slow comeback. However, this past winter 14 bald 
eagles died in my county, all in an area where we have regularly observed them 
feeding on dead animals from confinement hog facilities. Laboratories reported 
no traces of poison, yet a mysterious poisoning remained the number one 
suspect in the cause of the deaths.
Are our raptors again in danger of extinction? Are we going too far in the use 
of questionably tested products to treat disease-prone livestock in confinement 
facilities? Are genetically engineered pork growth hormones adequately long-
term tested?
In a lifetime of farming, I have learned some expensive lessons. Some 
methods and technologies are helpful, while others create more problems than 
benefits. Working with “Mother Nature” has been a much more productive and 
stress-free route than continually fighting her and upsetting her system of 
checks and balances. My farm is now more productive, more sustainable, and 
increasingly more environmentally and ecologically correct than any farm in 
this region. We put every acre of our farm to its highest and best sustainable
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use, whether it be trees, pasture or cropland. In any technology I incorporate 
into my farm operation, I try to direct all decisions in a manner that has a 
positive impact on all farmers, be they in Asia, Africa or any continent.
People of the land — farmers and indigenous cultures — have a treasure of 
knowledge based on common sense experiences. How does anyone put a price 
on the contributions of generations of farmers in selecting plants for higher 
productivity and better quality? Using hypothetical scenarios to justify taking 
ownership of genes, information and other living material are both unethical 
and immoral. We farmers and indigenous peoples have certain rights to health, 
happiness, land and self-determination. Attempts by others to jeopardize our 
way of life, our culture, or in any way significantly alter our ability to make a 
living on our land is an assault on our basic rights.
Some persons have had almost unlimited access to formal education 
combined with other opportunities. These advantages do not ensure that they 
are any more intelligent or superior in decision-making than people of the land. 
They need to be sensitive to farmers, and make a sincere effort to be “in touch.” 
At a recent urban/rural conference in our rural area, for example, some of the 
farmers (several highly educated) felt ignored and put down by some of the 
college people who assumed they were ignorant. Although I assured them it 
was not intentional, for many non-rural people it is a common perception.
People of the land, including indigenous cultures, have a treasure of 
knowledge based on their common sense, their survival skills and their 
cultural heritage. They should have the dominating decision-making power 
to alter their way of life, their culture or their ability to stay on their land. 
Patenting knowledge and information can also be judged by some as stealing 
from the past.
Their common sense life experiences, combined with their cultural heritage, 
qualify the people of the land to maintain ownership of all of their resources. 
Sometimes resources are held in common, based on community, cultural or 
tribal history. In these instances, all people need a long period of discussion 
about how any changes in the economic and social structure may affect them 
before they make decisions.
Intellectual property rights is somewhat of a misnomer. It is not a right. 
Rather it is an agreement, a sharing, or a leasing. Any taking or patenting of 
genetic information or material should be dis-allowed and replaced with a 
fair rental contract, if a consensus can be reached.
We must slow this ruthless rush to force new products and technologies 
onto the market. Unlike some other progressive countries, the U.S. refuses to 
consider the social and economic consequences these products and technolo-
gies impose on our society. We need to work our consciences. Ignoring the 
societal consequences dehumanizes our society and destroys the dignity of 
all who are left out of the process, and they suffer greatly as a result.
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Dignity is already being taken away from farmers and other basic producers 
of food and fiber. When the cost of growing and or producing food is higher 
than what the farmer receives, there is no dignity or value in that food or its 
production. It has a minus value. Approximately 75 percent of the farmers in 
this country are now in this crisis situation. They are holding on by a slave-like 
schedule that forces them to work off the farm to make up for the losses on 
their farms. We farmers are fast becoming part of the poverty and oppression 
that strangles our so-called Third World neighbors in Central America, South 
America, Africa and Asia.
When dignity is taken, pride and hope also disappear. People without dignity 
cannot help themselves — they can only struggle to survive. Desertification, 
destruction of the environment, and eventually the survival of the earth itself is 
put into grave danger. There are plenty of resources to provide a dignified living 
for all of us. The rich could still be rich — they simply do not need to be 
“filthy” rich!
Our policies, our research and our technology need to be directed toward a 
quality of life that enhances the dignity of all people on this planet, toward our 
children and our children’s children. We need to be repairing the damage to our 
earth and our society before we rush headlong at “creating” new “weeds” that 
pose grave questions for the future.
The Webster’s New World Dictionary definition of a weed is “a plant out of 
place.” It could also be used to describe a product or technology out of place.
As a qualified well-pump installer, I am very aware that more than 58 percent 
of all water wells in the U.S. are now polluted with commercial and farm 
chemicals. It may require 30 to 100 years to clean and make them safe, if ever. 
This pollution came from chemicals that were largely applied 10 and 15 years 
ago, while the pollution from increased usage since that time is yet to be seen.
Another weed example: The fast growing California Pinion Pine was 
introduced years ago as a better tree crop in the steep mountains in the Basque 
country of Spain. Spending some time with friends in that region three years 
ago, the tree farmers repeatedly showed me the Pinion Pine stands as not only 
a failure, but as depleting the nutrients of the shallow mountain soil. After the 
Pinion Pines were harvested, the soil was so depleted that no trees would make 
any worthwhile growth on these areas. They learned the expensive lesson that 
only native varieties could continue to grow and produce profitably and 
sustainability.
Farmers and indigenous people have been misled by sales people who 
assured them that certain farm chemicals were so safe that they sometimes 
drank a glass of atrazine, for example, to prove it. Atrazine is now proven to 
be carcinogenic, polluting much of our drinking water in the Midwest. We 
need to keep in mind that unethical researchers, companies and individuals 
hurt the image of all good researchers and scientists.
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The ethical and moral implications of emerging technologies need to 
be thoroughly examined and weighed as to their impact on cultures and 
economies. Will the economic and lifestyle impact be pleasantly progressive 
and stable, or will the impact be devastating to certain regions, countries or 
cultures? As an average American citizen, I need to know how my basic rights 
will be affected. What safeguards are in place or need yet to be developed to 
protect the health of people and the environment in the release of genetically 
engineered bacteria and other life forms? We must not allow governments to 
use food as a weapon to control and subjugate other countries or regions.
If we all do not take responsibility for the long-term problems following 
shortsighted decisions on patenting life forms and intellectual property rights, 
we will eventually all be losers. The earth is in grave danger; the land and the 
oceans are becoming polluted. Farmers in this country and around the world 
are being pushed off their land in record numbers. When large numbers of 
people are losing their rights and their land, we find a recipe for terrorism from 
which none of us can escape. People without hope feel they have nothing to 
lose by fighting back with violence. Forcing people off the land only creates 
more urban and rural ghettos, which will eventually drag us all down.
This rural crisis fuels rapid growing support for the militia and patriot groups 
that feel this country has betrayed them.
A serious problem is the growing sentiment to cut funding for public 
research. Legislators and congress people are responding to this sentiment 
and are proposing deep cuts in public funding for research in institutions of 
higher learning. Our country needs more public funding for research, not less. 
We need to balance the profit-driven motives of industry research with public 
research for the common good.
Historical lessons from Europe should remind us that any country that 
loses its family farm system of agriculture soon suffers a collapse of its entire 
economy. It then takes several hundred years to restore the family farm system 
and along with it — the economy.
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Ownership of Biodiversity: A Developing 
Country’s Perspective on an Open 
International Debate
Jose  Luis  Solleiro
Senior Researcher 
Centre for Technological Innovation 
National University of Mexico 
Mexico City, Mexico
The life sciences are changing at a rapid rate in their fundamental character. 
These changes are of two principal kinds. First, tremendous technical advances 
have been realized over the past couple of decades. It is now possible and, 
indeed, is common practice to transfer genetic material between completely 
dissimilar organisms. It is also possible to isolate and multiply for commercial 
use parts of organisms to, for example, mass-produced chemicals that are 
otherwise produced in much smaller quantities by plants. The second change, 
intimately connected with these scientific breakthroughs, is a strong and 
escalating trend toward the commercialization of the life sciences (Belcher 
and Hawtin 1991).
As a consequence, since the mid-1980s, the main industrialized countries 
have started international negotiations to encourage (or to force) the rest of 
the world to reduce unauthorized diffusion of new technologies. The risk of 
having their intellectual property pirated elsewhere would deter companies 
from exporting their products and technologies. It was concluded that the 
absence of strong intellectual property protection performs as an effective 
trade barrier (Jaffe and van Wijk 1995).
In this context, the protection of biological innovations was introduced in 
the GATT (General Agreement on Tariffs and Trade) talks around 1990, and 
has become the subject of specific provisions in the final agreement. In this 
way, an actual requirement for membership in the World Trade Organization, 
according to the Uruguay Round of GATT, is full adoption of the agreement 
on Trade Related Aspects of Intellectual Property Rights (TRIPs). TRIPs sets
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international standards for protection. Patents shall be available for any 
inventions in all fields of technology. Excluded from patent protection may 
be plants and animals other than microorganisms, and essentially biological 
processes for the production of plants and animals, other than nonbiological 
and microbiological processes. However, protection for plant varieties shall 
be provided either by patents or by an effective sui generis system or by any 
combination thereof (GATT 1994).
TRIPs has brought some peace of mind to those promoting stronger 
protection of intellectual property rights for biological innovations. But a 
concern remains: The access to genetic resources and the possibility of adopting 
a certain degree of control over these resources through different types of 
ownership. Although considerable progress has been made in developing an 
international framework for the conservation, use and access to plant genetic 
resources, it is still unclear if plant genetic resources are subject to ownership.
It is also unclear to what extent developing countries, where an important part 
of biodiversity concentrates, can make actual profits from sovereign rights 
contemplated in the Convention on Biological Diversity. This paper presents 
a perspective from the South to these questions.
From  a  Free  Flow  System  to  Sovereignty
During the 1970s, the United Nations Food and Agriculture Organization 
(FAO) Commission on Plant Genetic Resources was established as an 
intergovernmental policy forum. Although the FAO’s involvement in genetic 
resources dates back several decades, it was in 1983 that member governments 
established the International Undertaking on Plant Genetic Resources. The 
Undertaking is a nonbinding agreement to cooperate in the conservation 
of genetic material and to work together for its sustainable development. 
Regarding the ownership and control over plant genetic resources, the 
Undertaking declared all germplasm, including breeders’ lines and elite 
varieties, as common heritage. Most developing countries, and many developed 
countries, adhered to the Undertaking, but it had no legal standing. The U.S. 
did not adhere to the Undertaking, even after the modifications made later 
(Menon 1995).
Major changes concerning access to genetic resources have been taking place 
within the Commission. As mentioned before, according to the 1983 FAO 
International Undertaking on Plant Genetic Resources, common heritage meant 
free access. Article 5 of the Undertaking stated that adhering governments and 
institutions will make genetic resources under their control available “free of 
charge, on the basis of mutual exchange or on mutually agreed terms.” In 1989, 
the Undertaking was modified through the FAO resolution 4.89 on an agreed 
interpretation of the Undertaking including a recognition of breeders’ rights 
and farmers’ rights, and resolution 5.89 on farmers’ rights. Resolution 4.89 
clearly stated that the term “free access” did not mean “free of charge.” The
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last FAO conference, held November 1991, discussed another amendment 
to the Undertaking that endorsed “that nations have sovereign rights over 
their plant genetic resources and that breeders’ lines and farmers’ breeding 
material should only be available at the discretion of their developers during 
the period of development.”
“In other words, in less than a decade, the position had taken a 180 degree 
turn” (Menon 1995). This constitutes the first international agreement to 
recognize States’ sovereign rights with respect to plant genetic resources, 
as clarified by resolution 3.91. Under these last provisions, countries adhering 
to the Undertaking agreed to confer access to the samples of genetic materials 
under their control only for specific purposes, e.g., scientific research, plant 
breeding or conservation. This clearly excludes access with an aim to 
reproducing the materials for commercial purposes, such as for propagating 
seeds (Correa 1994).
Plant Breeders’ Rights, as provided for under UPOV (International Union 
for the Protection of New Plant Varieties) are not incompatible with the 
Undertaking. No reference is made regarding the compatibility of the 
Undertaking with the patenting of plant genetic resources. The granting 
of patent rights implies the restriction on the access to protected materials 
greater than in the case of breeders’ rights. The compatibility of the Undertak-
ing with patent rights is likely to be discussed in the framework of the ongoing 
process of the FAO Commission on Plant Genetic Resources. “Divergence’s of 
opinion may be anticipated, since many developing countries seem to view 
patenting of plants and plant varieties as incompatible with a policy of 
development and sustainable use of plant genetic resources” (Correa, 1994).
The  Convention  on  Biological  Diversity: From  Recognition to Compensation
The Convention on Biological Diversity was adopted at the Earth Summit in 
Rio de Janeiro, in June 1992, which was organized to address a broad range of 
environmental problems. The Convention represents an attempt to balance the 
interests of the gene-rich South with those of the gene-poor but technology-rich 
North. In December 1993, the Convention became, unlike the FAO’s Interna-
tional Undertaking, a legally binding framework for conserving and utilizing 
global diversity. It recognizes “national sovereignty” over all genetic resources, 
as well as the need to compensate developing nations for the resources that 
they have historically donated to the development of the world’s agriculture.
The Convention represents an agreement that grants access to those 
resources in exchange for compensation and access to technology. Article 1 
of the Convention describes its objectives. They include conservation of 
biological diversity, sustainable use of its components, fair and equitable 
sharing of the benefits arising out of the utilization of genetic resources, 
through (Siebeck 1994):
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Appropriate access to genetic resources;
Appropriate transfer of technologies (taking into account all rights 
over those resources and to technologies); and
Appropriate funding.
Article 3 of the Convention affirms that States have the sovereign right to 
exploit their own resources pursuant to their own environmental policies. 
Article 15 addresses access issues and states that the authority to determine 
access to genetic resources rests within the national governments and is subject 
to national legislation. This is elaborated as follows (Mugabe and Ouko 1994):
States shall facilitate access for environmentally sound use;
The access shall be subject to prior informed consent and based on 
mutually agreed terms; and
The Convention provides for the sharing of benefits derived from 
genetic resources with the country of origin, or the country 
providing such resources, if required in accordance with the 
convention.
The right of access by other contracting parties is, thus, dependent upon 
the conditions established by the legislation and competent authorities of each 
country. It is also subject to the country’s prior consent, provided further that 
“mutually agreed terms” are reached between the parties. This effectively 
implies that future transfers of genetic resources will be made under material 
transfer agreements designed to protect source nations’ interests in any 
resulting profits. Under the compromises of the Convention, this international 
sovereign right applies only to genetic resources possessed in in sui collections. 
Resources already outside the nationals as in international repositories, are not 
subject to such rights (Barton 1994).
Another obligation assumed by contracting parties is to provide . .in the 
case of technology subject to patents and other intellectual property rights . . .” 
for an “adequate and effective protection” of said rights (Article 16). This article 
may be read as requiring the patentability of genetic resources, but only defines 
the conditions of protection if and when such a protection is conferred (Correa 
1994).
An obligation is also stated for recipients of genetic resources to allow 
and facilitate access to technologies on mutually agreed terms and limited to 
technologies derived from the use of genetic resources. Intellectual property 
protection, as contemplated in Article 16, limits release of technology. There 
are no provisions for compulsory licensing (Siebeck, 1994). In this way, “the 
Convention, in a provision that is carefully balanced but lacks clear logic, also 
defined a developed-world duty to transfer technologies that are relevant to the 
conservation and sustainable use of biological diversity or make use of genetic 
resources. This is to be done in a way consistent with the adequate and effective 
protection of intellectual property rights” (Barton 1994).
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This contradiction regarding the access of developing countries to tech-
nologies of developed countries may have profound implications for the 
former. According to Walter Jaffe (1994), biodiversity offers interesting 
possibilities for introducing new biotechnologies and investments from the 
North, but to capitalize these possibilities developing countries require 
substantial and sophisticated scientific and technological resources. Unless 
developing countries rapidly create such capacities, the exchange with the 
North will take place in a very inequitable way, preventing access by developing 
countries to the technologies they require for sustainable use and conservation 
of their resources.
The financial needs of the Convention will be subscribed to primarily by 
the developed countries. These are to meet developing country expenses on 
conservation, as well as their access to technology. They could be drawn upon 
to pay for royalties. It seems quite wishful to assume that Global Environment 
Facility funds, created for this purpose, will be enough to enable developing 
countries to access the technologies they need to achieve the general objectives 
of the Convention.
It is therefore hard to imagine how national sovereignty over genetic 
resources can be implemented in countries that lack the legal infrastructure 
and, even more critical, that are not even aware of the diversity, quantity, 
location and potential of these resources. Accepting that it has been a major 
step for developing countries to get international recognition of the sovereignty 
and compensation for the value of biological resources, it is essential to keep 
working to improve the legal framework to deal with these issues at all levels 
and to build domestic capacities to identify conserve and use genetic resources 
and better negotiate the terms of future agreements.
For the latter objective, it seems essential for developing countries to monitor 
experiences like the famous Merck-INBIO agreement. Under this deal, INBIO 
agreed to inventory and supply samples of plants, microorganisms and animals 
collected from the Costa Rican rain forests over a period of two years. The 
contract gave Merck & Co., Inc., the exclusive rights to screen, develop and 
patent new products from these resources. In return, Merck agreed to pay 
INBIO one million dollars and share five percent of the royalties arising from 
the sale of products derived from these biological materials. This agreement 
drew criticism from many different writers and policy analysts. The main 
criticism has been directed at the fact that INBIO is a private organization 
and therefore had no rights to lay claims to what is seen as national heritage 
(Menon 1995). Nevertheless, the agreement constitutes a first attempt to solve 
the problem of implementing effective economic compensation for access to 
the genetic resources of the South.
Another interesting example comes from another drug company, Shaman 
Pharmaceuticals. The company announced its intention to return a percentage 
of profits back to all countries and communities it has worked with after
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any product is commercialized. Compensation will be funneled through the 
Healing Forest Conservancy, a nonprofit organization founded by Shaman 
for the conservation of biodiversity and the protection of indigenous knowl-
edge. Shaman’s research has already led to some patents. The company 
recognizes that the resulting royalties are based upon its own contribution 
and that of the communities from whom it received medicinal plants. The 
company has developed contracts with some indigenous communities in 
Latin America. However, it could be some time before it will be possible to 
determine the benefit of the arrangement for the communities involved 
(Crucible Group 1994).
These two cases do not constitute models for developing countries to 
follow, but they have the merit of pioneering an non-exploited field. In my 
opinion, the worst position to adopt before the possibility of negotiating 
material transfer agreements of this nature is the paralysis from analysis.
Some institutions from developing countries are losing real opportunities 
because of their passive attitudes and the fear of losing the “treasure of 
biodiversity.” This attitude shows that these institutions are forgetting a 
basic mathematical truth: a small percentage of something is always greater 
than 100 percent of nothing.
Recognition  of  Farmers' Contributions  to  Biodiversity  and  Agricultural  Technology
Since the early 1980s, a part of the South-North controversy over genetic 
resources has centered on questions of equity in the distribution of benefits 
arising from the use of plant genetic resources. On one hand, developing 
countries have questioned the fairness of assigning intellectual property rights 
to those who breed new plant varieties, while the work of farmers who have 
generated the plant diversity that constitutes the basis for modern breeding 
is not legally recognized. On the other hand, industrialized countries have 
stressed that plant breeders’ rights and patents are not a form of compensation 
but rather an incentive for innovation (Jaffe and van Wijk 1995).
The contribution made by generations of farmers to the conservation 
of germplasm and the improvement of species has been recognized by the 
international community, particularly under the FAO International Undertaking 
on Plant Genetic Resources and the Convention on Biological Diversity. Indeed, 
the dispute was partly resolved when, within FAO, the rights of farmers in 
developing countries were acknowledged in order to counterbalance the plant 
breeders’ rights granted in industrialized countries. Farmers’ rights were 
defined as rights arising from contributions of farmers in generating plant 
genetic resources, particularly in the centers of diversity, and have the purpose 
of ensuring full benefits to these farmers and supporting the continuation of 
their contributions (FAO 1989). An International Gene Fund would be created 
to give a concrete and substantial basis to the farmers’ rights.
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But even when the farmers’ contribution to agricultural innovation is widely 
recognized1, the way of compensating this contribution remains in the dark. 
The International Gene Fund failed to materialize, although it had the merit 
of bringing the issue to the international political agenda. The concept was 
further discussed during the Keystone International Dialogue on Plant Genetic 
Resources (Keystone International Dialogue on Plant Genetic Resources 1991), 
and during the Earth Summit on Environment and Development in 1992.
The Convention, however, follows the principle of national patrimony and 
recognizes sovereign rights of States (Jade and van Wijk 1995). According 
to Menon (1995), it is essential to recognize not only the sovereignty but also 
the result of the work of many generations of peasants as a common contribu-
tion to innovation. For this reason, the implementation of FAO’s farmers’ rights 
concept should be given greater attention as a source of ideas to materialize 
the compensation to farmers.
Such rights were not conceived by the FAO Conference as an exclusive right, 
but as a right to obtain compensation (Correa, 1994). This fits the situation in 
which the rights are attributed not to individuals but to a collective entity, and 
to cases in which the administration of the remuneration is administered by a 
collective organization.
An example of implementation of farmers’ rights at the national level is 
contained in a draft law on plant varieties protection under review in India. 
According to this document, a National Community Gene Fund would be 
established. Its funding would be partly supplied by a royalty paid by the seed 
industry, based on the sales of protected varieties. The funds would be used in 
trust of Indian farmers for collecting, evaluating, upgrading, conserving and 
utilizing genetic diversity.
This approach at the national level is certainly an important step, constitut-
ing a collective compensating system with impacts in the long run on farmers’ 
communities. However, the collective mechanisms do not solve the problem of 
compensating farmers at the global level, given the global nature of the values 
of germplasm farmers provide (Correa 1994).
Internationally, it is essential that intergovernmental negotiations address 
the creation of a mandatory funding mechanism to recognize, reward and 
protect the contributions of local communities, farmers and indigenous people 
(Shand 1993). It has to be understood, however, that such a task will demand 
a change in the attitudes of negotiators, a greater amount of good will, and a 
lot of creativity.
‘In a recent survey conducted by the author, managers of Mexican seed companies were interviewed 
and their answer to an explicit question about the contribution of land races to their breeding 
programs states clearly the essential role of these resources. Company managers also agree that it is 
important to recognize farmers' contributions and even compensate them economically, but there is 
no agreement or new ideas on the way to do that.
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Access: Bartering and Brokering Genetic 
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The intergovernmental committee that negotiated the Convention on Biological 
Diversity (CBD) (United Nations Environment Program 1992) at the United 
Nations Environment Program (UNEP) generally lacked agricultural represen-
tation from most countries. Thus, the representatives and negotiators embarked 
upon their negotiations with considerable misinformation and a lack of under-
standing which created an atmosphere of conflict: South vs. North. An example 
is the Merck-INBIO Agreement in which Merck & Co., Inc., paid to INBIO in 
Costa Rica a flat sum of $ 1 million to help seek biodiversity which could 
be analyzed for bioactive compounds and, if successfully marketed, would 
bring royalties. There was a general lack of understanding that biodiversity 
prospecting for other uses might require or take different approaches, particu-
larly that for agricultural biodiversity where the genes of interest must also be 
very specific and must fit other criteria of the breeders. Breeding agricultural 
plants is a dynamic process, not extractive. The germplasm must provide 
specific trait(s), be able to be crossbred and be free from tightly linked 
undesirable traits.
At the same time as the negotiation of the Convention was underway, the 
Food and Agriculture Organization (FAO) of the United Nations continued 
its effort to resolve the decade-old debate in its Commission on Plant Genetic 
Resources (CPGR): Who owns the world’s agricultural genetic resources? The 
CPGR was established in 1983 to implement the FAO’s International Under-
taking (IU) on Plant Genetic Resources, an FAO Resolution (8/83) (FAO 1983) 
to conserve and sustainably utilize agricultural genetic resources. The IU was 
triggered, to a large extent, by the expansion of breeders’ rights protection 
as more countries joined the treaty of the Union for the Protection of Newly 
Developed Varieties (UPOV). Social activist groups working with peasant 
farmers, such as the Rural Advancement Foundation International, challenged 
the equity when companies in developed countries obtained property protec-
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tion on cultivars of major food crops after inserting germplasm (particularly 
genes for disease and insect resistance) from farmer varieties (landraces). The 
companies made no provision for compensation to those farmer communities 
or countries from which the genes were obtained. (There has been no formal 
linkage in the international community between the exchanges and the 
utilization.) Some now call this proposed compensation, farmers’ rights.
The FAO’s IU attempted to make all germplasm, including that of private 
companies, freely available to all parties worldwide. Countries having strong 
private sector interests opposed this and did not sign onto the IU or did so with 
specific reservations to protect the private sector. Throughout a ten year period, 
generally nonconstructive debate ensued. The Keystone International Dialogue 
on Plant Genetic Resources, initiated in 1988, brought consensus in some areas 
relative to support for conservation in recognition of farmers’ rights, recogni-
tion of breeders’ rights, and the need for benefit-sharing with providers of 
germplasm (Keystone International Dialogue Series on Plant Genetic Resources 
1991). These consensus points became translated into agreed interpretations 
to the FAOs IU which were added to the original IU as attachments. Farmers’ 
rights are defined in the second addendum (1991) to the FAO IU, which does 
not advocate direct payment to farmers. The 1989 attachment clearly acknowl-
edges the need for a fund to preserve genetic resources, such as the FAO fund 
— a non-existent, voluntary but authorized fund — to support conservation 
and utilization to recognize farmer contributions over the many years.
The FAO Conference passed the voluntary but rather regulatory International 
Code of Conduct for Plant Germplasm Collecting and Transfer (FAO 1993). 
Besides stating some ethical principles for collectors and genebank managers, 
this Code suggests mechanisms for receiving benefits to the donors.
One item pressed to closure in October 1994 was the agreement by the 
International Agricultural Research Centers (IARC) to place their collections 
under the auspices of the FAO Commission. The issue of interest to all is 
the access to the large collections of the major food crops held at the IARCs. 
Developing country germplasm in the collections will still be available, but 
restrictions prevent any property protection placed on them directly by 
recipients. It does not deal with derivatives, and not everyone is satisfied with 
the agreement.
Current
The Commission on Plant Genetic Resources is negotiating a revised IU since 
some of its text is not in harmony with the Convention on Biological Diversity. 
A one-week extraordinary session of the normally biennial CPGR was held 
in November 1994, and country representatives expressed their expectations 
and positions on the integrated text of the IU and its annexes. Some countries 
were represented by some of the same negotiators as for the CBD, and the 
understanding of agricultural issues was little advanced. Additionally, many
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developing countries were represented only by the local permanent FAO 
representatives who have varying degrees of understanding of the issues at 
stake or of the related activities in their countries. The discussions went 
nowhere. The CPGR held a two-week session in late June 1995, and resumed 
negotiations on the 1U. The focus of the negotiating session was on the most 
difficult issues, thereby writing a prescription for potential failure. Property 
rights issues will remain very contentious as the issues will focus on access 
to genetic resources and farmers’ rights. All of this will be conducted in a 
political context — not scientific, not pragmatic, and not logical such as a 
concern for food security.
The success of these negotiations will likely impact heavily on future 
advances in crop breeding and production agriculture. Restricted access will 
affect developing and developed nations alike, depending on the crop. Since 
no nation’s agriculture is without interdependency of others, there will be many 
factors involved in what appears like a Chinese checkers match. For example, 
60 percent of the world’s food production is from crops and their relatives 
originally from Central and South America (maize, potato, sweet potato, 
cassava). But, rice from Asia is the world’s most important cereal, followed by 
wheat from Western Asia. It is hard to say how the African continent would 
fare since only 34 percent of its production is from crops native to Africa, 
primarily sorghum and millets. South America, at 94 percent dependency, is 
heavily dependent on the corn and beans from Central America and barley, 
oat, rice, wheat and soybean from different parts of Asia. Of course, the U.S. 
with its native sunflower — developed as a crop by the Russians — plants 
more than 99 percent of its crop acreage to non-native crops.
Access to genetic resources has been provided by formal exchanges between 
countries and less formal exchanges by institutes and scientists. Scientist 
exchanges have generally been with other scientists after visitation or meeting 
in scientific conferences. These exchanges are probably closest to the “mutually 
agreed terms” of the CBD since each has an expectation and there is reciprocity. 
The CBD is more oriented to bilateral arrangements which is the more normal 
way most exchanges are made. However, the rules of the game, until now, have 
been essentially multilateral, that is, there is a commonly accepted basis for 
exchange. If the CBD were to hold a strict accounting of exchanges, the lack 
of a multilateral arrangement would play hard on the countries that could 
least afford access to some needed genetic resources.
There is need for information and rational action on all fronts. The 
Conference of Parties to the Convention needs to understand the delicate 
balance between breeder access to genetic resources to thwart new pest 
breakouts and stable food supplies at a reasonable price. There are many 
questioning the global commodity exchange situation after the Uruguay 
Round of General Agreement on Tariffs and Trade (GATT) and its new 
successor World Trade Organization. Should all nations develop their own
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food production capacity? Some feel that with the increasing pressure on 
the environment, those countries best able to produce food under intensive 
agriculture should increase that sustainable capacity. Thus, import-dependent 
countries would remain so. However, no country feels comfortable being unable 
to control its food supply train. The U.S. exports approximately 60 percent of 
its wheat, 20 percent of its corn, and 35 percent of its soybean.
The U.S. Department of Agriculture (USDA) policy for the free flow of 
germplasm continues for the National Plant Germplasm System. During the 
period of 1990 through 1994, 182,678 samples were distributed to foreign 
requesters, about 92 percent to foreign public institutions, including the gene 
banks for repatriation. More than 41 percent of the germplasm was advanced 
germplasm and elite cultivars which went to public institutions for inclusion 
in their breeding programs. This is a significant contribution to development 
programs in other countries.
However, if de-registration of current pesticides were to occur without 
substitutes, U.S. crop losses would greatly reduce production and that left 
for export might not meet quality requirements of the importers. The impact 
would be considerable in international markets and the prices we all pay for 
grain and food. The impact on the U.S. for lack of access to genetic resources 
to provide genetic resistance to insects and diseases could thus be substantial. 
The ownership and exchange issue must be solved forthrightly.
The U.S. is greatly divided in its acceptance of the property rights on 
genetic resources. Institutions and breeders are divided, not necessarily 
along institutional lines. States are pressed financially to support crop 
development on crops not sufficiently lucrative to the private sector. Even 
fees from sales of those principal cultivars must support more than just those 
crops. However, most organizations feel that they could provide royalties when 
there has been an identifiable and substantial contribution from a plant to their 
new cultivar. If there is a benefit to the farmers, the farmers would justifiably 
pay for it in increased seed prices. However, depending on the market, they 
may not benefit when they sell the crop. With the increased yield obtained 
or protected by the gene(s), the cost per unit output will be fair or they will 
not pay it in the first place. In reality, they will pay since a protected crop is 
a value that farmers desire.
Thus, in the changing sense of equity, the public sector is moving to an 
understanding of the issues and accepts the need to pay for value received.
The private sector has generally been aggressive in contractually buying 
exclusive rights to germplasm of benefit and agreeing to pay for those benefits 
through royalty compensation. More importantly now, how will the process 
work? All organizations are more oriented to utilizing material transfer 
agreements (MTAs) to exchange germplasm in which the limitations to use 
are spelled out. Development of MTAs, which enable organizations such as 
the USDA to pass on germplasm and its associated obligatory requirements 
to others, may be a possible solution to the international germplasm impasse.
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However, tracking and monitoring the germplasm community for adherence 
to the ethical principles of acceptance and compliance with these principles 
will be important in maintaining such a global arrangement. This approach 
will have to be accepted by all for it to be effective. The biotechnology industry 
should foster legitimate exchange mechanisms and attempt to assure that future 
exchanges are transparent and fair.
The international community should consider some of the following points 
in establishing a protocol for germplasm exchange and benefits:
Provide open access to all genetic resources of food and agriculture;
Engage MTAs to enable research and breeding with the material;
Enable a brokerage system of recognized third parties to exchange the 
germplasm and provide annual balance sheets of exchanged 
germplasm;
Establish a tracking system and a compensation mechanism to support 
germplasm conservation activities, when appropriate; and 
Enable a bartering system where access is provided in exchange for 
training and/or technology.
If there is to be financial compensation where notable genes make contribu-
tions to new varieties or hybrids, a scale of declining royalty payments and a 
fixed time limit needs to be established for each contributing gene. The time 
limit on a particular variety may be fixed but the genes may be put into other 
derived varieties. The “profit” or market value of the cumulative sum of all 
new and old gene contributions could theoretically far exceed any expectations 
of profitability for any new variety. It must also be noted that value-added 
germplasm contributions also enter the equation, and that developing countries 
may now have to pay for that value when in the past, improved germplasm 
has been available at no cost. The proposed system will develop a bureaucracy 
and protectionism where there is no winner, particularly for the developing 
countries least able to afford it. When costs exceed benefits and the system 
is not working for the countries that need it, it will most likely be scrapped 
and bilateral conditions under mutually agreed terms will prevail.
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During the past two decades, improvements in agricultural productivity have 
been largely based on the introduction of a technology package that includes 
high-yielding plant varieties, intensive use of chemical fertilizers, herbicides 
and pesticides, and an abundant supply of water. Despite undeniable success 
in raising productivity, concerns exist about the environmental sustainability 
of this model. Use of large amounts of agrochemicals has caused severe soil 
and water pollution, and the development of strains resistant to pesticides. 
Water resources are becoming increasingly scarce. Moreover, the genetic base 
of important high-yielding varieties is increasingly uniform and, as a con-
sequence, they are susceptible to unpredictable outbreaks of disease and to 
the harmful effects of plant pests. Thus far, however, relatively few farmers 
in developing countries have had access to this new technology and capital- 
intensive methods of production.
Nonetheless, the emerging biotechnology revolution is stimulating hope 
that it will provide the basis for more sustainable agriculture in developing 
countries. This is because biotechnology today is different from previous 
agricultural technologies in two ways. First, biotechnology can enhance 
product quality by improving the characteristics of plants and animals.
Second, biotechnology may potentially conserve natural resources and improve 
environmental quality by using organisms for degradation of toxic chemicals 
and wastes, fertilizers and soil improvement, and the development of insect- 
and disease-resistant plant varieties. Many of these applications are, or will 
soon be, a reality, and they can have far reaching consequences for the solution 
of important problems of developing countries. It is paradoxical, however, that 
although developing countries are perhaps the main beneficiaries of agricultural 
biotechnology, its development is almost exclusively concentrated in highly 
industrialized countries. That is not surprising in light of the high-level 
scientific research and the capital it embodies (Solleiro 1995). Moreover, 
innovation is increasingly controlled by large multinational companies.
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In these conditions, it can be expected that the adoption of new biotechnolo-
gies by the developing economies will be concentrated in sectors of greatest 
economic development potential, will increase internal social differences, and 
will bring greater poverty to small producers and hired personnel.
Faced with this perspective, the only way to confront the above risks 
while taking advantage of existing opportunities will be by having a greater 
control over biotechnology in developing countries. That will depend to a 
great extent on the level of scientific and technological knowledge already 
attained in this area. But developing countries must not believe that they will 
be able to go “shopping” to the technology supermarkets of the industrialized 
countries (Deo 1991). On the contrary, given the barriers erected against the 
transfer of biotechnology, Third World countries will have to confront the 
problem of technology diffusion and define policies and practices that will 
make its use possible.
One of the most important policy instruments for the promotion of 
biotechnology development deals with intellectual property rights (IPR) 
protection. Developing countries are increasingly confronted with the fact 
that a number of bilateral and multilateral initiatives have been taken or are 
being implemented to “harmonize” intellectual property protection worldwide. 
“Harmonization” for most if not all countries will mean introducing much 
stricter intellectual property protection that can have far reaching consequences 
for the access to and the likelihood of broad diffusion of biotechnologies. This 
paper presents a brief analysis of the potential consequences to developing 
countries by the introduction of IPR regulations in accordance with these 
international trends.
Recent  Development  in  IPR Protection  for  Plant  Biotechnologies
Attempts to strengthen IPR protection regimes have been underway for more 
than a decade. Initially, the World Intellectual Property Organization (WIPO) 
served as the main forum. A committee of experts on Biotechnology Property 
and Industrial Property was established in 1984. Efforts to develop a new 
treaty on the protection of industrial property have been on-going since 1985. 
Conventions, however, require wide approval. Industrialized countries have 
been unsuccessful in getting the higher IPR standards they would like adopted 
in other countries through WIPO (Belcher and Hawtin 1991).
Some countries, led by the U.S., have subsequently embarked on bilateral 
negotiations to secure stronger protection for the intellectual property of 
their nationals. The U.S. has used its General System of Preferences, granting 
favored-trading status only to those nations that meet rigid IPR protection 
standards. European countries have had similar commercial policy instruments 
available to deal with IPR issues.
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An extension to these bilateral actions has been the multilateral negotiation 
of trade-related intellectual property issues under GATT. Indeed, the Trade- 
Related Aspects of Intellectual Property Rights (TRIPS) Agreement is the most 
comprehensive international instrument on intellectual property ever 
negotiated and adopted. The provisions contained in TRIPS constitute 
minimum standards. Thus, members cannot be obliged to provide a more 
extensive protection (Correa 1994).
In the area of patent rights, TRIPS contains a number of important 
provisions. According to article 27.3.b, parties may exclude from patentability:
plants and animals other than microorganisms, and essentially biological processes 
for the production of plants or animals other than non-biological and micro-
biological processes. However, members shall provide for the protection of plant 
varieties either by patents or by an effective sui generis system or by any combi-
nation thereof. This provision shall be reviewed four years after the entry into 
force of the World Trade Organization (WTO) Agreement.
This exception reflects the outstanding differences, even among industrial-
ized countries, on the patenting of plants and animals. The European Economic 
Community (EEC) proposals in GATT are aimed at maintaining the present 
position of the European countries which are members of the European Patent 
Convention. This position has so far been confirmed by the still-under-
discussion draft directive on patents relating to biotechnology.
Various elements of article 27.3.b need to be considered (Correa 1994). First, 
unlike European law and other legislation that followed the same approach, the 
article refers to “plants and animals” and not to certain classification thereof 
(varieties, races or species)'. In the absence of any distinction — and the fact 
that the second sentence of the same article introduces an exception for one 
particular classification (plant varieties) — the exclusion is to be interpreted in 
broad terms as being inclusive of animal and plants — animal races and animal 
and plant species.
Second, the reference to “essentially biological processes” is limited by the 
exclusion of “non-biological and microbiological” processes. The concept of 
microbiological processes as an exception to the exception is present in the 
European legislation and in the laws of various other countries. Its aim in the 
TRIPS context is to limit the exclusion of patentability to traditional breeding 
methods, while preserving the possibility to obtain protection. For example 
this is evident on developments based on cell manipulation or, with the
'The distinction is important. Thus, the prohibition to patent a variety does not prevent European 
countries to patent a plant, as such. The acceptance of a patent application on the “Harvard mouse” 
by the European Patent Office was, similarly, based on the judgment that it is not a “race” but a 
specifically altered animal which is patented.
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advances in biotechnology, the transfer of genes. Under the commented 
text, processes employing microorganisms (such as fermentation) are also 
patentable, in accordance with current practice in most countries.
More complex and new is the concept of “non-biological process.” How a 
plant or an animal can be produced by a process that is not totally or in part 
biological? The source and grounds of this text are untraceable. It will probably 
create more problems than it may solve.
Third, and as an exception to the general authorized exclusion, members 
must provide protection for “plant varieties” either by patents or by “an 
effective sui generis system or by a combination or both.” This obligation is 
another important basis for the expansion of the scope of intellectual property 
in a field that most developing countries keep as a part of the “public domain” 
till now. Although there is flexibility regarding the form of protection, the fact 
is that all GATT member countries will be bound to protect plant varieties.
The flexibility is here, again, a reflection of the lack of consensus among the 
industrialized countries themselves. While in the U.S. and in Japan a plant 
variety may be patentable, this is not the case in Europe. The reference to a sui 
generis system suggests the breeder’s rights regime. However, the possibility is 
open to combine the patent system with the breeders’ rights regime, or to 
develop other sui generis form of protection. It is unclear why in an instrument 
aimed at establishing universal standards, the form of protection of plant 
varieties has not been settled in a more straightforward way, like in other 
matters of equal or similar importance2. In any case, considerable freedom has 
been left for national legislation to design the system of protection in this area.
Fourth, article 27.3.b is the single provision in the whole TRIPS Agreement 
that is specifically subject to an early revision — four years after the entry-into- 
force of the Agreement. This period is even shorter than the transitional period 
contemplated for developing countries (article 65). This solution suggests how 
difficult a compromise on the biotechnology-related issues has been and the 
need for a deeper examination of the matter.
Two other provisions of the TRIPS Agreement should be mentioned here. On 
the one side — as indicated above — protection of a process is extended to the 
products directly made with said process (article 28.1.b). On the other, in civil 
proceedings relating to process patents, the reversal of the burden of proof is 
established (article 34). This principle may have a substantial impact in the 
biotechnology field, given the importance of process patents and the often 
broad claims admitted in this field.
2The UPOV (International Union for the Protection of Plant Varieties) convention is not mentioned 
in the TRIPS draft text nor are breeders rights considered a form of “intellectual property” under the 
Agreement. Another forgotten modality of protection are the utility models recognized in many 
developed and developing countries to protect “minor” inventions.
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Trends in the  Protection of Plant Genetic Materials
Within this international framework, it is widely accepted that an invention 
consisting of or using living matter should be protected by IPR. With respect 
to agricultural biotechnology, the main instruments for protection are patents 
and plant breeders’ rights. Patents are available on processes used to develop 
modified organisms or to produce biological products.
Patent protection is also available in a number of countries for plants that 
contain a novel gene. Patents covering genes are not generally confined to the 
sequence of a gene. The patent typically claims first, a gene or protein, standing 
alone, corresponding to that sequence; second, a vector or plasmid incorporat-
ing the sequence; and, possibly, third, a plant (of a particular range of species) 
that has been transformed by means of such a vector (and the descendants of 
the transformed plant). Thus, the patent holder gains effective control over use 
of the specified gene in genetic engineering (Barton 1994)
In this way a broad scope for protection is granted, which raises concerns 
about the possibility of extending it to many varieties and even to entire 
species. This can certainly pose serious threats to breeding activities in 
developing countries, which have been based rather upon capacities to adapt 
existing varieties to local conditions. Moreover, scope of protection can be also 
extended to characteristics of crops, which means that the patent holder could 
claim a monopoly over any variety expressing the same trait.
Due to these concerns, uncertainty still exists about the final validity of such 
patents. But, clearly their enforcement would erect important obstacles for 
biotechnology development and diffusion mainly in developing nations.
On the other hand, Plant Breeders’ Rights (PBR) are granted by governments 
to plant breeders to exclude others from producing or commercializing material 
of a specific plant variety for, minimally, 15 to 20 years. In order to be eligible 
for PBR, the variety must be novel, distinct from existing varieties, and uniform 
and stable in its essential characteristics.
The legislation for both patents and PBR contains provisions for limited 
unauthorized use of the protected matter. Patent legislation includes a research 
exemption that allows others to study the protected subject matter without 
reproducing or multiplying it for commercial purposes. PBR law has important 
limits designed to facilitate continued improvement of protected varieties. 
Under the so-called Breeders’ Exemption, any protected plant variety can be 
freely used as plant genetic resource for the purpose of breeding other varieties. 
Another important feature of PBR is a provision that allows farmers to re-use in 
their own exploitation the seeds they have obtained, a possibility that patents 
would exclude.
Demands exist to strengthen the minimum standards for protection of PBR 
under the International Union for the Protection of Plant Varieties (UPOV).
The main change introduced by the 1991 conference included the exclusion 
of the farmer’s privilege. The change also allowed member countries to adopt 
such provision while allowing the right-holder to prevent such a use on the
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grounds that its legitimate interest will be prejudiced. Another important 
provision is made to prevent the unauthorized exploitation of any variety that 
is considered to be “essentially derived” from a protected variety. (A variety 
is considered essentially derived for this purpose when it is derived from 
the protected variety and retains virtually the entire genetic structure of the 
protected variety.) In this regard, the revised convention may contribute to 
dissipating some of the breeders’ fears on the eventual impact of the patenting 
genes that may be incorporated in their protected varieties.
In summary, these new provisions respond to industry’s claims for a 
protection more similar to that conferred under the patent system. Again, 
these new provisions are meant to protect interests of multinational seed 
companies and seem to erect new barriers for developing countries’ access 
to agricultural biotechnologies.
Expected  Effects  of  Stronger  IPR Protection
As mentioned before, the new international framework for the protection 
of biotechnologies under IPR has brought some of peace in mind to those 
who had pressured for change. In a situation where strong IPR protection 
has been established, foreign biotechnology companies can be expected to 
be more interested in exporting their modem products, plant varieties and 
technologies to the country in question. The new framework could also be 
expected to produce an increase in private research activity, thanks to the 
economic incentive of the possibility of having a temporary monopoly posi-
tion granted by different IPR mechanisms. International Property Rights 
protection can also facilitate the rapid availability of technology and foreign 
modern varieties, via licensing agreements and other contractual agreements 
(DG1S 1991).
On the other hand, extension of patent protection to all subsequent genera-
tions of a patented living organism by broad claims or stronger PBR protection 
through the “essentially derived” principle will increase production costs for 
breeders and may also lead to a control over segments of cultivated crops by 
IPR holders. This will pose severe difficulties for most plant breeders and small 
farmers of developing countries to access the benefits of new agricultural 
biotechnologies.
Unfortunately, in most developing countries, lack of a competitive market, 
limited research facilities and lack of participation of private companies in 
innovative activities represent serious obstacles to capitalize the benefits of a 
modern system of IPR protection. Despite the evident progress made by many 
developing countries to adapt their regulations to TRIPS, it still will be difficult 
to enforce them. Most countries lack the institutions and personnel for safe-
guarding IPR. Under present conditions, with a weak innovation system, such 
protection will mainly benefit large foreign firms wanting to protect an export 
monopoly and not necessarily interested in manufacturing their biotechnology 
products in these countries.
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If innovation is to be encouraged, IPR protection is an important mechanism. 
But, it will not work in isolation. New regulations must be conceived within 
the framework of a national innovation system. This links research, technology 
development and diffusion as a continuous, interactive process in which local 
scientific and technological effort is crucial (Brenner and Komen 1994).
Figure 1 presents a simplified scheme of a system in which biotechnology 
and its regulatory framework should be integrated.
FIGURE 1
__________BIOTECHNOLOGY IN A NATIONAL SYSTEM OF INNOVATION_____________
PUBLIC AND PRIVATE ACTORS AND INSTITUTIONS
© OECD, 1994, International Initiatives in Biotechnology for Developing Country Agriculture: 
Promises and Problems. Reproduced by permission of the OECD.
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Implementation of an innovation-system approach is not only a question of 
increasing investments in R&D in order to have greater capacity for scientific 
research. It is also critical to facilitate the adaptation and assimilation of 
biotechnology developed in other countries. Protection of IPR will then play 
an important role creating a safe climate for technology transfer. But it has 
to be integrated to a new biotechnology strategy that should involve closer 
relationships between science, technology and the market for fostering 
innovations and their dissemination.
This process for formulating strategies and policies should follow a certain 
logical order so that the main actors of biotechnology development become 
committed to certain common objectives and obstacles to technology diffusion 
can be removed. Thus, the first thing is establishing long-term objectives and 
priorities, a necessity for making strategic decisions. The second step would 
involve establishing coherent programs for strengthening the institutional and 
managerial framework to address these priorities. Sound policy instruments are 
needed to ensure that researchers, enterprises, Non-Government Organizations 
and farmers participate in priority projects for introducing biotechnology. 
Finally, implementation requires continuous monitoring and assessment of 
achievements and obstacles to maintain quality of technical aspects. Implemen-
tation must also include an awareness of the socioeconomic impacts on the 
introduction of biotechnologies, and make timely corrective actions for 
attaining general objectives.
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